',6&/2685(
5('$&7('[ZIP_CODE]&2/$0(1'0(17
$&(0'6
$123(1/$%(/5$1'20,=('3+$6(3$5$//(/'26(5$1*,1*
08/7,&(17(5678'<2)627$7(5&(37)257+(75($70(172)3$7,(176
:,7+$1(0,$$1'/2:25,17(50(',$7(5,6.0<(/2'<63/$67,&
6<1'520(625121352/,)(5$7,9(&+521,&0<(/[ZIP_CODE]&<7,&
/(8.(0,$&00/
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW \RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG 
&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFD OWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH /DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHU KDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RU UHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFH UWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HO JHQHÂ¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLS OHV

x5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQL QJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGX DOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLR QDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQI RUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOF RPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\V HV
x&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFW OLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNV LQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFW HGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQV SUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVS URWHFWHGE\FRS\ULJKW
,QIRUPDWLRQDERXW&HOJHQHÂ¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODEL OLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFD OWULDOVFOLQLFDOWULDOVGDWDVKDULQJ

&(/*(1([ZIP_CODE],(7$5<,1)250$7,217676
7,&&
7,&,&
GQRWEHVKDQRWEHVK
DUFKHUVDQGDUFKHUVDQ
GUHJXODWLRQVHJXODWLRQV
HJDORUFRQWJDORUFRQW
HGWRFHUWDLQHGWRFH
UWDLQLQIRUPUWDLQLQIRUP
HFW&HOJHQHHFW&HOJHQ
QJSULQFLSQJSULQFLS OHVOH
JUH\VSDFHJUH\VSDFH
QWLILFDWLRQRQWLILFDWLRQR
WDLQFRQILGHDLQFRQILG
RQWDLQLGHQWRQWDLQLGHQ
\DOVRPD\FDOVRPD\
KHVLVJHQHUDKHVLVJHQH
VHDWWDFKPHVHDWWDFK
RG\RIWKHUHG\RIWKHUH
ERXW&HOJHQHRXW&HOJHQ
RIWKDWLQIRUPIWKDWLQIR
RQDERXWRXRQDERXWRX
DWLRQDERXWDWLRQDERXW
RXQGDWKWWSRXQGDWKWWS
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 1 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015TITLE PAGE
AN OPEN-LABEL, RANDOMIZED, PHASE 2, PARALLEL, 
DOSE-RANGING, MULTICENTER STUDY OF SOTATERCEPT 
FOR THE TREATMENT OF PATIENTS WITH ANEMIA AND 
LOW- OR INTERMEDIATE-1 RISK MYELODYSPLASTIC 
SYNDROMES OR NON-PROLIFERATIVE CHRONIC 
MYELOMONOCYTIC LE[LOCATION_006]EMIA (CMML)
INVESTIGATIONAL PRODUCT (IP): Sotatercept
STUDY NUMBER: ACE-011-MDS-001
DATE FINAL: 12 Jun 2012AMENDMENT No. 1 DATE FINAL: 13 Sep 2012
AMENDMENT No. 2 DATE FINAL: [ADDRESS_476889] NUMBER: 2012-002601-22
IND NUMBER: 103362
SPONSOR NAME / ADDRESS: Celgene Corporation
[ADDRESS_476890]
Summit, NJ [ZIP_CODE]
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or 
consultant for review by [CONTACT_10825], your staff, and ethics committee/institutional 
review board.  The information contained in this document is regarded as 
confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by 
[CONTACT_27614].  Persons to whom the information is disclosed must be 
informed that the information is confidential and may not be further 
disclosed by [CONTACT_476].
&(/*(1(35l is providel is provide
nt for reviefor revie
w board.  Thw board.  T
fidential andential a
may not be may not be
law or reaw or r
infin35235,(7$5<,1)250$7,21013013
Augug20132013
0404AugAug 2020
2012-[ZIP_CODE]-0
1010
3535
(/(/(((((
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 2 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015MEDICAL MONITOR / EMERGENCY CONTACT [CONTACT_72620]:
Name : 
[CONTACT_1641]:
Address: [ADDRESS_476891], Summit, NJ [ZIP_CODE]
Phone:  
E-mail : 
Note: The back-up 24-hour global emergency contact [CONTACT_184636](s) or Medical Monitor or designee for 
emergency calls.
Back-up 24-Hour Global Emergency Contact [CONTACT_184637]: 
&(/*(1([ZIP_CODE],(7$5<,<,,1)250$7,210500
250
only be useonly be use
onitor or dnitor or d
1
<, 1
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 3 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_380802] [CONTACT_27616], I indicate I have reviewed this protocol and find its content to be 
acceptable.  
<< ,1)250$7,210$0$5000
d its contend its conten
<
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 4 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_27503]:_______________________________________
By [CONTACT_27616], I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from
Celgene representatives, the Declaratio n of Helsinki, International Conference on 
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations governing the conduct of clinical studies.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210$0$5000
s studys study  at m atyy
, informed nformed
ocedures, iedures, i
rnational Crnational
nes, and locs, and lo
7$7$
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 5 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015COORDINATING PRINCIPAL INVESTIGATOR [INVESTIGATOR_27504]:
By [CONTACT_27616], I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as needed.
&(/*(1([ZIP_CODE],(7$5<5<5<,1)wiwi1)250$7,210$0$[ADDRESS_476892]
5<
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 6 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015PROTOCOL SUMMARY
Title of Study
An open-label, randomized, Phase 2, parallel, dos e-ranging, multicenter study of sotatercept for 
the treatment of patients with anemia and low- or intermediate-1 risk myelodysplastic syndromes
or non-proliferative chronic myelomonocytic leukemia (CMML)
Indication
Low- and intermediate-1 (int-1) risk myelodysplastic syndromes (MDS) or non-proliferative 
CMML by [CONTACT_380731] (IPSS, Appendix B ) with anemia 
(hemoglobin [Hgb] â‰¤9.0 g/dL)
Objectives
The primary objective of this study is to deter mine a safe, tolerable, and effective dose of 
sotatercept that results in the greatest frequenc y of erythroid hematological improvement (HI-E) 
in patients with anemia and low- or int-1 risk MDS or non-proliferative CMML.
The secondary objectives of this study are to evaluate the:
1. Safety of sotatercept
2. Rate of red blood cell ( RBC) transfusion independence in transfusion-dependent subjects
3. Time to HI-E4. Duration of HI-E
5. Time to progression to acute myeloid leukemia (AML)
6. Time to progression to events of higher risk MDS (ie, int-2 or high-risk IPSS)7. Progression-free survival (PFS)
8. Overall survival (OS)
9. Pharmacokinetics (PK) of sotatercept
Study Design
This is an open-label, randomized, Phase 2, parallel, dose-ranging, multicenter study of 
sotatercept for the treatment of patients with low- and int-1 risk MDS or non-proliferative 
CMML, (IPSS, Appendix B ), with anemia requiring a transfusion (subjects should have received 
at least 2 units of RBCs within 84 days prior to study enrollment).
The study is comprised of 2 parts:
Part 1
Subjects will be stratified by [CONTACT_380732] (EPO, < 500 versus
â‰¥500 mIU/mL) and by [CONTACT_380733] 56 days prior to study enrollment (< 4 
units of RBCs versus â‰¥4 units of RBCs), and assigned randomly to one of two treatment groups,&(/*(1(label, randlabel, rand
or the treatmor the treatm
IPSS, SS, AppeApp
22unittssofofff
e studystudy is cis c
Part 1Pa35235,(7$5<,1)250$7,21ive ve
ectctive doseive dose
alal improve imprll
e eCMMLCMML
dence in traence in tra
d leukemia (leukemia 
higher riskhigher risk
FS)S)
K) of sotatK) of sot
bje(3
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 7 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015wherein they will be administered sotatercept subcutaneously (SC) 0.1 mg/kg or 0.3 mg/kg once
every 3 weeks (Q3W).
Enrollment will continue without hiatus beyond rando mization of five sub jects into each of the 
0.1 mg/kg and 0.3 mg/kg treatment groups.  Following treatment of five subjects in each of the 0.1 mg/kg and 0.3 mg/kg treatment groups (w ith the last subject for each group having 
completed at least one cycle of 21 days), all available safety and efficacy data will be assessed by 
a Steering Committee (Section 4.4).  Based upon the occurrence of dose- limiting tox icity (DLT) 
(Section 4.1.1 ) inâ‰¤1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 
0.5 mg/kg treatment group w ill begin inclusion in the ra ndomization scheme.
Following treatment of at least six subjects in the 0.5 mg/kg treatment group (with at least six 
subjects having completed at least three cycles of  21 days each), all available safety and efficacy 
data will be assessed by a Steering Committee from all dose levels.  Based upon the occurrence 
of DLT in â‰¤ 1/6 subjects in Cycle 1 in the 0.5 mg/kg treatment group and an acceptable safety 
profile from all dose levels, the 1.0 mg/kg treat ment group will begin inclusion in the 
randomizatio n scheme.  
Following treatment of at least six subjects in the 1.0 mg/kg treatment group (with at least six
subjects having completed at least three cycle s of 21 days each), all available safety and efficacy 
data will be assessed by a Steering Committee from all dose levels.  Based upon the occurrence 
of DLT in â‰¤ 1/6 subjects in Cycle 1 in the 1.0 mg/kg treatment group and an acceptable safety 
profile from all dose levels, the 2.0 mg/kg treat ment group will begin inclusion in the 
randomizatio n scheme.  The 2.0 mg/kg so tatercept dose was reduced to 1.5 mg/kg for ongoing 
and newly enrolled subjects (Amendment 4).
Intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation up to 
1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on assessment 
by [CONTACT_380734].  Enrollment will continue beyond 
randomization in all dose levels (unless dose level[s] is closed due to safety reasons or lack of 
efficacy as recommended by [CONTACT_40972]) until up to a total of 20 subjects in each dose level.  
Meetings of the Steering Co mmit tee are planned periodically throughout the study to review all 
available safety and efficacy data.  For any treatment group, if â‰¥40% of the subjects (minimum 
four subjects experiencing an event) experience a DLT of related (suspected) adverse event (AE)
â‰¥Grade 2 (other than Hgb or hyperten sion DLT as defined in Section 4.1.1 ), the Steering 
Committee may recommend the closure of the treatment group.
In addition, if > 33% of the s ubjects (minimum two subjects experiencing an event) experience 
Hgb > 12 g/dL (not influenced by [CONTACT_27752]) sustained for â‰¥7 days, confirmed by [CONTACT_380735] â‰¥1 week apart, the Steering Committee may recommend the closure of the 
treatment group.
Moreover, if > 33% of the subjects (minimum two subjects experiencing an event) experience a 
hypertension DLT (Refer to Section 4.1.1 ) confirmed by [CONTACT_380736] [ADDRESS_476893] be followed as defined in Section 4.1.1 ). he he 
st six six 
and efficacyand efficac
he occurrene occurre
ceptable saceptable 
ioion nin the in the 
nt group (wgroup (w
lllavailableavailablll
vels.  Basedels.  B
ent groupnt group aa
p will beginp will begi
seewas reduwas redu
maymay be addbe adyy
/kg or 1.5 m/kg or 1.5 m
afetafety y and efand e
rrent dose rent dose
less dose leess dose 
Steering CSteering C
Commitmmit tee
ficacy dataficacy data
encing an encing an e
than than HgbHgb
ayy recomm recommyy
n, if >if >33%33%
12 g/dL12 g/dL (n(n
ssments ssments â‰¥â‰¥
eatmeatm ent grent g
MoreovMoreov
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 8 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015Additionally, for an y treatment group that accrues a minimum of 10 subjects or less if 
recommended by [CONTACT_40972] (with the last subject having received at least one 
complete cycle of 21 days), in the absence of any sign of efficacy (defined as an increase of Hgb 
> 1 g/dL in the absence of transfusion or at least a 50% reduction in the transfusion requirementsif the reduction observed is less than 4 units), the Steering Committee may recommend the 
closure of the treatment group.
Upon completion of up to [ADDRESS_476894] frequency of HI-E.
Part 2Following the assessment of efficacy and safety  parameters in Part 1, 15 additional evaluable 
subjects will be enrolled in Part 2 (Expansion Cohort) and complete treatment at the dose level of 
sotatercept that demonstrates the greatest frequency of HI-E.
Steering Committee Recommendation
Based on the 02 Mar 2015 Steering Committeeâ€™s review of safety, efficacy and pharmacokinetic 
data of subjects enrolled in the Part 1 dose levels, including the sotatercept 2.0 mg/kg cohort level:
Part 1 - The sotatercept 2.0 mg/kg cohort was close d.  Ongoing and newly enrolled subjects are 
to be dose reduced to sotatercept 1.5 mg/kg.
Part 2 - Subjects enrolled into Part 2 (Expansion Cohort) will receive sotatercept at 1.0 mg/kg. 
This update is reflected in Amendment 4.
Total Number of Subjects: Up to approximately 75-115 evaluable subjects
Study Population
This is a study of patients with low- and int-1 risk MDS or non-proliferative CMML, with 
anemia.  Subjects will be aged ![ADDRESS_476895] documented diagnosis of MDS or non-
proliferative CMML (white blood cell [WBC] count â‰¤13,000 /mm3,World Health Organization
[WHO], Vardiman, 2009) that meets IPSS ( Appendix B ) criteria for low- or int-[ADDRESS_476896] 2 units of RBCs within 84 days of enrollment for Hgb â‰¤9.0 g/dL.  Subjects will have had no response or loss of 
response to prior treatment with rHu EPO ( â‰¥40,000 U/wk x 8), or darbepoetin alpha ( â‰¥500 mcg 
Q3W x 4), or low chance of response to erythroid-stimulating factors reflected by [CONTACT_380737] > 500 mIU/mL.
Length of Study
The study is comprised of the following periods:
Screening â€“ Assessments to be performed up to 28 days prior to enrollment (Day 1).
Treatment â€“ Comprised of five complete cycles of [ADDRESS_476897] a sustained Hgb increase or a decreased transfusion burden by [CONTACT_380738] 5, but for a period less than or equal to 8 consecutive weeks (potential late 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21evaluable evaluable 
the dose lethe dose le
ficacy and pi[INVESTIGATOR_380712] p
tatercept 2.atercept 2
oing ing and neand ne
hortort))will rewill
mately mately 75-75-
and and intint--1r1
18 y18 yearsearsana
ood cellood cell  [[llW
hhat mat meets eets
LL..  AnemiaAnem
oollment follment f
reatmeatm ent went w
ow chance ow chanc
concentraticoncentrat
of Studyof Study
studystudy iiys cs c
ScreeniScreeni ngng
reatreat
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 9 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015responders) may continue treatment for up to an additional three cycles (Cycles 6-8) for the 
purpose of meeting response criteria.
End of Treatment â€“ Assessments to be conducted upon:
Completion ( â‰¥ 5 cycles) of participation in the Treatment Period of the study, prior to the first 
dose of sotatercept in the Extension Period.
Early (< 5 cycles) termination of participation in the Treatment Period of the study, after last 
dose of sotatercept.
Extension â€“ After completing 5 cycles of treatment (or up to 8 cycles for potential late 
responders), subjects who qualify for the Extension Period (refer to Section 4.1.2 ) may enter the 
Extension Period and continue treatment ,subject to Rules for Delay, Reduction, and 
Discontinuation of Treatment (Section 8.2.1 ), until disease progression (PD), treatment failure, 
or other reason, as appropriate, listed in Section 12, Discontinuations.  Visits will be once Q3W
to coincide with the schedule of treatment administration.
End of Extension â€“ Assessments to be conducted upon completion of participation in the 
Extension Period of the study.
Follow-up â€“ Following the End of Treatment (last dose of sotatercept administered) in the
Treatment Period or the Extension Peri od, follow-up w ill include a pregnancy test approximately
[ADDRESS_476898] treatment; assessment of efficacy (ie, Hgb levels, transfusions) 
approximately [ADDRESS_476899]; assessment 
of PK at a single time point [ADDRESS_476900] treatment; assessm ent of antidrug antibody 
(ADA) repeated every [ADDRESS_476901] treatment; and assessment of progression to AML and OS every [ADDRESS_476902]â€™s first 
administration of sotatercept.
The End of Trial is defined as either the date of the last visit of the last subject to complete the
study, or the date of receipt of the last data point from the last subject that is required for
primary, secondary  analysis, as pre-specified in the protocol and/or the
Statistical Analysis Plan, whichever is the later date.
The sponsor may decide to end the trial when all key endpoints and objectives of the study have 
been analyzed, and the availability of a roll-over protocol exists into which any subjects that 
remain on study may be consented and continue to receive treatment with IP.  It must be the opi[INVESTIGATOR_380713](s) continue to receive benefit from 
treatment with IP.  
Study TreatmentsIn Part 1, subjects will be randomized to one  of up to five treatment groups (contingent on 
number of treatment groups open at time of randomization) to be administered sotatercept
0.1 mg/kg, 0.3 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg by [CONTACT_368083] Q3W for a total
of 5-8 complete cycles of 21 days each in the Tr eatment Period.  Subjects may continue to 
receive treatment at the same dose and frequency in the Extension Period if protocol-defined 
criteria are met (refer to Section 4.1.2 ).  enter the ter the 
mment fent failurailufff
ll be ll be onceonc
artirticipatcipa ion
rcept adminept admin
ude ude a apregnpre
Hgb levels,Hgb levels
ted once ped once p
ntntfofor MDSMDS
treatmenttreatment ;
er the last ter the last
up to [ADDRESS_476903] data pot data po
 anaana
ichever is thichever is t
to end the to end th
e availabiliavailab
ayy bbye consee conse
vestvestigator igator
h IP.IP.h    
eatmmentsnts
art 1, sart 1, s ubjecubje
umber of trumber of tr
0.10.1mg/kgmg/kg
ff5-85-8ff52
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 10 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015Intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation up to 
1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on assessment 
by [CONTACT_380739]. Based on the Steering Committee assessment of efficacy, safety and PK data in Part 1, the sotatercept 2.0 mg/kg cohort was closed 
with ongoing and newly enrolled subjects dose re duced to 1.5 mg/kg in Part 1; 15 additional 
evaluable subjects will be enrolled in Part 2 (Expansion Cohort)at the 1.0 mg/kg dose level of sotatercept (Amendment 4).
In both Part 1 and Part 2, after completing five cycles of treatment (or up to eight cycles for 
potential late responders), subjects who quali fy for the Extension Period (refer to Section 4.1.2 )
may enter the Extension Period and continue  treatment, subject to Rules  for Delay, Reduction, 
and Discontinuation of Treatment (Section 8.2.1 ), until PD, treatment failure, or other reason, as 
appropriate, listed in Section 12, Discontinuations.
Overview of Procedures
Procedures to be conducted in this study incl ude, but are not limited to, medical history, height, 
record of prior medications and tr eatments , MDS disease history (including dia gnostic, 
karyotype, cytogenetics, and historic mutational analysis information [ie,SF3B1, and other 
MDS-related molecular mutations]), baselin e assessments and prior MDS therapy (ie, prior 
ESAs, non-ESA therapy), transfusion log (for co llection of all prior trans fusions [ie, red blood 
cell, pl atelets, whole bl ood, etc]) from at least [ADDRESS_476904] of prior/current ther api[INVESTIGATOR_014]/procedures, record of AEs, 
physical examination, vital signs, weight, blood pressure, electrocardiogram (ECG), Eastern 
Cooperative Oncology Group (ECOG) performance status, hematology, serum chemistry,  
, serum erythropoietin, urinalysis, pregnancy testi ng, PK, ADA, MDS response 
assessment, bone marrow aspi[INVESTIGATOR_337], smear of peripheral bl ood, bone marrow biopsy,
.[IP_ADDRESS].2 ))
ductiducti on, on, 
her reason, her reason,
mededicalical hisl
luding diaguding dia
attioin [i[ie,e,SFS
prior rior MDS M
llll priprillor trantra
prior to enrorior to enro
sion sio Hgb leHgb le
ent therapi[INVESTIGATOR_380714], pressure el
mance statumance stat
is, pregnans, pregnan
ar of perir of peri phpii
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 11 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015TABLE OF CONTENTS
TITLE PAGE ..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1. INTRODUCTI ON..................................................................................................17
1.1. Sotatercept for Treatment of Anemia in Lower (Low- or Intermediate-1) 
Risk MDS...............................................................................................................17
1.2. Sotatercept ..............................................................................................................19
1.2.1. Pharmacology Studies .............................................................................................19
1.3. Summary of Clinical Experien ce ............................................................................22
1.3.1. A011-01:  A Phase 1a Study in Healthy Postmenopausal Women (Single-
Dose)......................................................................................................................22
1.3.2. A011-02:  A Phase 1b Study in Healthy Postmenopausal Women (Multiple 
Doses) ....................................................................................................................23
1.3.3. A011-04:  A Phase 2a Study in Patien ts with Osteolytic Lesions of Multiple 
Myeloma ................................................................................................................25
1.3.4. A011-08: A Phase [ADDRESS_476905] IVES ...........................................................................................41
2.1. Primary Objective ...................................................................................................41
2.2. Secondary Ob jectives .............................................................................................41
3. STUDY ENDPOI NTS............................................................................................43
3.1. Primary Endpoint ....................................................................................................43
3.2. Secondary Endpoints ..............................................................................................43
4. OVERALL DESIGN OF THE STUDY..................................................................45
4.1. Design of Study......................................................................................................45
4.1.1. Dose- limiting Toxicity ............................................................................................48&(/*(STUDYSTUDY
PrimPri
.2..2.(1(3523.......................
.....................
ECTIVESTIVE
ObjectObject iveive.
ndaryndary  ObjecObjecyy
*(135,(7$5<,1)250$7,217
.....191
................ 1919
........................
n (Singlen (Single --
.....................
WoWomemen (Mn( M
........................
olytolytic Lesioic Le
........................
MetastatiMetastati cc
..........................50
,(75,(35,
&235
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 12 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476906]
[IP_ADDRESS].
[IP_ADDRESS].1)250$7,2199
.......656
..............656
.........................
..........................
..........................
1)
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 13 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 201510.6. Analysis of Efficacy ...............................................................................................79
10.7. Analysis of Sa fety...................................................................................................81
10.8. Interim Analy sis .....................................................................................................81
10.9. Pharmacokinetics ....................................................................................................82
10.10. Other Topi [INVESTIGATOR_1102]...........................................................................................................82
11. ADVERSE EV ENTS..............................................................................................83
11.1. Monitoring, Recording and Re porting of Advers e Even ts ....................................... 83
11.2. Evaluation of Adve rse Events.................................................................................83
11.2.1. Se riousness............................................................................................................. 83
11.2.2. Severity / In tensity..................................................................................................[ADDRESS_476907]/Independent Ethics Committee Review and 
Approval ................................................................................................................92&(/*(1([ZIP_CODE],(7$5<,1)250$7,2133
.......838
..............838
.........................
..........................
..........................
..........................
..........................
..................
.........................
..........................
.........................
........................
EventsEvents .....
.................
of Adverse of Adverse 
TIONSIONS ...
Y PROCEDPROCE
cycyContact[CONTACT_380740] C
Invenv
[IP_ADDRESS].
[IP_ADDRESS].
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 14 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476908] / Ethics Committee ................93
14.8. Closure of th e Study ...............................................................................................93
15. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] .....................................................94
15.1. Data/Documen ts .....................................................................................................[ADDRESS_476909] Reten tion....................................................................................................94
16. QUALITY CONTROL AND QUALITY ASSURANCE ........................................96
16.1. Study Monitoring and S ource Data Veri ficatio n......................................................96
16.2. Audits and Ins pections............................................................................................96
17. PUBLICATIONS ...................................................................................................97
18. REFERENCES.......................................................................................................98
19. APPENDICES ......................................................................................................101
Appendix A: The World Health Organization (WHO) Classification of the Myeloid 
Neoplasms and Leuk emia (Vardima n, 2009) .........................................................101
Appendix B: International Prognostic Scoring System for MDS (Greenberg, 1997) ..............102
Appendix C: International Working Group (IWG) Response Criteria in Myelodysplasia 
(Cheson, 2006) .....................................................................................................103
Appendix D: ECOG Performance Status Scale .....................................................................105
Appendix E: [LOCATION_001] Heart Association âˆ€Classification of Heart Failure .........................106
Appendix F: National Cancer Institute (NCI) Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0..................................................................107
Appendix H: Cockcroft-Gault Estimation Of Creatinine Clearance (Crcl) .............................109
&(/*(1(352ulult Est Eslltimattimat235,(âˆ€âˆ€5,(7$5<,1)250$7,2144
.......969
..............969
.........................
..........................
..........................
..........................
ion of the Mon of the
...............
MDS (GreeMDS (Gre
ponse Criteponse Cri
.........................
.....................
ClassificClassific
(NCI) Com(NCI) C
) Version 4) Versio
523
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 15 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476910] OF TABLES
Table 1: Hemoglobin, Mean Change from Baseline (Study A011-02, a Phase 1b 
Study in Healthy Postmenopausal Women) .............................................................24
Table 2: Adverse Events Reported in â‰¥ 5 % Percent of Subjects Overall (Study A011-
04)..........................................................................................................................27
Table 4: Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for â‰¥ 28 Days (Study A011-04)...............................................................28
Table 5: Primary Efficacy Analysis: Subjects with Hemoglobin Increase from 
Baseline of at Least 1 g/dL for 28 Consecuti ve Days â€“ Per Protocol Set, 
Central Laboratory Results  (Study A011-08) ..........................................................30
Table 7: Schedule of Assessments ........................................................................................54
Table 8: Rules for Delay, Reduction, and Discontinuation of Treatment ...............................71
Table 9: Sotatercept Dose Reduction Levels .........................................................................72
Table 10: 95% Confidence Intervals for Selected Sample Sizes and Response Rates ..............78
&(/*(1([ZIP_CODE],(7$5<,1)..........................
reatmenteatment
................ ....)250$7,21........2828
.....................
ple Sizes ane Sizes )21)2
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 16 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476911] OF FIGURES
 
 
 
 
 
Figure 4: Design of Study ......................................................................................................46
&(/*(1([ZIP_CODE],(7$5<,1)250$.......................... 40$7,210$7
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 17 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE]. INTRODUCTION
Myelodysplastic syndromes (MDS) are a spectrum of hematologic malignancies characterized 
pathologically by [CONTACT_18451] m orphologic dysplasia and clinically by [CONTACT_380741] . There is considerable variation in both the 
clinical manifestation and severity of individual disorders within this group, ranging from the 
relatively mild and painless condition of refractory anemia (RA) to the much more severe 
refractory anemia with an excess of blasts (RAEB) that often progresses to acute leukemia 
(Heaney, 1999).  The current treatment algorithm is based dominantly on risk stratification using the International Prognostic Scoring System (IPSS, Appendix B , Greenberg, 1997 ). In patients 
with low- or intermediate-1 (int-1) risk groups by  [CONTACT_380742] ( Komrokji, 2011 ).
More than 90% of patients diagnosed with MDS will have anemia during their course of disease; 
and 30%-50% of patients will be transfusion-dependent. Red blood cell (RBC) transfusion 
dependence is an independent adverse prognostic factor in MDS ( Komrokji, 2011 ).  Anemia in 
MDS results from ineffective erythropoiesis. Accelerated apoptosis is the hallmark of early 
disease, while up-regulation of survival signals and clonal evolution are features of higher risk 
disease. Impaired clonogenic growth of pr imitive erythroid progenitors and impaired 
erythropoietin r eceptor signaling are major causes of anemia. Inflammatory cytokines and 
immune suppression within the microenvironment amplify accelerated apoptosis and the inherent 
defective erythroid maturation. Options for treating anemia in low- or int-1 risk MDS are limited. Erythroid-stimulating agents (ESAs) offer response rates of 20%-40%. Lenalidomide,
in non-deletion (5q) (non-del [5q]), lower risk MDS transfusion independence (TI), response 
rates are 26% with TI response duration less than a year ( Raza, 2008 ). Azacitidine and 
decitabine yield hematological improvements in approximately 40% of patients; however, most 
patientsâ€™ responses are typi[INVESTIGATOR_380715]. Although bone marrow transplantation 
(BMT) can cure low and int-[ADDRESS_476912] majority of patients with low-
or int-1 risk MDS will remain RBC transfusion- dependent and succumb from complications of 
the disease or iron overload rath er than progression of the disease.  There is an unmet need to 
develop novel agents for treating anemia in lower risk non-del (5q) MDS ( Komrokji, 2011 ).
1.1. Sotatercept for Treatment of Anemia in Lower (Low- or
Intermediate-1) Risk MDS
Treatment with sotatercept resulted in increased hematocrit (HCT), hemoglobin (Hgb), and 
absolute RBC number in both nonclinical and clinical studies.  The rapid and sustained increases 
in Hgb and HCT were observed in two Phase 1 studies in healthy volunteers, a Phase 2a study in subjects with multiple myeloma (MM), and a Phas e [ADDRESS_476913] cancer. The 
ability for sotate rcept to increase rapi[INVESTIGATOR_380716].
In Phase 1 single-dose and mu ltiple-dose studies of sotatercept in postmenopausal women 
(Studies A011-01 and A011-02, respectively), a Phase 2 study in subjects with osteolytic lesions &(/*(1([ZIP_CODE],(7$5<,1)250$7,21n using using 
patients patients 
atatioion of n of 
r course ofcourse of
RBC) transfBC) transf
okjikji, 2011, 201 )
is the hallms the hallm
on are featun are feat
ogenigenitors antoiii
a. . InflammInflamm
fy acceleraty accelerat
nemia in nemia in lolo
response raresponse 
MDS transfuMDS transfu
han a year han a year 
nts in approts in appr
duratidurati on.on
MDS, given DS, giv
the significthe signif
n the majon the majo
n RBC n RBC trat
ad rather thad rathe
for treating or treating
aterceptatercept ff
ntermeerme diadi
nt with sotawith so
tte e RBCRBC nu
Hgbgband HCand H
subjects wiubjects wi
abilitbility y fo
nic
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 18 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015associated with MM that examined  concurrent administration of sotatercept with melphalan, 
prednisolone, and thalidomide (MPT) anti-m yeloma therapy (Study A011-04), and a Phase [ADDRESS_476914] effects of sotatercept were dose-
dependent and time-dependent.  These Phase 1 and Phase 2 clinical data are consistent with the 
increased hematologic parameters observed in nonclinical studies. Results from the four completed clinical studies A011-01, A011-02, A011 -04, and A011-08 are summarized in the
Section 1.3,Summary of Clinical Experience.
Although the mechanism(s) underlying the stimulat ory effect of sotatercep t on eryth ropoiesis is
not fully understood, the result of clinical experience in healthy subjects showed a rapid and 
sustainable increase in mature erythrocytes released into circulation, suggesting that this impacts 
late stages of eryt hropoeisis.   
 
  
 
 
Activin Receptor Signaling
The activins (A-E) are a group of proteins that form dimers and heterodimers.  All are part of the 
superfamily of transforming growth factor- Î² (TGF-Î²) proteins.  The activin first described, 
activin A was initially identified as a gonadal differentiation factor involved in modulating 
secretion of follicle-stimulating hormone (FSH) from the pi[INVESTIGATOR_2117] ( Ying, 1988 ).  Subsequently, 
the pleiotropic nature of activin A has become more apparent ( Woodruff, 1998) .  There is a 
growing body of data suggesting a role for activins in bone remodeling, specifically as a negative 
regulator of bone growth ( Perrien, 2007 ).  Before the two molecules were shown to  be id entical 
(Rivier, 1985 ), activin A was also descri bed as erythroid differentiation factor (EDF), effecting 
the maturation and differentiation of RBCs ( Murata, 1988) .  The mechanism(s) by [CONTACT_380743] 
A influences erythropoiesis r emains under investigation and, in fact, there are data from in vitro 
and in vivo studies that support erythropoiesis-stimu latory ( Shiozaki, 1992; Shiozaki, 1989 ) and 
erythropoiesis-inhibitory effects ( Nakao, 1991 ).
The high-affinity activin type II receptor (ActRIIA) binds a number of ligands in the TGF- Î²
superfamily including activins A and B, myos tatin, and other growth differentiation factors 
(GDFs), as well as a num ber of the bone morphogenetic protein (BMP) family members.  The 
ligand-bound ActRIIA then recruits the low-affinity Type I receptor (ActRIA or ALK-4) and 
then the receptor heterocomplex, through its cytoplasmic protein kinase activity, activates the SMAD sign aling cascade to eventually influence nuclear transcriptional f actors ( Chen, 2002; 
Mathews, 1994 ).  The competitive binding of activin recep tor ligands in the blood and tissues by 
[CONTACT_380744]  
.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21esisesiisis
id and d and 
at tht thisisimpaimpa
mers and hmers and h
Î²)Î²)proteinprotein s
fferentfferent iatiio
H) fromH) from  thethemm
me memomore are a
for activinsfor activin
[ZIP_CODE]).  Befor).  Be
described describe
oon of RBCn of RBC
remains unremains 
upport eryupport e ty
oryry effects (effects yy
activin tctivin t ypeype
cludingcluding actai
well as a nuwell as a nu
und ActRInd ActRI
he receptor he receptor 
ADADsignalisignali
Mathews, 1Mathews, 1
thhe sotate sota&25)251)21),1)<, 1
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 19 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE].2. Sotatercept
Sotatercept (ActRIIA-IgG1Fc) is a fusion pr otein consisting of the extracellular domain (ECD) 
of activin receptor IIA (ActRIIA) fused to the human IgG1 Fc domain, which includes the heavy 
chain hinge and constant domains CH2 and CH3.  The ECD sequence of ActRIIA is  completely 
conserved among numerous species including mouse, rat, cynomolgus monkey, and humans;thus mouse, rat, and cynomolgus monkeys have been considered relevant species for nonclinical 
evaluation of sotatercept.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  (1(*(1/*((/*(/&(&(&35,(7$5<,1)250$7,210$50$250
,1)<, 1<, 15<$5<7$57$(7$5,(7$7$7
352352335235(3 5(31(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 20 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 &(/*(1([ZIP_CODE],(7$5<,1)250$7,217$70$0$
250)251)21),1)
5<$5<7$5(7$5,(35,(352352335235(3 5(31((1(*(1*(/*(&(&(&
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 21 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
.5235,(7$5<,1)250$7,21$0$5050250)251)21),1)<, 15<
(7$5,(75,(35,235523535(3 5(31((1(*(1*(/*(/*&(/&(&&
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 22 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
 
 
 
 
 
 
 
1.3. Summary of Clinical Experience
1.3.1. A011-01:  A Phase 1a Study in Healthy Postmenopausal Women (Single-Dose)
Sotatercept was first studied in a Phase 1a,  single center, randomize d, double-bli nd, placebo-
controlled, single-dose, dose-escalation study in healthy, postmenopausal women ( Ruckle, 
2009 ).  Sotatercept was diluted in normal saline was administered as an IV infusion (over 
approximately 1 hour) or as a SC injection on Da y 1.  Dose levels were 0.01, 0.03, 0.1, 0.3, 1.0, 
and 3.0 mg/kg IV and 0.03 and 0.1 mg/kg SC.  A total of 48 subjects were enrolled; five active 
and one placebo subject at each of the IV and SC dose levels.  All subjects were followed for 4months following a single-dose administration.  
The pharmacokinetic (PK) profile of sotatercept was linear.  The overall mean exposure (AUC) 
was proportional to doses (0.01 to 3.0 mg/kg IV, and 0.03 and 0.1 mg/kg SC).  Across IV doses ranging from 0.1 through 3.0 mg/kg, the mean CL ranged from 0.092 to 0.128 mL/h/kg, the 
volume of distribution ranged from 73.7 to 110 mL/kg, and the mean terminal half-life in serum 
(t
1/2, z) ranged from 23.7 to 31.8 days, with no apparent dependence on dose.  After SC 
administration of 0.03 and 0.1 mg/kg, sotatercept was completely absorbed, and the mean t 1/2,z 
was approximately [ADDRESS_476915] commonly occurring (ie, those occ urring in more than [ADDRESS_476916] in an y treatment 
group) treatment-emergent adverse events (AEs) were  headache, infusion site reaction, injection 
site hemorrhage, and toothache.  The majority of the injection site reactions and injection site 
hemorrhages were in the first IV cohort and were related to infiltration of the IV site.  The majorities of treatment-emergent AEs were mild in severity and were j udged to be unrelated to 
sotatercept.  No death, serious AE (SAE), or AE leading to discontinuation was reported.  
Changes in RBCs, Hgb, reticulocytes, liver function tests, glucose, uric acid, amylase, and lipase occurred in some subjects.  Mild, transient elevations in pancreatic enzymes, liver enzymes, or 
glucose were reported as AEs in five subjects.  
There were no clinically significant changes from baseline in vital signs, physical examination, 
endocrine function, or electrocardiogram (ECG).  Preservation of adrenal cortical function was 
monitored through evaluation of serum electrolytes  (sodium and potassium) and through cortisol 
response to adrenocorticotropic hormone (ACTH) stimulation.  omen (Singmen (Sing
doubldoubl e-e-blinbli
pausal usal wowm
d as an IV ias an IV
vels were 0vels were
8 subjects wsubjects
eveevels.  All sls.  Al
was linear. was linear
IV, V, and and 0.00.0
ean CL ranan CL ran
to 110to 110 mLm
, wi, withthiinnhho a
/kg, sotaterkg, sotater
hhnnhho apparo appar
ringng(i(ie, thoe, th
ent adverseent adver
toothache. toothache
in the firstin the first
atmentatment -em
No death, sNo death, s
n RBCsRBCs , H, H
d in sod in so me me
cose were rose were r
There wereThere were
endocrinndocr
i0$7,21$7$0$7
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 23 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015No clinically significant finding was observed at doses up to 3.0 mg/kg IV, and sotatercept was 
well tolerated in healthy, postmenopausal women in single doses up to 0.1 mg/kg SC and 3.0 
mg/kg IV, the highest dose tested in this study.  
1.3.2. A011-02:  A Phase 1b Study in Healthy Postmenopausal Women (Multiple 
Doses)
Study A011-02 was a Phase 1b, single-center, randomized, double-blind, placebo-controlled, 
multi-dose, dose-escalation study to evaluate the safety, tolerability and pharmacodynamics of 
sotatercept in healthy postmenopausal women.  Four cohorts of 10 subjects each were planned at 
the following doses: 0.1, 0.3, 1.0, and 2.0 mg/kg administered SC.  Within each cohort, subjects were to be randomized to either active or placebo treatment in an 8:[ADDRESS_476917] in the 
1.0 mg/kg cohort experienced an SAE of progre ssive and persistent hypertension that was 
attributed to a rapid and significant increase in both Hgb (up to 20 g/dL) and HCT (up to 57.3%).  
Due to symptoms of headache, nausea, eye pain, dizziness, and vomiting approximately [ADDRESS_476918] was hospi [INVESTIGATOR_380717] 2 
hypertension.  Head magnetic resonance imaging (MRI), fundoscopy, and ECG were performed 
and were reported as normal. The hypertension was monitored and initially managed with 
antihypertensive medication.  The headache resolved following corrective treatment by 
[CONTACT_40145].  The SAE resolved on Day [ADDRESS_476919] received aspi[INVESTIGATOR_380718].  Further 
details can be found in the Investigatorâ€™s Brochure . In addition, two subjects who were treated 
with sotatercept 1.0 mg/kg showed increases in Hgb but were asymptomatic at the time of the consultation and underwent prophylactic phlebotomies.
Based on the magnitude of the hematopoietic response, the Sponsor suspended dose escalation to 
the 2.0 mg/kg dose and further dosing in all cohorts as a result of this dose- limiting SAE of 
hypertension, attributed to a pharmacodynamic eff ect at the 1.0 mg/kg dose level.  A total of 31 
subjects were enrolled and treated.  Doses of sotatercept administered included 0.1, 0.3, and 1.0 
mg/kg (Cohorts 1, 2, and 3 respectively).  All subjects randomized to active treatment in Cohort [ADDRESS_476920], 
and RBCs were observed (see Table 1 below for changes in Hgb):
&(/*(d tt*(1([ZIP_CODE],(7$5<,1)250$7,21ed at ed a
ubjects bjects 
were to ere to 
doses.  All doses.  All 
ed SAE waed SAE w
ne subject inne subject i
pertensipertensi onon
g/dL) and HL) and H
omitming apga
oninitoritoriiing anng
undoscopy,ndoscopy
nitored andtored ani
fofollollwing wing 
detectidetecti on on 
 The hypeThe hyp
catcatioion.  Fon.  Fo
y and continand continyy
râ€™s Brochurs Brochur
increases inncreases 
hylacthylact ic phic ph
he hematophe hematop
urther dosinrther dosin
d to a pharmd to a phar
ed and tread and trea
1, 2, and [ADDRESS_476921]
mized to pmized to 
oollollowing awing a
and RBCnd RBC
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 24 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015Table 1: Hemoglobin, Mean Change from Baseline (Study A011-02, a Phase 1b Study 
in Healthy Postmenopausal Women)
Evaluation Time PointMean Change from Baseline (g/dL)
Placebo
(N=7)aSotatercept
0.1 mg/kg
(N=8)Sotatercept
0.3 mg/kg
(N=8)Sotatercept
1.0 mg/kg
(N=8)
Baseline Mean, pre-Dose 1 13.20 13.11 13.30 12.71
Day 8 0.17 0.68 0.85 1.21
Day 15 -0.27 0.43 0.44 1.75
Day 29 0.27 0.61 1.21 2.68b
Day 36 0.56 0.64 1.89 2.96
Day 43 -0.02 0.89 1.21 2.85
Day 57 0.27 1.28 1.64b2.09
Day 64 0.53 1.11 2.49 2.21
Day 71 -0.10 1.34 2.09 1.66
Day 85 0.38 1.18b2.55 1.86
Day 92 0.00c1.04 1.60c3.80c
Day 99 -0.20 1.21 3.20c1.28c
Day 113 -0.02 1.30 1.29 1.04
Day 141 0.30 0.95 0.34 2.30
Day 169 0.20c0.06 - 2.00c
aThe number of placebo subjects with data decreases over time as a result of the early termination of the study (ie, 
there were placebo subjects in each dosing cohort).  There were seven placebo subjects with data at baseline, Days 8, 15, and 36; six subjects with data at Days 29, 43, 57, and 85; five subjects with data on Days 71 and 113; four subjects with data on Day 64; three subjects with data on Day 141; two subjects with data on Day 99; and one 
subject with data on Days 92 and 169.
bNumber of doses administered per treatment group:  0.1 mg/kg, four doses; 0.3 mg/kg, three doses; 1.0 mg/kg, two doses.  Data beyond this study day were considered follow-up results.
cn=1.
-Data not available.
Source: CSR A011-[ADDRESS_476922] notable 
AEs were those related to increases in hematologic laboratory measures in the 1.0 mg/kg dose 
group: HCT, Hgb, and RBC count.  The AEs of increased Hgb and/or HCT were reported for seven of the eight subjects in this dose group.  These events were reported as mild or moderate 
elevations; all were considered probably related to  study drug treatment.  Three of the subjects in 
the 1.0 mg/kg group with elevated Hgb underwent phlebotomies and all Hgb elevations resolved by [CONTACT_1008]-up period.  No eryth roid lineage AEs were reported in the 0.1 or 0.3 &(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$71.7575$7$7$7
2.682.68bb0$
2.995022225)264bb)2)2)2)2
2.492.491
2.09<,5555<$544$5$5$5$51.211.217$1.301.30(7
005,(350353535233533 ta decreases decreases 
osing cohortosing cohort
ta at Days 29ta at Days 2
hree subjectsree subjec
2 and 169. and 169
tered per treatered per tre
is study day  study day
ee..
111-02-02ini--textex
han thhan th e SAeS A
s were thoswere thos
group: HCTroup: HCT
seven of even of 
vatt
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 25 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015mg/kg treatment groups.  Hemoglobin for all subjects with elevations returned to within normal 
limits by [CONTACT_2054].  
Paresthesia and dizziness were reported more frequently in the sotatercept groups, though the 
events were < Grade 2 and generally not considered drug related.  Other frequently reported events (eg, fatigue, upper respi[INVESTIGATOR_4416]) di d not appear to increase with dose and were 
generally mild.  
Adrenal cortical function was monitored through evaluation of serum electrolytes (sodium and 
potassium) and through cortisol response to ACTH stimulation.  All ACTH stimulation test 
results were normal.  
The PK profile of sotatercept was linear after SC administration.  Both AUC
0-28dand maximum 
concentration (C max) were dose proportional from 0.1 to 1.0 mg/kg following the first SC 
administration.  The t 1/2, z of sotatercept following the last dose in all three dose groups was 
identical, with mean t 1/2, z being approximately 23 days.  Based on one-compartmental modeling, 
the mean apparent total clearance (CL/F) ranged from 3.05 to 3.90 mL/d/kg and the mean 
apparent volume of distribution (Vz/F) range d from 97.47 to 103.03 mL/kg, with no apparent 
dependence on dose.  
Bone mineral density was assessed by [CONTACT_751]- energy X-ray absorptiometry (DXA).  A 
dose-dependent increase in the BMD of the total hip from baseline to end of study was observed, 
with a significant and rapid increase of 2.4% in the 1.0 mg/kg dose group, compared to a 0.7% decrease in the placebo group.  Bone mineral density  results for lumbar spi[INVESTIGATOR_380719] 0.4% to 1.0% from baseline to study end in all active treatment groups, compared 
with a 0.5% decrease in the placebo group.
1.3.3. A011-04:  A Phase 2a Study in Patients with Osteolytic Lesions of Multiple 
Myeloma 
Study A011-04 was a Phase 2a, multi-center, randomized, double-blind, placebo-controlled, 
multiple-dose, parallel group, dose-escalation study  to evaluate the safety, tolerability, and 
efficacy of sotatercept in subjects with osteolytic lesions of MM.  
In this study, subjects were randomized in a 4:1 ratio to one of three doses of sotatercept (0.1, 
0.3, and 0.5 mg/kg) or placebo, administered every 28 days by [CONTACT_10530], for up to four doses 
over a 3-month period. Sotatercept was evaluated in combination with the anti-myeloma therapy 
of melphalan (4 mg/m
2on Days 1 to 7), prednisolone (40 mg/m2on Days 1 to 7), and 
thalidomide (100 mg per day) (MPT). The sites, Sponsor and Sponsor representatives were 
blinded to treatment assignment.  
Thirty subjects were randomized and received at least one dose of study treatment: si x subjects 
received placebo, 24 subjects received sotatercept (eight subjects per dosing cohort [0.1, 0.3, and 
0.5 mg/kg sotatercept]).  Twenty-six (86.7%) s ubjects completed the study.  Two subjects 
discontinued study treatm ent due to AEs, including one subject in each of the 0.1 and 0.5 mg/kg 
dose groups.  Two subjects discontinued study tr eatment due to non-AE reasons including one 
subject in the 0.1 mg/kg dose group who withdrew consent and was discontinued, and one subject in the 0.3 mg/kg dose group who was discontinued at the request of the investigator.  
In this study, 50.0% of subjects were female and the mean (range) age was 60.9 (41 to 79) years.  &(dii&(/*(1([ZIP_CODE],(7$5<,1)250$7,21mmaximum aximum 
st SC st SC 
groups wasgroups was
artmemnttalalmml
g and the mg and the m
L/kg, wikg, wi thtiinh
tiommetry (D(Dy
eline to endeline to e
/kg dose grg dose g
ullts fts flllor lor lfffumull
in allin a  activactivl
Patients wiPatients w
-center, ran-center, ran
escalatscalat ioionn
ts wits wi ththiii ososhhtete
randomizedrandomiz
acebo, admacebo, a
.SotaterceSotaterce
g/mg/m22mon Daon Da
0 m0 mg per dg per dm
atment assiatment ass
bjects wereects were
ed placeboed placebo
mg/kg sotamg/kg sot
scontinuescontinue
dose grodose gr
bje
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 26 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015The mean time since diagnosis of MM was 3.3 years, the majority of subjects had stage III MM 
disease at screening (83.3%) and had received prior chemotherapy (93.3%).  A total of 43.3% of 
subjects were receiving bisphosphonates at screening, which continued during the study.  
Fourteen out of 24 subjects (58%) who received sotatercept received three doses or more (four 
out of eight subjects in the 0.5 mg/kg dose cohort, five out of eight subjects in the 0.3 mg/kg 
dose cohort, and five out of eight subjects in the 0.1 mg/kg dose cohort).  
 
 
 
 
 
 
 
 
 
Table [ADDRESS_476923] frequent AEs â‰¥5% in all treatment groups  
  
&(/*(1([ZIP_CODE],(7$5<,1)250$7,215% in all tr5% in all t$70$50$[ZIP_CODE])21)2,1)<, 1<, 15<$5<7$5(7$(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 27 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015Table 2: Adverse Events Reported in â‰¥ 5 % Percent of Subjects Overall
(Study A011-04)
Sotatercept Treatment Group
Placebo
(N=6)0.1 mg/kg
(N=8)0.3 mg/kg
(N=8)0.5 mg/kg
(N=8)All Sotatercept
(N=24)
Preferred 
TermaAny 
Grade Grade â‰¥3Any 
Grade Grade â‰¥3Any 
Grade Grade â‰¥3Any
Grade Grade â‰¥3Any
Grade Grade â‰¥3
Subjects with 
â‰¥one AE1 (16.7%) 5 (62.5%) 3 (37.5%) 7 (87.5%) 15 (62.5%)
Neutropenia 1 (16.7%) 2 (25.0%) 2 (25.0%) 3 (37.5%) 7 (29.2%)
Leukopenia 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%) 2 (8.3%)
Granulo-
cytopenia0 (0.0%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 3 (12.5%)
Anemia 0 (0.0%) 1 (12.5%) 1 (12.5%) 1 (12.5%) 3 (12.5%)
RTI 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (4.2%)
Thrombo-
cytopenia0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 1 (4.2%)
Pyrexia 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
BP increased 0 (0.0%) 1 (12.5%) * 0 (0.0%) 0 (0.0%) 1 (4.2%)
Bronchitis 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Compression 
fracture0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Pathological 
fracture0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 1 (4.2%)
BP = blood pressure; RTI = respi[INVESTIGATOR_1092].
aAdverse events (AEs) were those that were treatment-emergent, defined as newly acquired or worsened during or after 
administration of first dose of study treatment. A subject with multiple occurrences of an AE counted only once under each 
preferred term. 
* Indicates the adverse event was assessed by [CONTACT_325697] (possibly, probably, or definitely) to study drug 
(sotatercept or placebo).  
&(/*(1([ZIP_CODE],35353535mentent--emergentemergen
A subject wiA subject w
by [CONTACT_380745],(7$5%))55$5(0.0%)(0.0%)$5$5$5$50 (0.0%)0 (0.0%)7$$$
($
00,((((<,1)222.5%).5%))2)2)2)20 (0.0%)0 (0.0%)1)2)2)2)
1 (12.5%1 (12.1
0<
5,($5< ,50$7,[ZIP_CODE].5%)62.577$77 (29.2%)7 (29.2%0$$0$
2 (8.32 (8000$[PHONE_7921]
)250
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 28 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476924] dose of 
sotatercept/placebo and sustained for â‰¥ 28 days from baseline at any time as presented in 
Table 4 .
Table 4: Number of Subjects with an Increase in Hgb from Baseline at Any Time and 
Sustained for â‰¥28 Days (Study A011-04)
Increase in 
HemoglobinDose Sotatercept/Placebo
0.1 mg/kg
(N=8)0.3 mg/kg
(N=8)0.5 mg/kg
(N=8)Placebo
(N=6)Overall
(N=30)
â‰¥1.0 g/dL 5 3 7 4 19
â‰¥1.5 g/dL 3 3 5 2 13
â‰¥2.0 g/dL 2 3 2 0 7
Source: Table [IP_ADDRESS] , Clinical Study Report A011-04 .
Improvements in hip bone mineral density were observed in selected sotatercept dose groups. A 
mean percentage increase from baseline in hip BMD was observed in the 0.1 mg/kg and 0.3 
mg/kg sotatercept dose groups at Days 85 and 169/early termination; whereas, the placebo group showed a mean percentage decrease at both time points.
As with serum bone biomarkers, the BMD results  tended to be more variable in subjects who 
were on bisphosphonates. In subjects who were not taking bisphosphonates, a maximum mean &(/*(1([ZIP_CODE],(7$aftafter adminer admin
yys fs fromromf  bas basmm
with an Incrith an Inc
Days (Studays (Stu
52 g/kkggkkk
N=8N=8)0.[PHONE_7922]
55(
331(((((1**(*able [IP_ADDRESS] [IP_ADDRESS]
mprovemprovemm enen
mean percmean perc
mg/kg mg/kg,21
7$5<,1)250$7,2
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 29 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476925] BMD parameters (total, hip, and lumbar spi[INVESTIGATOR_050]) in most 
sotatercept dose groups; whereas, there was a maximum mean percent decrease in the placebo 
group.  Further, substantial improvements in BMD were observed in some subjects, and these 
improvements were more likely to occur in subjects who received the full course of sotatercept treatment.  Review of individual data showed that 8/24 (33.3%) subjects who received 
sotatercept had a â‰¥ 5% increase from baseline in spi[INVESTIGATOR_380720].  Further, a â‰¥ 5% increase in BMD was observed in 4/6 subjects who 
received all four sotatercept doses versus 2/8 subjects who received three doses and 2/10 subjects 
who received one or two doses.  One of 6 (16.7%) subjects who received placebo also showed a 
â‰¥ 5% increase in spi[INVESTIGATOR_380721].
Taken together, these data, suggest a beneficial pharmacodynamic effect of sotatercept on 
erythropoiesis in a patient population with cancer CIA.
1.3.4. A011-08: A Phase [ADDRESS_476926] cancer. Subjects were randomized to one of three sotatercept (0.1, 0.3, and 
0.5 mg/kg) treatment groups or to a placebo treatment group. Planned enrollment included 30 subjects in each of the three sotatercept treatment groups and 15 subjects in the placebo 
treatment group (2:2:2:1 ratio). Study treatment  was administered vi a SC injection every 
28 days for up to 4 treatments (Days 1, 29, 57, and 85). Subjects were administered concurrent 
treatment with a myelosuppressive chemotherapy regimen for metastatic breast cancer per 
standard of care at the study site.
Due to changes in guidance for the treatment of CIA and a slower than expected rate of 
enrollment, the study was termin ated after [ADDRESS_476927] one dose of treatment: five subjects in the placebo treatment group, eight 
subjects in the sotatercept 0.1 mg/kg treatment group, 10 subjects in the sotatercept 0.3 mg/kg treatment group, and seven subjects in the sotatercept 0.5 mg/kg treatment group. The majority 
of subjects (29/30 [96.7%]) were white; all of the subjects were female; with a median age of 51 
years; and age ranged from 32 to 74 years. Demographic characteristics were similar across treatment groups.
Fourteen of 30 (46.7%) subjects completed study treatment. Fourteen  subjects in the three 
sotatercept treatment groups combined and two subjects in the placebo treatment group prematurely discontinued study treatment. Of th e 16 subjects who withdrew during the treatment 
period, eight subjects (50.0%) disc ontinued due to PD, four subjects (25.0%) withdrew consent, 
three subjects (18.8%) discontinued due to an AE, and one subject (6.3%) discontinued due to administration of an ESA.
Of the 25 subjects in the three sotatercept treatment groups combined, four (16.0%) were 
administered the planned four doses of study treatment. In the 0.1 mg/kg, 0.3 mg/kg, and 0.5 mg/kg treatment groups, respectively, 1/8 (12.5%), 3/10 (30.0%), and 0/7 (0.0%) subjects 
were administered all four doses of sotatercept. Fourteen of 25 (56.0%) subjects in the three 
sotatercept treatment groups combined skipped and/or had at least one dose modification during the treatment period. One of five (20.0%) subjects in the placebo treatment group was 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ts ts 
d a d a 
t on on 
ancer withncer wit
rolled studrolled stu
of CIA CIA in win w
ree sotaterc sotater
PlPlanned enanned
s and 15 suand 15 s
ministered inistered
5).5).Subjectubject
regimen foregimen fo
nt of CIA at of CIA 
er 30 subjeer 30 sub
ment: ment: five
kg treatmenkg treatmen
ects in the ects in the 
were whitewere white
m 3232to 74 to 74 
.7%) subje7%) subje
tment groupment group
discontinuediscontinue
ght subject subjec tst
ubjects (18bjects (18
inistration inistration 
OfOf the 25 s the 25 sff
adminisdmini
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 30 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015administered all four doses, and 3/5 (60.0%) subjects had skipped a dose and/or had a single dose 
modified during the treatment period.
The primary efficacy endpoint was the rate of he matopoietic response, defined as the proportion 
of subjects who demonstrated a Hgb increase â‰¥ 1 g/dL from baseline for [ADDRESS_476928] dose of study treatment, in the absence of RBC transfusion or 
treatment with an ESA ( Table 5 ).
Table 5: Primary Efficacy Analysis: Subjects with Hemoglobin Increase from 
Baseline of at Least 1 g/dL for 28 Consecutive Days â€“ Per Protocol Set, 
Central Laboratory Results (Study A011-08)
Sotatercept Treatment Group
Placebo
(N=5)0.1 mg/kg
(N=5)0.3 mg/kg
(N=9)0.5 mg/kg
(N=4)All 
Sotatercept
(N=18)
Responder 1 (20.0%) 0 (0.0%) 3 (33.3%) 2 (50.0%) 5 (27.8%)
Nonresponder 4  (80.0%) 5 (100%) 6 (66.7%) 2 (50.0%) 13 (72.2%)
Five of the 18 (27.8%) subjects in the three sotatercept (0.1, 0.3, and 0.5 mg/kg) treatment 
groups combined demonstrated a response (ie, were responders). One of five (20.0%) subjects in the placebo group demonstrated a response. Response rates among subjects in the sotatercept 
0.3 mg/kg (33%) and 0.5 mg/kg (50%) treatment groups were greater than those in the 
sotatercept 0.1 mg/kg (0%) and placebo (20%) treatment groups, and suggest a possible sotatercept dose-response relationship.
 
 
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210$
gg
=4)4)All All
SotatSot502(50.0%)50.0%)2222
2 (50.0%2 (50.0%1)
<<<<, 0.3, and 0.0.3, and 0
onders).nders). OO
rates amrates am onon
roups were roups were
reatment grreatment gr
35,235235235235(31((1(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 31 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015&(/*(1([ZIP_CODE],(7$5<,1)250$7,211([ZIP_CODE],(7$5<,1)250$7,2
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 32 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015Assessments of safety in this study were consistent with the known profile of safety of 
sotatercept. Overall, 20 of 25 (80.0%) subjects in the three sotatercept treatment groups 
combined and all five (100%) subjects in the placebo treatment group reported â‰¥ [ADDRESS_476929] that sotatercept is safe and demonstrates hematopoietic activity 
when administered as repeated doses of 0.1, 0.3, or 0.5 mg/kg administered every [ADDRESS_476930] hematopoietic response following each repeated treatment of sotatercept at doses of 0.3 or &( [ZIP_CODE],(7$5<,1)250$7,21were consistere cons
.0%) subjec0%) subjec
subjects in tubjects in t
vestigator avestigato
mbombolic evelic35,(7$5<,1)250$7,21
1((1((1*(1/*((/*(/&(&(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 33 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE].5 mg/kg, but also indicate that responses decline during the intervals between repeated 
treatments. These data suggest that a shorter dosing interval might result in a more sustained 
hematopoietic response and provide a rationale for a dosing interval of less than 28 days.
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,210$70$50
)251)21),1<, 15<$5<$57$(7$5,(75,(35,[PHONE_409](3 5(31((1(*(1/*((/*(/*
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 34 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE]$5<,1)250$7,217$5<,1)250$7,2
&(/*(1([ZIP_CODE],(7$
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 35 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
 
 (/*(1([ZIP_CODE],(7$5<,1)250$7,2135235,(7$5<,1)250$7
(1(35
/*((/*&(/&(&
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 36 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 &(/*(1([ZIP_CODE],(7$5<,1)250$7,21$0$70$5025025)21)2,1)<, 15<$5<$57$5(7$,(7
352352335235
1((1((1*(/*((/*&(/(/
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 37 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 &(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7055025)251)21)
<, 15<$5<$57$5(7$,(7
2352352335235(31(31((1(*(1*(**
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 38 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
 
 
 
 
1.5. Rationale for Study
In normal hematopoiesis, TGF- Î² inhibits proliferation of hematopoietic stem cells ( Sitnicka, 
1996 ), and negatively regulates erythropoiesis ( Zermati, 2000a; Zermati, 2000b ).  Because TGF-
Î² signaling generally has a negative effect on cell growth, inactivation of this pathway may 
prevent suppression of primary hematopoietic stem  cells and facilitate terminal erythroid 
maturation.  Increased plasma concentrations of TGF- Î², and upregulation and overactivation of 
SMAD2, have been reported in bone marrow progenitors in patients with MDS and provide 
evidence of activation of sustained TGF- Î² signaling in MDS ( Zhou, 2011 ).  Thus, activation of 
SMAD2 by [CONTACT_4722]- Î² signaling may be an important event in ineffective hematopoiesis, and 
inhibition of SMAD2 could stimulate hematopo iesis from primary MDS progenitors.  Evidence 
to support this concept is provided in the observation that in vivo administration of LY-2157299, 
an antagonist of TGF- Î² receptor I kinase, improved anemia in a transgenic mouse model 
overexpressing TGF- Î² and stimulated hematopoiesis in bone marrow from patients with MDS 
(Zhou, 2011 ).   
 
 
 
 
 
 
 
 
  
Sotatercept has the potential to provide benefit in  a variety of conditions in which ineffective 
erythropoiesis c ontributes significantly to anemia and overall disease morbidity, including MDS.  
The ability of sotatercept to rapi[INVESTIGATOR_380722].
1.6. Summary
Based on the safety data from the two completed  Phase 1 studies, single doses of sotatercept up 
to 3.0 mg/kg IV and multiple doses of sotatercept up to 0.3 mg/kg SC were generally well-&(/*(pt has the phas the p
opoiopoiesis conis con
abilitabilit yyofofff
supports theupports th&associssoci atea35,(7$5<,1)250$7,21em cells (m cells ( SiSi
i,2000b2000b ).  B)
n of this pan of this p
itate terminate termi
regulation egula
patpatieientns wiw
DS (DS (Zhou,Zhou,
nt in ineffent in ineffe
s fros from mprimri
atation that ion th ini
proved anemroved anem
atopoiesis topoiesis 7
0$7
352352335235(3 5(31((1(*(1
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 39 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015tolerated in healthy postmenopausal women.   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Additionally, preliminary review of available safety data from ACE- 011-MDS-001 in the 
0.1 mg/kg, 0.3 mg/kg, 0.5 mg/kg, and 1.0 mg/kg dose levels shows a benign safety profile 
consistent with the known safety profile of sotatercept, with no new safety signals identified.  Furthermore, analysis of clinical and PK/PD data from completed studies at single dose levels up 
to 3.0 mg/kg IV (A011-01) and multi-dose levels  up to 1.0 mg/kg SC (A011-02) in regards to 
dose required for a sustained hemoglobin incr ease, support exploration of dose levels up to 
2.0 mg/kg.
ACE-011-MDS-[ADDRESS_476931] monitoring procedures to ensure that safety is appropriately 
and adequately monitored and would continue at dose levels up to 2.0 mg/kg. They include a Steering Committee that will closely monitor saf ety and efficacy data throughout study conduct, 
weekly hemoglobin and blood pressure m onitoring required per protocol, specific dose 
reduction/modification/discontinuation guidelines and clearly-defined dose- limiting toxicity 
definitions to ensure safety is adequately  assessed at all dose levels prior to each treatment 
administration.
As with all biologics, there is the potential for anti -drug antibodies that can be associated with 
increased drug clearance and hypersensitivity reaction.  Celgene will monitor the data and 
communicate to Investigators any ne w findings.  Investigators shoul d monitor subjects for signs 
and symptoms of injection site and hypersen sitivity reacti ons.  Treat injection site and &(/*(1(35235ilable safetlable saf
d d 1.1.0 m0 mg/kggmm
profile of soprofile of 
al land PK/Pand PK/P
and mand m ululmtitll-d
ned hemogned hem
011includesincludes
momonitnitoredor
mmittee mmittee thth
emoglomoglo binbin
on/mon/ odificodific
nitnitioions ns to eto e
dministratdministrat
As wiAs wi ththiii250$7,21$70$750$50
)21)2,1)<, 1<, 15<$5<7$57$(7$5,(75,(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 40 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476932] who develops hypersensitivity to sotatercept.
Please refer to the Investigator Brochure for additional detailed information on the 
pharmacology, toxicology, drug metabolis m, clinical studies, and AE profile, of sotatercept.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 41 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476933] frequenc y of erythroid hematological improvement (HI-E)
in patients with anemia and low- or int- 1 risk MDS or non-proliferative CMML.
2.2. Secondary Objectives
The secondary objectives of this study are to evaluate the:
1. Safety of sotatercept
2. Rate of RBC transfusion independence in transfusion-dependent subjects3. Time to HI-E
4. Duration of HI-E
5. Time to progression to acute myeloid leukemia (TPAML)6. Time to progression to events of higher risk MDS (TTPHR) (ie, int-2 or high risk IPSS)
7. Progression-free survival (PFS)
8. Overall survival (OS)9. Pharmacokinetics (PK) of sotatercept
 
 &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ctss
TPHR) TPHR) ((ieie
23552335235
1(3(1((1
/*((/(/*&(/(/&(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 42 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
 
 
 
 
 
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2150$[ZIP_CODE]
1)2
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 43 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE]. STUDY ENDPOINTS
3.1. Primary Endpoint
The primary endpoint of this study is the rate of HI-E ( Appendix C ) starting before the 
completion of five cycles of treatment. Subjects who have a sustained Hgb increase or a 
decreased transfusion burden by [CONTACT_42334] 5 but for a period less than or equal to 8 
consecutive weeks (potential late responders) may continue treatment for up to an additional three cycles (Cycles 6-8) for the purpose of meeting response criteria.
#HI-E [(for subjects that require a transfusion of < 4 units of RBCs) in the 8 weeks 
prior to randomization (Part 1) or start of therapy (Part 2)] is an increase â‰¥1.5 g/dL 
Hgb sustained over a period â‰¥8 weeks in the absence of RBC transfusion; or
#HI-E [(for subjects that require a transfusion of â‰¥4 units of RBCs) in the 8 weeks 
prior to randomization (Part 1) or start of therapy (Part 2)] is a decrease â‰¥4 units of 
RBCs transfused over a period of 8 week s, relative to the number of units of RBCs 
transfused in the 8 weeks immediately prior to Day 1.
3.2. Secondary Endpoints
The secondary endpoints of this study are:
1. Safety of sotatercept âˆ€based upon assessments listed in Section 10.7.
2. RBC transfusion independence in transfusion-dependent subjects ( Appendix C ).
3. Time to HI-E ( Appendix C ).
4. Duration of HI-E ( Appendix C ).
5. Time to progression to AML; the time between randomization (Part 1) or start of therapy 
(Part 2) and the date of progression to AML ( Appendix C ).
6. Time to progression to events of higher risk MDS; the time between randomization (Part 
1) or start of therapy (Part 2) and date of progression to events of higher risk MDS (eg,
int-2 or high-risk IPSS, Appendix B ).
7. Progression-free survival (PFS) âˆ€the time between randomizatio n (Part 1) or start of 
therapy (Part 2) and PD ( Appendix C ) or death.
8. Overall survival (OS) âˆ€the time between randomization (Part 1) or start of therapy (Part 
2) and death.
9. Concentration of sotatercept in serum.weeks weeks 
â‰¥â‰¥1.51.5g/dLg/dL
siosion; orn; o
s) s) in the in the 88
decrease decreaâ‰¥
umber of umber of uu
ts listed in ts listed 
sioionn--dependepen
;ththe time be time
ogression togression 
o o events of events of
py(Part 2)(Part 2)y
k IPSS,k IPS ApA
free survivee surviv
Part 2)Part 2) andand
all survivaall surviva
)and deathnd death
ConcentConcen
&&
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 44 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015 
 
 
 
 
 
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,2125
<, 15<$57$5(7$5,(35
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 45 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE]. OVERALL DESIGN OF THE STUDY
4.1. Design of Study
This is an open-label, randomized, Phase 2, parallel, dose-ranging, mu lticenter study of 
sotatercept for the treatment of patients with lo w- and int-1 risk MDS or non-proliferative 
CMML, by [CONTACT_56623] ( Appendix B ), with anemia (Hgb â‰¤9.0 g/dL).
The study is comprised of 2 parts:Part 1
Subjects will be stratified by [CONTACT_380746] (< 500 versus â‰¥500 mIU/mL), by 
[CONTACT_380747] 56 days pri or to study enrollment (< 4 units of RBCs versus â‰¥4 
units of RBCs), and assigned randomly to one of two treatment groups wherein they will be 
administered sotatercept, SC, 0.1 mg/kg or 0.3 mg/kg Q3W.
Enrollment will continue without h iatus beyond rando mization of five sub jects into each of the 
0.1 mg/kg and 0.3 mg/kg treatment groups.  Followi ng treatment of five subjects in each of the 
0.1 mg/kg and 0.3 mg/kg treatment groups (w ith the last subject for each group having 
completed at least one cycle of 21 days), all availab le safety and efficacy data will be assessed by 
a Steering Committee (Section 4.4).  Based upon the occurrence of dose- limiting tox icity (DLT)
(Section 4.1.1 ) in â‰¤1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 
0.5 mg/kg treatment group will begin inclusion in the randomization scheme.  
Following treatment of at least six subjects in the 0.5 mg/kg treatment group (with at least six 
subjects having completed at least three cycles of 21 days each), all available safety and efficacy 
data will again be assessed by a Steering Committee from all dose levels.  Based upon the occurrence of DLT in â‰¤ 1/6 subjects in Cycle 1 in the 0.5 mg/kg treatment group and an 
acceptable safety profile from all dose levels, the 1.0 mg/kg treatment group will begin inclusion 
in the ra ndomizatio n scheme.  
Following treatment of at least six subjects in  the 1.0 mg/kg treatment group (with at least six
subjects having completed at least three cycles of 21 days each), all available safety and efficacy 
data will again be assessed by a Steering Committee from all dose levels.  Based upon the occurrence of DLT in â‰¤ 1/6 subjects in Cycle 1 in the 1.0 mg/kg treatment group and an 
acceptable safety profile from all dose levels, the 2.0 mg/kg treatment group will begin inclusion 
in the rando mization scheme.  The 2.0 mg/kg sotatercept dose was reduced to 1.5 mg/kg for 
ongoing and newly enrolled subjects (Amendment 4).
Intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation up to 
1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on assessment 
by [CONTACT_380739].  Enrollment will continue beyond 
randomization in all dose levels (unless dose level(s) is closed due to safety reasons or lack of 
efficacy as recommended by [CONTACT_40972]) until up to a total of 20 subjects in each 
dose level.  Meetings of the Steering Committee are planned periodically throughout the study to 
review all available safety and e fficacy data.  F or any treatment group, if â‰¥40% of the subjects 
(minimum four subjects experiencing an event) experience a DLT of related (suspected) AE â‰¥ &(/*(1([ZIP_CODE],(7$5<,1)250$7,21/mL), by[CONTACT_380748]), by
[CONTACT_380749]â‰¥â‰¥
n they willthey wil
subjects intsubjects i
fivevesubjecsubjec
for each gror each gro
nd efficacynd effica
rence of nce of dodo
g/kg and 0.3kg and 0
randomizarandomiza
0.5 mg/kg 0.5 mg/kg
ofof [ADDRESS_476934] easththreh
ed by a Steed by a S
â‰¤ 1/6 subjeâ‰¤ 1/6 su
rofile frorofile fro mm
attioion schemn schem
newly enronewly enro
iate cohorte coho
g/kg and upg/kg and up
the Steerinhe Steerin
east east thhreereehhh
randoando mim
ica
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 46 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015Grade 2 (other than hypertension and hemoglobin DLT as defined in Section 4.1.1 ), the Steering 
Committee may recommend the closure of the treatment group.  
In addition, if > 33% of the subjects (minimum two subjects experiencing an event) experience 
hemoglobin > 12 g/dL (not influenced by [CONTACT_27752]) sustained for â‰¥7 days, confirmed by [CONTACT_380735] â‰¥1 week apart, the Steering Committee may recommend the closure of the 
treatment group.
Moreover, if > 33% of the subjects (minimum two subjects experiencing an event) experience a 
hypertension DLT (Refer to Section 4.1.1 ) confirmed by [CONTACT_380736] [ADDRESS_476935] be followed as defined in Section 4.1.1 . Additionally, for any treatment group that 
accrues a minimum of 10 subjects or less if recommended by [CONTACT_40972] (with the 
last subject having received at least one complete cycle of 21 days), in the absence of any sign of efficacy (defined as an increase of Hgb > 1 g/dL in the absence of transfusion or at least a 50% 
reduction in transfusion requirements if reduction seen is less than 4 units), the Steering 
Committee may recommend the closure of the treatment group.
Figure 4: Design of Study
aIntermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation up to 1.0 mg/kg and up 
to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on assessment by [CONTACT_380750] d ata when at least six subjects have at least three cycles of treatment in the current 
dose level
bRandomization to the sotatercept 0.5 mg/kg SC Q3W treatment group may begin only after treatment of fivesubjects in the 0.1 mg/kg SC and five subjects in th e 0.3 mg/kg SC treatment groups with the last subject for each 
group having completed at least one cycle of 21 days, and an assessment of all available safety and efficacy data for all subjects.Subjects 
who meet 
eligibility 
criteria 
and 
provide 
written 
informed 
consentAfter 
5- 8
cycles of
treatment, 
assess 
erythroid 
hematologic 
response 
(HI-E)
No Response
Discontinue 
treatment Response
Continue 
treatment Q3WSotatercept 0.1 mg/kg SC Q3W
Sotatercept 0.3 mg/kg SC Q3W
bSotatercept 0.5 mg/kg SC Q3W
Up to [ADDRESS_476936]
treatment Part 1
Progression or 
Therapeutic failure
Discontinue treatmenta,cSotatercept 1.0 mg/kg SC 
Q3W
a, dSotatercept 1.5 
(formerly 2.0) mg/kg
SC Q3W
&(/*(1(352Intermediate Intermediate 
to 2.0 mg/to 2.0 mg/
availabavailab
ose/*(1(/*(1/*(1/*(1/*(1se
ntinue
tment 111152335353535(3(3(3(3P(((((23233535,,(7$5$$
(7$5$5$5$5
5,((7$5(7$5(7$5Q3W
5,(75,(75,(75 mg/kg 5 mg/kg SCSQ3Q
(
((35,235,35,tatercept 1.0
Q3W
222323232323232323$5<,1)250$7,21ment nt 
onalal
nt group thnt group th
ttee tee(wi(withthiithh
nce of anynce of an
n or at leasn or at lea
)), the Steer, the S
a, dS$5$5
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 47 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015cRandomization to the sotatercept 1.0 mg/kg SC Q3W treatment group may begin only after treatment of at least 
six subjects in the 0.5 mg/kg treatment group (or current dose level if intermediate cohort is added) with at least six subjects having completed at least th ree cycles of 21 days each, and an a ssessment of all available safety and 
efficacy data for all subjects. 
dRandomization to the sotatercept 2.0 mg/kg SC Q3W treatment group may begin only after treatment of at least six subjects in the 1.0 mg/kg treatment group (or current dose level if intermediate cohort is added) with at least 
six subjects having completed at least th ree cycles of 21 days each, and an a ssessment of all available safety and 
efficacy data for all subjects.  Per Steering Committee assessment on 02 Mar 2015, the sotatercept 2.0 mg/kg dose was reduced to 1.5 mg/kg.  Subjects already receiving sotatercept 2.0 mg/kg were dose reduced to 1.5 mg/kg(Amendment 4).
Upon completion of up to [ADDRESS_476937] frequency of HI-E.
Part 2 (Expansion Cohort)Following the assessment of efficacy and safety  parameters in Part 1, [ADDRESS_476938] frequency of HI-E.
Steering Committee Recommendation 
Based on the 02 Mar 2015 Steering Committeeâ€™s review of safety, efficacy and pharmacokinetic 
data of subjects enrolled in the Part 1 dose levels, including the sotatercept 2.0 mg/kg cohort level:
Part 1 - The sotatercept 2.0 mg/kg cohort was closed.  Ongoing and newly enrolled subjects are 
to be dose reduced to sotatercept 1.5 mg/kg.
Part 2 - Subjects enrolled in Part 2 (Expansion Cohort) will receive sotatercept at 1.0 mg/kg.  
This update is reflected in Amendment 4.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21will bel be
results esults 
tional evalutional eval
 oof f sotatercsotaterc
etty,y, efficac eff
the sotatercthe sotater
.  Ongoing   Ongoin
n Cohortn Cohort ))ww
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 48 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE].1.1. Dose-limiting Toxicity
The following are DLTs if treatment-related (suspected):
Dose-limiting Toxicity (DLT) Definition
Hemoglobin Hgb > 12 g/dL (not influenced by [CONTACT_27752]) 
sustained for â‰¥ 7 days, confirmed by [CONTACT_380735] â‰¥ 1 week apart.
Hypertension*
Subjects within normal limits (WNL) and not 
receiving antihypertensive treatment at baselineâ‰¥ Grade 2 (140 mmHg systolic BP [blood pressure]
or 90 mmHg diastolic) according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI CTCAE) version 4.0 (current 
active minor version) ( Appendix F )
Prehypertensive subjects  (systolic BP 120 - 139 
mmHg or diastolic 80-89 mmHg) and not receiving 
antihypertensive treatment at baselineSystolic â‰¥ 140 or diastolic increase â‰¥ 90 mmHg 
AND:
Introduction of anti-hypertensive treatment
OR
An increase of > 20 mmHg (systolic or diastolic) 
from baseline
For patients with blood pressure controlled on 
antihypertensive treatment at baselineSystolic BP increase â‰¥ 140 or diastolic increase 
â‰¥90 mmHg AND:
More intensive antihypertensive treatment than 
previously used at baseline
OR
Additional antihypertensive treatment than 
previously used at baseline.
Any other treatment-related (suspected) toxicity â‰¥ Grade 2 per NCI-CTCA E version 4.0 (curre nt 
active minor version)
* Hypertension DLT should be confirmed by [CONTACT_380751] 5 minutes apart with the patient seated for approximately 10 minutes prior to the initial reading.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7
BP [blood BP [blood
ording to therding to the
on TerminolTermi
I CTCAE) vCTCAE) 
ion) (on AppenAppen0$
â‰¥ 140 or dia40 or dia
troduction troduction
OROR
An inAn in
frf5,
trolled on trolled on 
elineeline
other treatmother treatm/*
&(*HypertenHyperten
approappro
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 49 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE].1.2. Study Periods
Both Part 1 and Part 2 of the study ar e comprised of the following periods:
Screening â€“ Assessments to be performed up to 28 days prior to enrollment (Day 1).  If 
screening assessments, with the exception of Hgb and blood pressure, are conducted within 7 days of enrollment (Day 1), they  are not required to be rep eated at enrollment (Day 1).  
Hemoglobin and blood pressure must be a ssessed within 8 hours prior to study drug 
administration (or closest time prior to dosing that is logist ically feasible for the study site).
Treatment â€“ Comprised of five complete cycles of 21 days each of treatment on a schedule of 
Q3W.  Subjects requiring â‰¥4 units of RBC at baseline who fail to demonstrate, after completing 
five cycles of treatment, a decrease â‰¥4 units of RBC transfused over a period of 8 weeks, 
relative to the units of RBCs transfused in the 8 weeks immediately prior to enrollment (Day 1), 
will discontinue treatment.  Subjects requiring < [ADDRESS_476939] sustained 
Hgb increase by [CONTACT_42334] 5 but for a pe riod less than or equal to 8 consecutive weeks 
(potential late responders) may continue treatmen t for up to an additional three cycles (Cycles 6-
8) for the purpose of meeting response criteria.  Subjects requiring â‰¥ [ADDRESS_476940] a sustained decrease in transfusion requirements by [CONTACT_42334] 5 but for a period of less than or equal to 8 consecutive w eeks (potential late responders) may also continue 
treatment for up to an additional three cycles (Cycles 6-8).
End of Treatment â€“ Assessments to be conducted upon:
#Completion ( â‰¥5 cycles) of participation in the Treatment Period of the study, prior
to the first dose of sotatercept in the Extension Period.
#Early (< 5 cycles) termination of participation in the Treatment Period of the study,
after last dose of sotatercept.
Extension â€“ After completion of 5 cycles of treatment (or up to 8 cycles for potential late 
responders), subjects who meet at least one of the criteria listed below may enter the Extension 
Period, subject to Rules for Delay, Reductio n, and Discontinuation of Treatment (Section 8.2.1 ), 
until PD, treatment failure, or other reason, as appropriate, listed in Section 12, Discontinuations.  
HI-E (Non-transfusion-dependent [NTD] subjects) with an increase â‰¥ 1.5g/dL Hgb from 
baseline, sustained over a period of â‰¥ 8 consecutive weeks in the absence of RBC transfusions.
HI-E (Transfusion-dependent [T D] subjects) with a decrease â‰¥ [ADDRESS_476941] a 1.0 g/dL rise in Hgb compared to baseline at the investigatorâ€™s 
discretion.
TD subjects exhibiting a 50% reduction in transfusion requirement compared to baseline at the 
investigatorâ€™s discretion.
End of Extension â€“ Assessments to be conducted upon completion of participation in the 
Extension Period of the study.
Follow-up â€“ Following the end of treatment (last dose of sotatercept administered) in the 
Treatment Period or the Ex tension Period, follow-up w ill include a pregnancy test approximately&(/*(1([ZIP_CODE],(7$5<,1)250$7,21of of 
pletpleing ing 
eks, ks, 
entent(Day(Day 1yy
have sustaihave susta
secutive ecutive ww
hhree cyclesree cycleshhh
nitts of RBCs of R
d of Cycle 5of Cycle 5
ders) may aers) may 
he Treatmhe Treatm
ensioensio nnPeriPer
rticipatticipat ioion ni
es of treatms of treat
st one of thst one o
Reducteduct ioion
ther reather rea sonson
endent ndent [NT[N
a period ofa period 
ependent [Tpendent 
cutcutive weekive wee
riior to Dayor to Da
ectctssexhibitexhibit
on.on
subjectsubject ssexex
investigatornvestigato
nd ofnd of
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 50 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476942] treatment, assessmen t of efficacy (ie, Hgb levels, transfusions) 
approximately [ADDRESS_476943] of sotatercept on hematopoietic endpoints in subjects with low- and 
intermediate-1 risk myelodysplastic s yndromes or non-proliferative CMML, by [CONTACT_56623]
(Appendix B ).  The randomized, parallel-group, design is typi[INVESTIGATOR_380723] 2 studies evaluating a 
range of doses for an investigational drug.  Subjects will be ra ndomized to tr eatment groups to 
limit scientific bias within the study.  The dur ation of treatment of 15 weeks (5 cycles) has been
shown to be adequate to assess safety and to demonstrate a pharmacodynamic effect of sotatercept on hematopoietic parameters  in both h ealthy volunteers and p atients.
 
 
 
 
 
 
 
 
 
  
Dose escalation in 100% incr ement from 0.5 mg/kg to 2.0 mg/kg Q3W is proposed to achieve 
adequate separation in the systemic sotatercept exposure between doses.  This would facilitate 
the evaluation of the dose-response relationship for effectiveness and toxicity as well as to 
minimize the number of subjects exposed to likely sub-therapeutic doses. Intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation up to 1.0 mg/kg and up to 
2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg /kg respectively) based on assessment by [CONTACT_380752].  Three cycles of data in six subjects in the current
dose level will ensure that an adequate amount of safety and efficacy data is available prior to 
dose escalation or treatment group closure at dose levels where limited multi-dose clinical data is available from previous studies (eg, 1.0 mg/kg and 2.0 mg/kg).  
Note:  Based on the 02 Mar 2015 Steering Co mmitteeâ€™s review of safety, eff icacy and 
pharmacokinetic data of subjects enrolled in the Part 1 dose levels, including the sotatercept 2.0 mg/kg cohort level:
Part 1 - The sotatercept 2.0 mg/kg cohort was closed.  Ongoing and newly enrolled subjects are 
to be dose reduced to sotatercept 1.5 mg/kg.
Part 2 - Subjects enrolled in Part 2 (Expansion Cohort) will receive sotatercept at 1.0 mg/kg.  &(/*(1(35235rorom m 0.5 m0.5
ic sotaterceic sotaterc
onse relationse relatio
jects exposjects exp
) may) may bby[CONTACT_380753]
g/kg or 1.5g/kg or 1.5
able safetle safet yy
nt in the cunt in the c
l ensure ensure l thth
atioion or trean or tre
e froe fro m m prevpre
e:  Based oe:  Based o
pharmacokiharmacok
2.02.0mg/kmg,1)250$7,21ed to d to 
evaluatevaluat ingin
mment groupent group
(5 cy5 cycles) eshh
mic effect omic effect o
y voy voluluntnteere
<, 1<, 15<$5<7$57$(7$5,(75,(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 51 ACE-011-MDS-001 Amendment 4 Final: 04 Aug [ZIP_CODE].3. Duration of the Study
Both Part 1 and Part 2 of the study are comprised of the following periods:
Screening â€“ Assessments to be performed up to 28 days prior to enrollment (Day 1).
Treatment â€“ Comprised of five complete cycles of [ADDRESS_476944] a sustained Hgb increase or a decreased tr ansfusion burden by [CONTACT_42334] 5 but for a 
period less than or equal to 8 consecutive weeks (potential late responders) may continue 
treatment for up to an additional three cycles ( Cycles 6-8) for the purpose of meeting response 
criteria.
Extension â€“ After completing 5 cycles of treatment (or up to 8 cycles for potential late 
responders), subjects who qualify for the Extension Period (refer to Section 4.1.2 ), may enter the 
Extension Period and continue treatment ,subject to Rules for Delay, Reduction, and 
Discontinuation of Treatment (Section 8.2.1 ), until PD, treatment failure, or other reason, as 
appropriate, listed in Section 12, Discontinuations.
Follow-up â€“ Following the End of Treatment (last dose of sotatercept administered) in the 
Treatment Period or the Extension Peri od, follow-up w ill include a pregnancy test approximately
[ADDRESS_476945] treatment, assessmen t of efficacy (ie, Hgb levels, transfusions) 
approximately [ADDRESS_476946] that is required forprimary, secondary  analysis, as pre-specified in the protocol and/or the
Statistical Analysis Plan, whichever is the later date.
The sponsor may decide to end the trial when all key endpoints and objectives of the study have 
been analyzed, and the availability of a roll-over protocol exists into which any subjects who
remain on study may be consented and continue to receive treatment with IP.  It must be the 
opi[INVESTIGATOR_380713](s) continue to receive benefit from treatment with IP.  
4.4. Steering Committee
A Steering Committee will be established by [CONTACT_380754].  The Steering Committee will be comprisedof Study Investigators, an Independent Cardiologist, representatives of Celgene, and may include additional ad hoc members.  The Steering Commit tee w ill advise and recommend to the s ponsor:
#Inclusion of the 0.5 mg/kg treatment group in the rando mization scheme, based upon 
the occurrence of DLT (Section 4.1.1 ) in â‰¤1/5 subjects in Cycle 1 in the 0.1 mg/kg 
and 0.3 mg/kg treatment groups and a review  of all available safety  and eff icacy data 
following treatment of five subjects in each of those treatment groups (with the last 
subject for each group having completed at least one cycle of 21 days).&(/*(1([ZIP_CODE],(7$5<,1)250$7,21may enter thmay enter th
nd d 
her reason, er reason
dministeredministe
regnancy tegnancy 
vels, transfuels, transf
ce per monte per m
chever is fichever is f
e last treatmlast treatm
mment, and ent, and 
ng the fing the f rst rsi
f the last visthe last v
oint from toint from t
alysis, as palysis, as p
the later dathe later d
e trial whene trial when
litity yofof a rola rolf
ented and ented and 
r that the rer that th
ring Comring Com
CoCommittee wmmittee w
nvestivestigatogato
nalnal ad hoc d hocl
##InIn
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 52 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015#Inclusion of the 1.0 mg/kg treatment group in the rando mization scheme, based upon 
the occurrence of DLT (Section 4.1.1 ) in â‰¤ 1/6 subjects in Cycle 1 in the 0.5 mg/kg 
treatment group and a review of all available safety and efficacy data (with at least six 
subjects in the 0.5 mg/kg treatment group having completed at least three cycles of 21 
days each).
#Inclusion of the 2.0 mg/kg treatment group in the rando mization scheme, based upon 
the occurrence of DLT (Section 4.1.1 ) in â‰¤ 1/6 subjects in Cycle 1 in the 0.5 mg/kg 
treatment group and a review of all available safety and efficacy data (with at least six subjects in the 1.0 mg/kg treatment group having completed at least three cycles of 21 
days each).  The 2.0 mg/kg sotatercept dose was reduced to 1.5 mg/kg for ongoing 
and newly enrolled subjects per Amendment 4.
#Inclusion of additional intermediate dose levels (not to exceed 2.0 mg/kg) based on 
assessment of all available safety and efficacy data at time of dose escalation to up to 
1.0 mg/kg and up to  2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively).  
#Discontinuation of enrollment and/or treatment in treatment groups without signal of 
efficacy or with unacceptable risk to the sa fety of the subject.  For any treatment 
group that accrues a minimum of 10 subjects or less if r ecommended by [CONTACT_131458] (with the last subject having received at least one complete cycle of 21 
days), in the absence of any sign of efficacy (defined as an increase of Hgb > 1 g/dL in the absence of transfusion or at least a 50% reduction in transfusion requirements if 
the reduction observed is less than 4 units).  
#Closure of a study treatment group:
âˆ€if â‰¥40% of the sub jects (minimum four subjects experiencing an event) 
experience a DLT of related (suspected) adverse event â‰¥ Grade 2 (other than a 
hemoglobin or hypertension DLT as defined in Section 4.1.1 ).
âˆ€if > 33% of the subjects (minimum two subjects experiencing an event) 
experience hemoglobin > 12 g/dL (not influenced by [CONTACT_27752]) sustained for
â‰¥7 days, confirmed by [CONTACT_380755] â‰¥1 week apart.
âˆ€if > 33% of the s ubjects (minimum two subjects experiencing an event) 
experience a hypertension DLT (refer to Section 4.1.1 ) confirmed by [CONTACT_380756] [ADDRESS_476947] be followed as defined in Section 4.1.1 . 
#Changes to the protocol or conduct of the study based upon emerging clinical or 
scientific data from this and/or other studies.
#Procedures to ensure the safety of subjects and integrity of study data.
#Procedures to meet the overall goals and objectives of the study.
Meetings of the Steering Co mmit tee will occur: &(/*(1([ZIP_CODE],(7$5<,1)250$7,21six six 
ofof21 2ff
going oing 
/kg) based og) based 
scalatscalat ioion tn
pectpectively)ively)
groups witgroups w
ject.  ect.  For aFor a
recoecmmenmmen
t least one cleast o
fined as an ned as an 
reduction reductio
  
mum mum fofour sur s
d (suspected (suspecte
siionon DLT aDLT n
ects (minimcts (minim
gloglobin >bin > [ADDRESS_476948] seat
CommittCommitt
harmoharmo
mumu
##ChCh
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 53 ACE-011-MDS-001 Amendment 4 Final: 04 Aug 2015#Following treatment of at least five subjects in each of the 0.1 mg/kg and 0.3 mg/kg 
treatment groups (with the last subject for each group having completed at least one cycle of 21 days).
#Following treatment of at least six subjects in the 0.5 mg/kg treatment group (with at 
least six subjects having completed at least three cycles of 21 days each).
#Following treatment of at least six subjects in the 1.0 mg/kg treatment group (with at 
least six subjects having completed at least three cycles of 21 days each).
#Following treatment of at least six subjects in the 2.0 mg/kg treatment group (with at 
least six subjects having completed at least three cycles of 21 days each).
#Following treatment of at least six subjects in any additional interim treatment group 
(eg, 0.75 mg/kg or 1.5 mg/kg) if previously recommended to be opened by [CONTACT_40972] (with at least six subjects having completed at least three cycles
of 21 days each).
#Following treatment of each block of approximately five to six subjects in each 
ongoing treatment group (with all subjects in each block having completed at least 
three cycles of 21 days each).
#Ad hoc
Additional details of the function and schedule of meetings of the Steering Committee will 
be specified in the Charter of the Steering Commit tee.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21th h at at 
mment groupent group
d by [CONTACT_380757] e 
east east ththree rehh
ixsubjectssubjec
having comaving com
etetings oings o f thh
tee.tee
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 54 ACE-011-MDS-001 Amendment 4 Final: 4 AUG [ZIP_CODE]. TABLE OF EVENTS
Table 7: Schedule of Assessments
Period Screening TreatmentEnd of 
Treatment
Periodror 
Early 
Termination ExtensionsEnd of 
Extension
PeriodtFollow
-up
Cycle Cycle 1 Cycle 2 Cycle 3 Cycle 4Cycle 5 (up 
to 6-8 for 
potential 
late 
responderss)After 
Completion 
of 
Treatment 
PeriodFor 
extension 
subjects-
upon 
discontin-
uation of 
study 
treatment
Daya- [ADDRESS_476949] to sotatercept in IVRS system-â€¢ - - - --- --- --- -- - - - -
Administer sotatercept - â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- - â€¢ --
Medical history, Height â€¢ - - - - --- --- --- -- - - - -
Record prior meds and treatments â€¢ - - - - --- --- --- -- - - - -
MDS disease history and baseline 
assessment and prior therapyb â€¢ - - - - --- --- --- -- - - - -
Transfusion logbâ€¢â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ â€¢v
Record current therapi[INVESTIGATOR_014] (including 
concomitant medications)/procedures â€¢â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ â€¢v
Record adverse eventscRecord on an ongoing basis.
Physical exam, including weight + 
vitalsd â€¢â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ -
&(/*(1(35priprietet35235,(7$5<,1)250$7,21e Corporae Corpora
21
f 
mentment
riodiodrror or
Early Early 
TerminatioTerminat000$
)50
Cycle yc 44Cycle Cycle 5(5(up up 
to t6-8 forfor
potentpo
ll
re)))2
5<1)
181 5181 5$$$5$5$55
77$$5
---777$7$7$$$
5,(77$$
â€¢â€¢ -- -5,5,5,(((
3355,(
-- - -[PHONE_7923]
[ZIP_CODE]
55
----2223232355223
------[ZIP_CODE]
(3355
â€¢ --(((333
11((3
â€¢â€¢ -111(1(1(((
(11((
*(((*â€¢â€¢/*/*/*(/(/*(//
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 55 ACE-011-MDS-001 Amendment 4 Final: 4 AUG 2015Table 7: Schedule of Assessments (Continued)
Period Screening TreatmentEnd of 
Treatment 
Periodror 
Early 
Termination ExtensionsEnd of 
Extension 
PeriodtFollow
-up
Cycle Cycle 1 Cycle 2 Cycle 3 Cycle 4Cycle 5 (up 
to 6-8 for 
potential 
late 
responderss)After 
Completion 
of 
Treatment 
PeriodFor 
extension 
subjects-
upon 
discontinu
ation of 
study 
treatment 
Daya- 2 8  t o  01 8 1 5 181 5181 5181 5181 5
Blood Pressuredâ€¢ â€¢ â€¢ â€¢ â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢ â€¢ â€¢ â€¢ -
ECGdâ€¢ ---- - - â€¢ --- -- â€¢ -- â€¢ -- -
ECOG performance statusdâ€¢â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ -
Hematologye assessed prior to each 
treatment
Include CBC with diff and retic countâ€¢ â€¢ â€¢ â€¢ â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢â€¢ â€¢ â€¢ â€¢ â€¢e
Serum chemistryfâ€¢â€¢ â€¢ â€¢ â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ -
Urinalysishâ€¢â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ -
Serum Erythropoietin â€¢â€¢ â€¢ â€¢ â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- -
Pregnancy testingiâ€¢â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ â€¢
Pharmacokineticsj-â€¢ â€¢ â€¢ â€¢â€¢â€¢â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ â€¢
&(/*(priprietet*(1(333 --- â€¢â€¢[ZIP_CODE]((33
â€¢â€¢â€¢â€¢1(1(1(((
(11(((
â€¢â€¢â€¢â€¢(1(1(111(11
--*(
(/(/*(/5235,(7$5<,1)250$7,21e Corporae Corpora
21
tionion ExtensiExtens777,2
50$7
p p 
or or 
ential ntial 
late late 
respondersespondersss))After After 
CompleCompl
T505050
1)50
15 1 815 1<<<<5<<â€¢â€¢â€¢â€¢â€¢5<5<5<<<
7$$55<<
----7$7$7$$$
(77$$
--â€¢â€¢(7(7(777
55,(77
â€¢â€¢â€¢â€¢555,5,5,(((
223355,
-- â€¢[PHONE_7924]
552233
55525252
/352
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 56 ACE-011-MDS-001 Amendment 4 Final: 4 AUG 2015Table 7: Schedule of Assessments (Continued)
Period Screening TreatmentEnd of 
Treatment 
Periodror 
Early 
Termination ExtensionsEnd of 
Extension 
PeriodtFollow
-up
Cycle Cycle 1 Cycle 2 Cycle 3 Cycle 4Cycle 5 (up 
to 6-8 for 
potential 
late 
responderss)After 
Completion 
of 
Treatment 
PeriodFor 
extension 
subjects-
upon 
discontinu
ation of 
study 
treatment 
Daya- 2 8  t o  01 8 1 5 181 5181 5181 5181 5
Antidrug antibody (ADA)k-â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢ -- â€¢â€¢ â€¢ â€¢k
MDS response assessmentl- - - - - --- --- --- -- â€¢ - â€¢â€¢u
Bone marrow aspi[INVESTIGATOR_337], standardm
(with iron staining);Peripheral blood 
smearn â€¢ - - - - --- --- --- -- â€¢ - â€¢ -
aVariations of Â± [ADDRESS_476950] be recorded on the appropriate CRF.  In the Follow-Up Period (for those visits not requiring sample collection 
only), a variation of Â± 15 business days of the schedule visit are permitted.
bMDS disease history and baseline assessment and prior therapy - to include date of diagnosis, WHO subtype, IPSS ( Appendix B ), and blast percentage, cytopenia and karyotype; 
cytogenetics and historic molecular mutational analyses -(ie, SF3B1, and other MDS related molecular mutations), at ori ginal diagnosis (including all historical data) and at 
study baseline (assessed during the screening period prior to Day 1 dosing); and record of prior therapy for MDS including histor y of administration of erythropoiesis stimulating 
agents.  For baseline MDS disease assessment, if bone marrow biopsy and/or aspi[INVESTIGATOR_380724] [ADDRESS_476951] had no additional treatment (including ESAs and steroids) since sample obtainment.  Supportive care (ie, transfusio ns) since sample obtainment is acceptable.  
All transfusions (ie, RBC, platelets, whole blood, etc) are to be recorded at baseline from at least 12 weeks prior to enrollment ; up through [ADDRESS_476952] time prior to RBC transfusions, if available. .
&(priprietet(/*(1(3(((([ADDRESS_476953] beaa
chedule visit ahedule visit a
tand prior and prior thethe
ationtional analyal analy
eening period eening period 
ssessment, ifessment, if bb
atment (includatment (includ
elets, whole belets, whole
on hemoglobion hemoglob3533553335353555335535,(7$5<,1)250$7,21e Corporae Corpora
21
tionion ExtensiExtens777,2
50$7
p p 
or or 
ential ntial 
late late 
respondersespondersss))After After 
CompleCompl
T505050
1)50
15 1 815 1<<<<5<<
-- -â€¢5<5<5<<<
7$$55<<
----7$7$7$$$
(77$$
----(7(7(777
3355,(77
33353535553355
23552335
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 57 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476954] 
treatment, any SAE related to treatment should be reported.
dIf physical examination, vital signs (except blood pressure), weight, or ECOG performance status were done within [ADDRESS_476955] be assessed 
within 8 hours prior to study drug administration (or closest time prior to dosing that is logistically feasible for the study s ite).  Monitoring of blood pressure may be performed at 
home on nondosing days.  For home monitoring, a plan with instructions and thresholds regarding when to contact [CONTACT_380758].  In the absence of clinically significant changes in blood pressure after five cycles of treatment, monitoring frequency may decrease to 
once per cycle at the investigatorâ€™s discretion.  ECG should be  performed during screening, Cycle 3 Day 1, Cycle 5 Day 1, and a t the End of Treatment Period.  In the absence of 
clinically significant changes in ECG readings after completion o f five cycles of treatment, ECGs will no longer be required until  the End of Treatment Period unless deemed 
necessary by [CONTACT_093].  
eHematology, including CBC with differential and reticulocyte count are done at baseline and weekly during the treatment period.   In the Follow-Up Period, Hematology values
(ie, Hgb levels) will be collected approximately [ADDRESS_476956], to assess potential late response to sotatercept after discontinuation.  
fSerum chemistry includes sodium, potassium, chloride, CO2 (bicarbonate), calcium, magnesium, phosphorus, BUN, creatinine, gluco se, amylase, lipase, albumin, total protein, 
alkaline phosphatase, bilirubin (total and direct), AST/SGOT, ALT/SGPT, LDH, creatinine clearance (per Cockcroft-Gault formula) .
hUrinalysis includes albumin (quantitative), bilirubin, creatinine (quantitative), glucose, Hgb, total protein (quantitative), keto nes, pH, albumin/creatinine ratio, protein/creatinine 
ratio, .
iPregnancy tests for females of childbearing potential.  A female of childbearing potential is a sexually mature female who: 1) h as not undergone hysterectomy or bilateral 
oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any time in  the preceding 24 consecutive months). Urine or 
serum pregnancy tests must occur within [ADDRESS_476957] occur imm ediately pri or to each treatmen t; approximately 
every 28 days during delays in treatment; at discontinuati on of treatment; and approximately [ADDRESS_476958] treatment.
Note:  Local laboratory assessments are allowed in cases when timely results are needed (eg, randomization, study treatment dos ing decisions, hematology assessments between 
clinic visits).  Whenever possible a â€œsplitâ€ sample should also be forwarded to the central laboratory for analysis.  Local lab oratory data should be collected in the eCRF. 
jPharmacokinetics - Blood samples will be collected for assessmen t of pharmacokinetics in all subjects as per the schedule in Table [ADDRESS_476959] treatment. At 
each pharmacokinetics time point, approximately 3 mL blood will be collected and serum prepared 
kAntidrug antibody (ADA) - Blood samples will be collected for assessment of ADA in all subjects.  During the Treatment Period the  sample must be collected prior to each 
administration of sotatercept on days of treatment administration .  During the Extension Period the sample must be collected prior to every other administration of sotatercept on 
days of treatment administration as per the schedule of assessment of pharmacokinetics .  A blood sample will be collected for the assessment of ADA at the end of the Extension 
Period.  At the end of the treatment, assessment of ADA will be repeated every [ADDRESS_476960] treatment.  If a serum sample is provided for assessment of 
pharmacokinetics, the assay for ADA will be performed on that serum sample and an additional sample need not be provided.  If a serum sample is not provided for assessment 
of pharmacokinetics (ie, during the Follow-up Period) a serum sample (  must be 
provided for the assay of ADA.
lMDS response assessment - per International Working Group (IWG) Response Criteria in Myelodysplasia ( Appendix C ), to include best response at end of treatment.
mBone marrow aspi[INVESTIGATOR_337], standard (with iron staining) - for: local assessment of cytogenetics employing standard banding overall and FISH for del (5q) only; preparation of smears
with Wright and Giemsa stain for local and central assessment of cell differential, morphology, and cellularity; standard asses sment by [CONTACT_4133].  For central assessment, 
refer to central lab manual for staining requirements.  During screening, if cytogenetic results from within [ADDRESS_476961] did not receive treatment (including ESAs and steroids) since sample obtainment.  Supportive care (ie, transfusions) sin ce sample obtainment is acceptable.
nPeripheral blood smear - <0.1 ml of peripheral blood for preparation of smear with Wright and Giemsa stain for local and central assessment of cell morphology.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e Corporae Corpora
21
priprietet4242after the laafter the 
d to be repeatto be repea
cyclesycles . In addn ad
od pressure mod pressure m
of blood pressuof blood pre
event significevent signific
monitoring frmonitoring f
he End of Treae End of Tre
il the End of T the End of
perioderiod .  . In Inthethe
nths after the lhs after
UN, creatinine,, creatinine,
kcroftcr-Gault fGault f
roteinotei (quantit(qua
sexually matusexually m
nths (ie, has hnths (ie, has h
or serum pregnr serum preg
imatelymately 28 day28 da
needed (eeded egeg, ran, ran
he central labhe central lab
acokinetics inacokinetics
he Extension Phe Extensi
ADAADA .  A blooA blo
l be collected be collected
ll be collectedl be collected
or assessment or assessment 
rationation .    DuringDurin
ssessment of pssessment
DA will be repDA will be rep
rmed on that med on that
eriod) a serumeriod) a serum
nal Working Gal Working
ron staining)ron staining)
cal and central and centra
ining requiremining requirem
nt (including nt (includin
.1 ml of perip1 ml of perip<,5<
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 58 ACE-011-MDS-001 Amendment 4 Final: 4 AUG 2015 
 
 
 
rFor Extension Subjects â€“ assessments should be completed prior to the first dose of sotatercept in the Extension Period .  For Early Termination Subjects â€“ assessments to be 
completed after last dose of sotatercept.
sAfter completing 5 cycles of treatment (or up to 8 cycles for late responders), subjects who qualify for the Extension Period (re fer to Section 4.1.2 ) may continue therapy until 
PD or treatment failure in the Extension Phase following a Q3W visit schedule.  Subjects who have a sustained Hgb increase or a de creased transfusion burden by [CONTACT_380759] 5 but for a period less than or equal to eight consecutive weeks (potential late responders) may continue treatment for up to an additional three cycles (Cycles 6-8) for the 
purpose of meeting response criteria.
tEnd of Extension Period â€“ Assessments to be conducted upon comp letion of participation in the Extension Period (discontinuation of sotatercept).
uMDS Response Assessment during Follow-up Period to include only progression to AML and OS assessed every [ADDRESS_476962] administration of 
sotatercept. 
vAssessment of efficacy (ie, Hgb levels, transfusions) to continue approximately [ADDRESS_476963], to assess potential late response to sotatercept af ter discontinuation.
&(/*(1([ZIP_CODE],(7$5<priprietet5<,1)250$rmination Subrmination Sub
r tor toSection Section [ADDRESS_476964] up to an ad
iscontinuationiscontinuation
6 mmonths up tonths u
ent and repeatent and
o sotatercept ao sotatercep$7,21e Corporae Corpora
217,2$7,20$70$
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 59 ACE-011-MDS-001 Amendment 4 Final: 4 Aug [ZIP_CODE]. PROCEDURES
Procedures conducted on the day of treatment should be conducted prior to administration of 
treatment.  Deviation of Â± 5 busine ss days from the day of the scheduled assessment is permitted
during the Treatment Period, Extension Period, and Follow-Up Period (for visits that require 
sample collection).  Other Follow-up Period visits will have a Â± [ADDRESS_476965] be recorded on the 
appropriate CRF.
If physical examination, vital signs (except bl ood pressure), weight, or ECOG performance 
status were done within [ADDRESS_476966] to sotatercept in the interactive voice response system (IVRS) system
-Subjects who meet all eligibility criteria (Sections 7.2and 7.3) will be stratified and 
randomized utilizing a validated IVRS.  A subject will be randomized to a Treatment 
Group once a unique multi- digit subject identif ication number has been assigned by 
[CONTACT_54537]. Subjects should be  rando mized prior to preparation ) of the first 
treatment (ie, on the same day, if logistically po ssible).  Randomization is not applicable 
in Part 2.  However, the subject should st ill be registered in the IVRS system prior to 
preparation of the first study treatm ent (ie, on the same day, if logist ically possible).
2. Administer sotatercept â€“ See Sections and 8.2.
3. Medical history
4. Height â€“ without shoes5. Record prior meds (medications) - within th e 8-week period prior to enrollment (Day 1)
6. Record prior treatments - within the 8-week period prior to enrollment (Day 1)
7. Myelodysplastic Sy ndrome or non- proliferative CMML disease history and bas eline
assessment and prior therapy - to include date of diagnosis, WHO subtype, IPSS 
(Appendix B ), and blast percentage, cytopenia, karyotype and historic molecular 
mutational analysis data - (ie, SF3B1, and other MDS-related molecular mutations) at 
original diagnosis and at study baseline (a ssessed during the screening period prior to 
Day 1 dosing); and record of prior therapy for MDS including history of administration 
of erythropoiesis stimulating agents and transfusions.  For baseline MDS disease assessment, if the results of a bone marrow  biopsy and/or aspi[INVESTIGATOR_20336] [ADDRESS_476967] 
did not receive additional treatment (in cluding ESAs and steroids) since the sample 
obtainment).  Supportive care (ie, trans fusions) since sample obtainment is acceptable.
  ule e
d for d for 
on the on the 
G performaG perform
at Dayat Day 1.1y
oof f EventsEvents
ce responsece respo
7.27.2and and 7.37.3
ct will be rawill be 
ficatioficatio n nun nu
or to preparr to prepar
cally possibally poss
ld std still ill be rebe re
mmentent(i(ie,eonon
ectionection s
ss
s (ms (medicatiedi
reatmreatm entsent
splastsplast ic icSySy
mentment and pand p
ppendixpendix BB))
mutationalmutationa
orioriginalginal
DayDay 11y
ofof35
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 60 ACE-011-MDS-001 Amendment 4 Final: 4 Aug [ZIP_CODE]. Transfusion log â€“ include all transfusions from at least 12 weeks prior to enrollment 
(Day 1) up through [ADDRESS_476968] of current therapi[INVESTIGATOR_014] (including concomitant medications)/procedures10. Record of AEs â€“ include AEs beginning from the time of provision of written informed 
consent to participate in this study to [ADDRESS_476969] treatment.  
11. Physical examinatio n â€“ by [CONTACT_6764]
12. Vital signs â€“ Pulse rate, weight (without shoes)
13. Blood pressure (systolic and diastolic, after approximately 10 minutes seated, mean of 
two measurements, approximately 5 minutes apart) should be assessed during screening and on a weekly basis during the first five cycles.  In addition, blood pressure should be 
recorded (at home by [CONTACT_380760] ) approximately [ADDRESS_476970] be assessed within 8 hours of study drug administration (or closest time prior to dosing that 
is logistically feasible for the study site).  Monitoring of bl ood pressure may be done at 
home on non-dosing days.  For home monitoring, a plan with instructions and thresholds 
on when to contact [CONTACT_380761].  In the absence of clinically significant changes in blood 
pressure after five cycles of treatment, monitoring frequency may decrease to once per cycle at the investigatorâ€™s discretion.  
14. ECG â€“ 12-lead with rhythm strip - ECG s hould be performed during screening, Cycle 3 
Day 1, Cycle 5 Day 1, and at the End of Treatment Period.  In the absence of clinically significant findings in ECG readings after completing five cycles of treatment, ECGs will 
not be required until the end of Treatment Period unless deemed necessary by [CONTACT_1275].
15. ECOG performance status ( Appendix D )
16. Hematology
#Hemoglobin (Hgb) - must be assessed prior to each treatment administration
#Hematocrit (Hct)
#RBC count
#Absolute reticulocyte count
#Platelet count
#WBC count and differential
#Absolute neutrophil count (ANC)
#Mean corpuscular volume (MCV)
17. Serum chemistry
#Sodiummmean of ean of 
g screeningg screenin
sure shouldsure should
after initfter init iai
ood pressurood pressur
ime prior tme pri
d pressure mpressure m
ththinstructnstruc
ant increasent increase
nically signnically sig
frequency frequency
ould be ould be perper
Treatment Treatmen
after compafter comp
eatment Peratment Pe
(AppendixAppendix
Hgb) b) --mumstst
t (Hct)t (Hct)
ountunt
bsolute retibsolute reti
PlPlateltelet cet
##WBCWB
##
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 61 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015#Potassium
#Chloride
#CO2 (bicarbonate)
#Calcium
#Magnesium
#Phosphorus
#BUN
#Creatinine
#Glucose
#Amylase
#Lipase
#Albumin
#Total protein
#Alkaline phosphatase
#Bilirubin (total and direct)
#AST/SGOT
#ALT/SGPT
#LDH
#Creatinine clearance [(per Cockcroft-Gault formula) Appendix H ]
19. Serum erythropoietin&(/*(1([ZIP_CODE],(7$5<,1)250$7,21Cockcroft-ockcroft- G
1(3(1*(1/*((/(/*&((
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 62 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 201520. Urinalysis
#Albumin (quantitative)
#Bilirubin
#Creatinine (quantitative)
#Glucose
#Hemoglobin
#Total protein (quantitative)
#Ketones
#pH
#Albumin / creatinine ratio
#Protein / creatinine ratio
Note:  Clinical laboratory evaluations (serum ch emistry, hematology, absolute reticulocyte 
count, , serum eryth ropoietin, urinalysis) w ill be performed by a central 
laboratory.  
Local laboratory assessments are allowed in cases when t imely results are needed (eg, 
randomization, study tr eatment and chemotherapy dosing decisions, hematology assessments 
between clinic visits).  Whenever possible a â€œsplitâ€ sample should also be forwarded to the central laboratory for analysis.  Local la boratory data should be collected in the eCRF.
21. Pregnancy testing âˆ€Pregnancy tests, with a minimum sensitivity of 25 mIU/ml, for
females of childbearing potential.  A female of childbearing potential is a sexually mature female who: 1) has not undergone hysterectomy or bilateral oophorectomy; or 2) has not 
been naturally postmenopausal for at least 24 consecutive months (ie, has had menses at 
any time in the preceding 24 consecutive months). Urine or serum pregnancy tests must occur within [ADDRESS_476971] 
occur immediately prior to each treatment; approximately every 28 days during delays in 
treatment; at discontinuation of treatment; and approximately [ADDRESS_476972] treatment.
22. Pharmacokinetics âˆ€Blood samples will be  collected for assessment of pharmacokinetics 
in all subjects as per the schedule in Table [ADDRESS_476973] treatment. At each PK time point, &(/*(1([ZIP_CODE],(7$5<,1)250$7,21hematolhematol ogo
lysis) will blysis) will b
ses when tes when t
hherapyerapy dosdosyy
le a â€œsplitâ€ le a â€œspli
llaboratoryaborat
nancy testsnancy tests
g potential.g potentia
not undergonot under
ostmstenopaunop
e precedinge precedi
n 3 days prn 3 days pr
mmediately mmediately 
mment; at dient; at di s
atmmentnt..
..PharmacPharmac
in inall sall 
samsam
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 63 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015approximately 3 mL blood will be collected and serum prepared
.  
23. Antidrug antibody (ADA) âˆ€Blood samples will be co llected for assessment of ADA in 
all sub jects.  During the Treatment Period the sample must be co llected prior to each 
administration of sotatercept on days of treatment administration .  During the Extension 
Period the sample must be collected prior to every other administration of sotatercept on 
days of treatment administration as per the schedule of assessment of PK .  A blood 
sample will be collected for assessment of ADA at the end of the Extension Period.  At
the end of the treatment, assessment of ADA will be repeated every [ADDRESS_476974] treatment.  If a serum sample is provided for assessment of PK, the assay for ADA will be performed on that serum sample and an additional sample need not be 
provided.  If a serum  sample is not provided for assessment of PK (ie, during the Follow-
up Period) a serum sample  
 must be provided for the assay of ADA.  
24. MDS response assessment âˆ€per the International Working Group (IWG) Response 
Criteria in Myelodysplasia ( Cheson, 2006 ;Appendix C ), to include best response at end 
of treatment
25. Bone marrow aspi[INVESTIGATOR_337], standard:
#For local assessment of cytogenetics and cen tral review of cytogenetics reports.  
Methods should employ:
âˆ€Standard banding methods overall, and
âˆ€Fluorescence in-situ hybridization (FISH) for d5q only.
#For preparation of smears with Wright and Giemsa stain for local and central
assessment of cell differential, morphology, and cellularity.  For central assessment, 
refer to central laboratory manual for staining requirements.
#For standard assessment by [CONTACT_4133].
âˆ€During the screening period, if cytogenetic results from within [ADDRESS_476975] 
did not receive additional treatment (in cluding ESAs and steroids) since sample 
obtainment.  Supportive care (ie, transfusions) since sample obtainment is acceptable.
  
26. Peripheral blood smear âˆ€< 0.1 mL of peripheral blood for preparation of smear with 
Wright and Giemsa stain for local and central assessment of cell morphology.  Refer to central lab manual for staining requirements.
  &(/*(1([ZIP_CODE],(7$5<,1)25DADA.  
p (IWG) Re(IWG
clude best rclude best 
l review ofreview ol
ndnd
on (FISH) fn (FISH)
WWririWWWght andght an
al, morphol, morph l
mmanualanual florf
ent by[CONTACT_380762] p
reeningeening per
receive addreceive add
nmentment ..    SuSu
cceptable.cceptable.
pheralpheral blbllloodoo
right and Gght and G
centralcentral llllabab
&(/&(50$7,21year year 
assay for say for 
not be ot be 
ng the Follong the Follo
&25
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 64 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015 
 
 
 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$0$
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 65 ACE-011-MDS-001 Amendment 4 Final: 4 Aug [ZIP_CODE]. STUDY POPULATION
7.1. Number of Subjects and Sites
It is anticipated that up to approximately 140 subjects will be ra ndomized to achieve 75-115
evaluable s ubjects (S ection 10.3): up to 20 subjects in each of the sotater cept 0.1 mg/kg, 0.3 
mg/kg, 0.5 mg/kg, 1.0 mg/kg and 2.0 mg/kg treatment groups, and following the assessment 
of efficacy and safety parameters in Part 1, an additional [ADDRESS_476976] 
frequency of HI-E.
Intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation 
up to 1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on 
assessment by [CONTACT_380763] (refer to Section4.1.).  Up to 20 subjects may also be enrolled at these interim treatment groups.  
Note:  Amendment 4:  Based on the 02 Mar 2015 Steering Committeeâ€™s review of safety, 
efficacy and pharmacokinetic data of subjects enrolled in the Part 1 dose levels, including the sotatercept 2.0 mg/kg cohort level:
Part 1 - The sotatercept 2.0 mg/kg cohort was closed.  Ongoing and newly enrolled subjects are 
to be dose reduced to sotatercept 1.5 mg/kg.
Part 2 - Subjects enrolled into Part 2 (Expansion Cohort) will receive sotatercept at 1.0 mg/kg.  
This is a multicenter study that will be conducted at up to approximately [ADDRESS_476977] satisfy the following cr iteria to be enrolled in the study:
1. Provide written informed consent prior to the conduct of any study-specific assessment or 
procedure.
2. Age !18 years at the time of signing the informed consent form.
3. Able to adhere to the study visit schedule and other requirements of the protocol.4. Documented diagnosis of MDS or non-proliferative CMML (WBC â‰¤13,000 /mm
3,
WHO, Vardiman, 2009) that meets IPSS ( Appendix B ) criteria for low- or int-1 risk 
disease.
5. Anemia defined as requiring transfusion â‰¥2 units of RBCs within 84 days of enrollment 
for Hgb â‰¤9.0 g/dL.
6. No response or loss of response to  prior treatment with rHu EPO ( â‰¥40,000 U/wk x 8 or 
equivalent), or darbepoetin alpha ( â‰¥500 mcg Q3W x 4 or equivalent), or low chance of 
response to ESAs reflected by [CONTACT_380764] > 500 mU/mL.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21art rt
e escalate escalat ioio
ely) based oely) based 
ta when at when at
(r(refefer to Ser to Sfff
ment groupsnt grou
mmitteeâ€™s remitteeâ€™s re
e Part 1 dosart 1 do
going and ngoing and 
ohortohort ))willwill
ducted at ucted at 
ng cring cri teria tteria ii
mmed consened consen
s at the timat the tim
here to the here to the
mented diented di aga
HOO, VardimVardim
diseasease..
5.5.AnemiaAnemi
fofor Hr H
6.6.
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 66 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476978] had no response or loss of response to no greater than 2 prior lines of 
treatment for MDS or non-proliferative C MML (not including treatment with ESAs or 
lines discontinued due to intolerance). Prior treatment with multiple agents given in 
combination will be considered one line.  
8. All previous therapy, including ESAs, granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), must have been 
discontinued â‰¥28 days before enrollment
9. Eastern Cooperative Group (ECOG) performance status ( Appendix D )âˆƒ2.
10. Adequate renal function reflected by [CONTACT_380765] < 1.[ADDRESS_476979] and creatinine clearance >
50 mL/min according to Cockcroft-Gault formula ( Appendix H ).
11. Total bilirubin âˆƒ3.0 mg/dL, except if associated with primary shunt hyperbilirubinemia
(idiopathic dyserythropoietic jaundice).
12. AST (SGOT) and ALT (SGPT) âˆƒ3.[ADDRESS_476980].
13. Females of childbearing potential participating in the study are to use highly effective 
methods of birth control during study participation and for 112 days (approximately five 
times the mean terminal half-life of sotatercept [23 days] based on multiple-dose PK 
data) following the last dose of sotatercept. Fe males of childbearing potential must have 
a negative serum beta-human chorionic gonadotropin ( Î²-HCG) or urine pregnancy test 
within three days of sotatercept dosing (Day 1). Subjects must be counseled concerning 
measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept. A female of childbearing potential is a sexually mature woman who has not 
undergone a hysterectomy or bilateral oophorectomy or who has not been 
postmenopausal for at least 24 consecutive months (ie, who has had menses at some t ime 
in the preceding 24 months).
14. Males must agree to use a latex condom during any sexual con tact with females of 
childbearing potential while participating in the study and for 7 months (210 days)
following the last dose of sotatercept, even if he has undergone a successful vasectomy.  
Subjects must be counseled concerning measures to be used to prevent pregnancy and 
potential toxicities prior to the first dose of sotatercept.
15. Free of metastatic malignancy (other than MDS) for ![ADDRESS_476981] from enrollment:
Patients with MDS with chromosome 5q dele tion without documented treatment failure to 
lenalidomide (ie, loss of response or no response after 4 months of treatment, intolerable to 
treatment, or having other cytope nia precluding use of treatment).
1. Women who are pregnant or breast feeding (women who are lactating must agree not to 
breast feed) or planning to become pregnant or breast feed during the period of treatment 
and for [ADDRESS_476982] dose of sotatercept.ance nc>>
bilirubinemilirubinem
to use highto use hig
12 day2 day s (aps (ap
based on mased on 
f childbearf childbe
in (Î²n (Î²--HCGHCG
Subjects mubjects 
d potentd potent ial iat
ntial ntial is a ses a se
ophorectomophorecto
cutive moncutive mon
ex condoex condo m
e partie pa cipatcipa
of sotatercef sotaterce
unseled connseled con
s pris prior to thor t
atiatic malignc mali
lusion Crlusion C
ce of any oe of any o
s wiwthhi MDMDhh
idoidomide mide (i(
eatmeatm entent, o, o
1.1.W
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 67 ACE-011-MDS-001 Amendment 4 Final: 4 Aug [ZIP_CODE]. Males who do not agree to use a latex condom or non-latex condom NOT made of natural 
(animal) membrane during sexual contact [CONTACT_380766] a 
pregnant female while participating in the study and for at least 7 months (210 days)
following the last dose of sotatercept, even if he has undergone successful vasectomy.
3. Major surgery within 30 days prior to Day 1
4. Incomplete recovery or incomplete healing of wounds from previous surgery.
5. Subjects with classification of 3 or higher heart failure as classified by [CONTACT_380767] (NYHA) ( Appendix E ).
6. History of deep vein thrombosis, pulmonary emboli, embolic stroke, or myocardial 
infarction occurring within the past 6 months.  Local central line thrombosis is allowed.
7. Subjects requiring ongoing anticoagulant treatment (eg, Coumadin, warfarin, heparin) 
during the course of the study.  Aspi[INVESTIGATOR_9022].  
8. History of severe allergic or anaphylactic reaction or hypersensitivity to recombinant 
proteins or excipi[INVESTIGATOR_38852] (refer to the Investigatorâ€™s Brochure 
for further information).
9. A condition, including laboratory abnormality, that, as determined by [CONTACT_093], 
places the subject at unacceptable risk if he/s he was to participate in the study or that 
potentially confounds interpretation of data from the study.
10. Concurrent use of anticancer cytotoxic chemotherapeutic agent or treatment.11. Known positive for human immunodeficiency virus (HIV) or infectious hepatitis type C
or active infectious hepatitis type B.
12. Clinically significant anemia unrelated to myelodysplastic disease (eg, iron, B12 or folate 
deficiencies, autoimmune or hereditary hemolysis, active gastrointestinal bleeding, and 
chronic renal insufficiency).
13. Thrombocytopenia (platelet count < 30,000/ %L).
14. Uncontrolled hypertension (systolic blood pressure [SBP] â‰¥140 or diastolic blood 
pressure [DBP] â‰¥90).  
15. Treatment with another investigational drug or device within [ADDRESS_476983] is known, within 5 times the half-life prior to dosing, 
whichever is longer.
16. Prior exposure to sotatercept (ACE-011).17. Any significant medical condition, laboratory a bnormality, or psychiatric  illness that, as 
determined by [CONTACT_093], would prevent the subject from participating in the study
or providing written informed consent.
18. Any condition including the presence of laboratory abnormality that, as determined by 
[CONTACT_093], places the subject at unacceptable ri sk if he/she were to participate in the 
study.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ial l
s allowed.s allowed.
rin, heparinrin, heparin
ity y to recomto recom
InvestInvest igatig
etermined betermined b
o partio par cipatcipa
he studyhe study .
hherapeutierapeuti cc
encyncyvirus (virus
ated to myeed to mye
editaryeditary hemhey
elelet count <et count <
ensioensio n (n (systs
90).  90).  
h another ih another
e o of f ththe pree pre
er ier is ls longeon
or exposurer exposure
Any signifAny signif
determideterm
or pror p
18.8.A
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 68 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 201519. Any condition that, as determined by [CONTACT_093], confounds the interpretation of
data from the study.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 69 ACE-011-MDS-001 Amendment 4 Final: 4 Aug [ZIP_CODE]. DESCRIPTION OF STUDY TREATMENTS
 
 
 
 
 
 
 
 
 
 
 
8.2. Treatment Administration and Schedule
Sotatercept will be administered after reconstitu tion as an SC (subcu taneous) injection to 
subjects by [CONTACT_380768].  Subcutaneous injections will be given in the upper arm, abdomen, or thigh.  Calculated doses requiring reconstituted volume greater than 2 mL should be divided equally 
into two syringes and injected into two separate sites. Rotate sites for each injection.
Subjects will be assigned to be administered treatment as per one of the following regimens:
#Sotatercept 0.1 mg/kg SC Q3W
#Sotatercept 0.3 mg/kg SC Q3W
#Sotatercept 0.5 mg/kg SC Q3W
#Sotatercept 1.0 mg/kg SC Q3W
#Sotatercept 1.5 mg/kg SC Q3W (Amendment 4)&(/*(1(352ministratministrat
nistered aftnistered 
taff at the aff at th
bcutaneous bcutaneous 
s s requirequi riiiingng
nges and inges and i n
will be ll be assas
#SotaSot
##5,(7$5<,1)250$7,217
250)25
<, 15<
7$5(7$5,(35235523
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 70 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015#Sotatercept 2.0 mg/kg SC Q3W (cohort closed â€“ Amendment 4)
Additional intermediate dose levels may be added (eg, 0.75 mg/kg SC Q3W or 1.5 mg/kg 
SC Q3W, not to exceed 2.0 mg/kg SC Q3W) if recommended by [CONTACT_380769] (Refer to Section 4.1) at time of dose escalation to 1.0 mg/kg and 2.0 
mg/kg respectively).  
Note:  Amendment 4:  Based on the 02 Mar 2015 Steering Committeeâ€™s review of safety, 
efficacy and pharmacokinetic data of subjects enrolled in the Part 1 dose levels, including 
the sotatercept 2.0 mg/kg cohort level:
Part 1 - The sotatercept 2.0 mg/kg cohort was closed.  Ongoing and newly enrolled subjects are 
to be dose reduced to sotatercept 1.5 mg/kg.
Part 2 - Subjects enrolled into Part 2 (Expansion Cohort) will receive sotatercept at 1.0 mg/kg.  
Subjects who have a sustained Hgb increase or a decreased transfusion burden by [CONTACT_380759] 5 but for a period less than or equal to 8 consecutive weeks (potential late responders) 
may continue treatment for up to an additional three cycles (Cycles 6- 8) for the purpose of 
meeting response cr iteria.  After completing the Treatment Period, subjects who qualify for 
the Extension Period (refer to Section 4.1.2 ) may continue treatment in the Extension Period 
until PD or therapeutic failure.  
8.2.1. Rules for Delay, Reduction, and Discontinuation of Treatment
Subjects must have Hgb assessed and results available within 8 hours (or closest time prior 
to dosing that is logistically feasible for the study site) prior to each study drug 
administration.
For subjects who are transfusion independent (ie, transfusion burden of < 4 units of RBCs in 
the eight weeks prior to randomization or enro llment), baseline (ie, Cycle 1 only) pre-dose 
Hgb should be < 9.0 g/dL prior to dosing administration.
Subjects must have blood pressure assessed within 8 hours (or closest time prior to dosing 
that is logistically feasible for the study site) prior to each study drug administrati on.  Blood 
pressure values should be confirmed by [CONTACT_292017] 5 
minutes apart with the patient seated for approximately 10 minutes prior to initial reading.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21cts are ts are 
at 1.1.00mg/kgmg/k
rdendenby [CONTACT_380770] r
6-88) f) for theorfff
d, subjectsd, subjects
atment in thtment in t
ation of Tration of Tr
able abl wiwiththiiini
udydysisiyyte) te) iipripr
ndentndent ((ie, ie, tt
n or enrolln or enroll
dosing admdosing adm
ssure assesssure asse
for the studfor the stud
be confirmebe confirm
e epatiatient seen
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 71 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Table 8: Rules for Delay, Reduction, and Discontinuation of Treatment
Observation Action
#Hypertension DLT as defined in 
Section 4.1.1 . #Discontinue treatment
#Treatment-related (sus pected) toxicity â‰¥ 
Grade 3 (other than Hgb or Hypertension)#Discontinue treatment
#Treatment-related (sus pected) toxicity â‰¤ 
Grade 2 that delays treatment by [CONTACT_726] 
3 months#Discontinue treatment
For Hemoglobin â‰¤ 11 g/dL (prior to dosing)
#Hgb < 2 g/dL increase (not influenced by 
[CONTACT_27752]) at Day [ADDRESS_476984] dose#Continue current dose
#Hgb > 2 g/dL increase (not influenced by 
[CONTACT_27752]) at Day [ADDRESS_476985] dose#Continue dosing - one level dose reduction 
(see Table 9 ).
For Hemoglobin > 11 g/dL and â‰¤ 12 g/dL (prior to dosing)
#Hgb < 2 g/dL increase (not influenced by 
[CONTACT_27752]) at Day [ADDRESS_476986] dose#Dose delay until Hgb â‰¤11 g/dL and 
hypertension < SBP 140 mmHg and < DBP 
90 mmHg
#Dosing can commence ![ADDRESS_476987] be < 11 g/dL.
#Subsequent ACE-011 dosing will resume 
21 days following this revised treatment dose date
#Hgb > 2 g/dL (not influenced by 
[CONTACT_27752]) increase at Day [ADDRESS_476988] dose#Dose delay
#Hold dose for one treatment visit
#Re-evaluate Hgb & BP prior to resuming 
treatment
#If Hgb < 11 g/dL and hypertension < SBP 
140 mmHg and < DBP 90 mmHg at the next scheduled visit, resume dosing - one 
level dose reduction (See Table 9 )
&(/*(1(3523by y 235,(7$5<,delay until delay un
pertension <pertension <
90 mmHg90 mmH
Dosing Dosing 
origiorig
ded< ,1)250$7,[ZIP_CODE]$70$50
one level done lev)2
r to dosing)to dosing,1
##<,
5,
y 21 from lay 21 from l23
*(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 72 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Table 8: Rules for Delay, Reduction, and Discontinuation of Treatment (Continued)
Observation Action
For Hemoglobin > 12 g/dL and â‰¤ 14 g/dL
#Hgb > 12 g/dL and â‰¤ 14 g/dL (not 
influenced by [CONTACT_27752]) sustained for 
â‰¥7 days, confirmed by [CONTACT_380755] â‰¥
1 week apart#Dose delay
#Hold dose for one treatment visit
#Re-evaluate Hgb & BP prior to resuming 
treatment
#If Hgb < 11 g/dL and hypertension < SBP 
140 mmHg and < DBP 90 mmHg at the next scheduled visit, resume dosing - two 
level dose reduction (see Table 9 )
For Hemoglobin > 14 g/dL
#Hgb >14 g/dL(not influenced by 
[CONTACT_27752]), sustained for â‰¥7 days, 
confirmed by [CONTACT_380755] â‰¥1 week 
apart#Discontinue treatment (see Section 12)
Note:  Local laboratory assessments are allowed in cases when timely results are needed (eg, 
randomization, study treat ment dosing decisions, hematology assessments between clinic visits).  
Whenever possible a â€œsplitâ€ sample should also be forwarded to the central laboratory for 
analysis.  Local laboratory data should be collected in the eCRF.  When indicated, per dose modification rules ( Table 8 ) the dose of sotatercept should be reduced as per the schedule in
Table 9, Sotatercept dose reduction levels.
Table 9: Sotatercept Dose Reduction Levels
Sotatercept 
Treatment Group0.1 mg/kg 0.3 mg/kg 0.5 mg/kg 1.0 mg/kg 1.5 mg/kgb2.0 mg/kgb
Dose Reduction #1 0.075 mg/kg 0.1 mg/kg 0.3 mg/kga0.75 mg/kg 1.0 mg/kga1.5 mg/kg 
Dose Reduction #2Discontinue 
treatment0.075 mg/kg 0.1 mg/kg0.5 mg/kg 0.75 mg/kg 1.0 mg/kg
Dose Reduction #3Discontinue 
treatment0.075 mg/kg0.3 mg/kg 0.5 mg/kg 0.75 mg/kg
Dose Reduction #4Discontinue 
treatment0.1 mg/kg 0.3 mg/kg 0.5 mg/kg
Dose Reduction #5
(if applicable)0.075 mg/kg 0.1 mg/kg 0.3 mg/kg 
Dose Reduction #6
(if applicable)Discontinue 
treatment0.075 mg/kg 0.1 mg/kg
Dose Reduction #7
(if applicable)Discontinue 
treatment0.075 mg/kg
Dose Reduction #8Discontinue 
treatment
aDose reduction #1 for 1.0 mg/kg and 2.0 mg/kg treatment groups may be to 0.5 mg/kg and 1.0 mg/kg respectively, at the 
investigatorâ€™s discretion.  Subsequent dose reductions should then continue to follow Table 9 (eg, dose reduction #2 for 1.0 
mg/kg treatment group would be 0.3 mg/kg).SBP BP 
g at the t the 
osing osing --two two
bleble99))$7
25ment (see Secent (see Se)2
<en timelyn timely reyy
ogyy assessm assessyy
warded to thwarded to t
n the eCRFn the eCR
pt should bpt should 
n Levelsn Levels
g/kg 0g/kg3335230.1 mg/kg0.1 mg/kg52222
0.075 m0.075 5
(3DD(3(3(3(31(
*(n #5#5
e)*(*(*(*( eduction #6duction #6
pplicable)plicable)/****
Dose ReductiDose Reducti
(if applicabf applic&(&
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 73 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015bSotatercept dose level 2.0 mg/kg has been discontinued, ongoing and newly enrolled subjects dose reduced to sotatercept 1.5 
mg/kg (Amendment 4).
A dose reduction will be maintained unless subsequent dose reductions are indicated.  Doses
may not be increased.
If applicable, for additional intermediate tr eatment groups opened per r ecommendation by [CONTACT_380771] (eg, 0.75 mg/kg, 1.5 mg/kg, Refer to Section 4.1), dose level reduction 
should st ill follow Table 9 (eg, if starting dose level is 0.75 mg/kg, dose reduction #1 would be 
0.5 gm/kg, dose reduction #2 would be 0.3 mg /kg, and so on).  If intermediate treatment group 
dose level is not found on Table 9 , dose should be decreased by 25% for each required dose 
reduction step.
8.3. Method of Treatment Assignment
8.3.1. Part 1
Subjects will be stratified by [CONTACT_380732] (< 500 versus â‰¥500 
mIU/mL) and by [CONTACT_380747] 56 days prior to study enrollment (< 4 RBC units 
versusâ‰¥4 RBC units), and then assigned randomly to one of two treatment groups wherein they 
will be administered sotatercept, SC, 0.1 mg/kg or 0.3 mg/kg Q3W.  An IVRS will be utilized to 
ensure an equal weight central randomization based on a permuted-block ra ndomization method 
according to stratification factors defined in Section 4.1, Design of Study.  Following treatment 
of five subjects in each of the 0.1 mg/kg and 0.3 mg/kg treatment groups (with the last subject 
for each group having completed at least one cycle of 21 days), all available safety and efficacy 
data will be assessed by a Steering Committee (Section 4.4).  Based upon the occurrence of DLT
(Section 4.1.1 ) in â‰¤1/5 subjects in Cycle 1 in the 0.1 mg/kg and 0.3 mg/kg treatment groups, the 
0.5 mg/kg treatment group will begin inclusion in the randomization scheme.  
Following treatment of at least six subjects in the 0.5 mg/kg treatment group (with at least six
subjects having completed at least three cycles of  21 days each), all available safety and efficacy 
data will be assessed by a Steering Committee from all dose levels.  Based upon the occurrence 
of DLT in â‰¤ 1/6 subjects in Cycle 1 in the 0.5 mg/kg treatment group and an acceptable safety 
profile from all dose levels, the 1.0 mg/kg treatment group will begin inclusion in the 
randomizatio n scheme.  
Following treatment of at least six subjects in the 1.0 mg/kg treatment group (with at least six
subjects having completed at least three cycles of 21 days each), all available safety and efficacy 
data will be assessed by a Steering Committee from all dose levels.  Based upon the occurrence 
of DLT in â‰¤ 1/6 subjects in Cycle 1 in the 1.0 mg/kg treatment group and an acceptable safety 
profile from all dose levels, the 2.0 mg/kg treatment group will begin inclusion in the 
randomizatio n scheme.  The 2.0 mg/kg so tatercept dose was reduced to 1.5 mg/kg for ongoing 
and newly enrolled subjects (Amendment 4).
Intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation up to 
1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on assessment 
by [CONTACT_380734].  Enrollment will continue beyond
randomization in all dose levels (unless dose level[s] is closed due to safety reasons or lack of &(/*(1([ZIP_CODE],(7$5<,1)250$7,210 versusversuâ‰¥5â‰¥5
enrollmentenrollmen
eatment grotment gro
W.   An IVRIV
mutedmuted -blockblo
esign of Stusign of S
treatment geatment
 21 days),  21 days), 
ction ction 4.44.4). 
he 0.1 mg/ke 0.1 mg/
oon n in the rain the r
ctsctsin the 0in the
ree cyree cy clescleo
CommitteCommitte
cle 1 in the le 1 in the 
the 1.0 mg/he 1.0 mg/
of at lof at l east easts
mmpleted at pleted at mm
essed by[CONTACT_380772]  a y
1/6 subject1/[ADDRESS_476989]
m m all doseall dose
mizatizion schns c h
newlynewly enenyyroronnn
Intermnterm ediaedia
1.0 m.0 mg/gmm
th
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 74 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015efficacy as recommended by [CONTACT_40972]) until up to a total of 20 subjects in each 
dose level.  
Meetings of the Steering Co mmit tee are planned periodically throughout the study to review all 
available safety and efficacy data.  For any treatment group, if â‰¥40% of the sub jects (minimum 
four subjects experiencing an event) experience a DLT of related (suspected) adverse event â‰¥ 
Grade 2 (other than hemoglobin or hypertension DLT as defined in Section 4.1.1 ), the Steering 
Committee may recommend the closure of the treatment group.
In addition, if > 33% of the subjects (minimum two subjects experiencing an event) experience 
hemoglobin > 12 g/dL (not influenced by [CONTACT_27752]),sustained for â‰¥7 days, confirmed by [CONTACT_380735] â‰¥1 week apart, the Steering Committee may recommend the closure of the 
treatment group.
Moreover, if > 33% of the subjects (minimum two subjects experiencing an event) experience a 
hypertension DLT (refer to Section 4.1.1 ), the Steering Committee may recommend the closure 
of the treatment group.  In order to harmonize DLT assessment for hypertension across the study, 
additional guidance must be fo llowed as defined in Section 4.1.1 . Additionally, f or any treatment 
group that accrues a minimum of 10 subjects or less if reco mmended by [CONTACT_40972] 
(with the last subject having received at least one complete cycle of 21 days), in the absence of 
any sign of efficacy (defined as an increase of Hgb > 1 g/dL in the absence of transfusion or at 
least a 50% reduction in transfusion requirements if the reduction is less than 4 units), the Steering Committee may recommend the closure of the treatment group.
8.3.2. Part [ADDRESS_476990] frequency of HI-E.
Steering Committee Recommendation 
Based on the 02 Mar 2015 Steering Committeeâ€™s review of safety, efficacy and pharmacokinetic 
data of subjects enrolled in the Part 1 dose levels, including the sotatercept 2.0 mg/kg cohort 
level:
Part 1 - The sotatercept 2.0 mg/kg cohort was closed.  Ongoing and newly enrolled subjects are 
to be dose reduced to sotatercept 1.5 mg/kg.
Part 2 - Subjects enrolled into Part 2 (Expansion Cohort) will receive sotatercept at 1.0 mg/kg.  
8.4. Packaging and Labeling
The IP will be lab eled per local regulatory requirements. Additional information may be 
included on the label as applicable per local regulations.
8.5. Investigational Product Accountability and Disposal
Accountability for sotatercept is the responsibility of the investigator.  Investigational clinical 
supplies must be received by a designated person at the clinical site and kept in a secured 
location.  The investigational site must maintain  accurate records indicat ing dates and amounts of 
sotatercept received, to whom it was administered (subject-by-subject accounting), and accounts &(/*(1([ZIP_CODE],(7$5<,1)250$7,21ce 
by[CONTACT_380773]) experiennt) experien
mmend the mend the
nsinsionon acrosacrosn
onallynally , f, of
by [CONTACT_380774] 21 days)f 21 days)
the absenche ab
ctctioion nis lesle
eatmeatm ent grent gr
yparamparam eterete
ete treatmeete treatme
E.E.
on on 
ng Cong Co mmitm
Part 1 dosPart 1 dos
2.0 mg/kg 2.0 mg/kg
sotatersotater cepce
enrolled inenrolled i
PackaginPackagin
will wibe lbe labab
luded on thuded on th
[IP_ADDRESS]
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 75 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015of sotatercept accidentally or deliberately destroyed or returned.  Unless otherwise notified, all 
vials of sotatercept, both used and unused, should be saved for drug accountability.  The used 
vials may be discarded, per the institutionâ€™s standard practice, after drug accountability has been 
completed.  The investigator must return all unused vials of sotatercept to Celgene at the end of the study, or the sotatercept may be destroyed at th e clinical site with the permission of Celgene.  
For either scenario, the outcome must be doc umented on the drug accountability log.  Celgene 
will instruct the investigator on the return, disposal and/or destruction of IP.
8.6. Investigational Product Compliance
Accurate recording of all IP administration will be made.  The investigator or designee is 
responsible for accounting for all IP that is administered during the course of the study.
8.7. Overdose
Overdose, as defined for this protocol, refers to sotatercept dosing only.  On a per dose basis, an 
overdose is defined as the following amount over the protocol-specified dose of sotatercept 
assigned to a given patient, regardless of any associated adverse events or sequelae.  
SC 10% over the protocol-specified doseOn a schedule or frequency basis, an overdose is defined as anything more frequent than the 
protocol required schedule or frequency.  Complete data about drug administration, including 
any overdose, regardless of whether the overdose was accidental or intentional, should be reported in the case report form.  See Section 11.1 for the reporting of adverse events associated 
with overdose.  
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21y.
a per dosea per dos
doose of sotase of 
s or sequels or seque
nynyththyying ingmom
bout drug adut drug 
ccidental orccidental 
r the reportr the report
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 76 ACE-011-MDS-001 Amendment 4 Final: 4 Aug [ZIP_CODE]. CONCOMITANT MEDICATIONS AND PROCEDURES
9.1. Permitted Concomitant Medications and Procedures
9.1.1. Medications
During screening, and during the study, subjects should take only stable doses of medications for 
chronic conditions that are not specifically exclude d by [CONTACT_760].  Concomitant medications 
will be recorded throughout the course of the study at each visit.
9.1.2. RBC Transfusions
Concurrent treatment for anemia with blood transfusions is recommended when Hgb is < 8 g/dL 
or at the discretion of the investigator if Hgb is â‰¥8 g/dL and associated with symptom(s) of 
anemia (eg, hemodynamic or pulmonary compromise requiring treatment) or com orbidity
justifying a threshold â‰¥8 g/dL Hgb.
9.2. Prohibited Concomitant Medications and Procedures
Concomitant growth factors (G-CSF or GM-CSF) are not allowed except in case of febrile 
neutropenia.
Iron supplementation within 7 days of Day 1 (besides an oral multivitamin with iron) will not be 
allowed.  If a subject becomes iron deficient during study treatment (ferritin < 100 ng/mL 
[< 224.7 pmol/L] or transferrin saturation < 20%), treatment with iron supplementation is at the 
discretion of the investigator.
No ESA is allowed.
No concurrent treatment with another investigational agent is allowed.Concomitant anticoagulant treatment (eg, Cou madin, warfarin, heparin) is not allowed during 
study treatment.  Aspi[INVESTIGATOR_9022].
9.3. Required Concomitant Medications and Procedures
None.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ss
Hgb is <gb is < 88
ymptommptom (s)(s
r comr com orbiorbid
oceduresocedure
wed except wed exc
noraloralmmllululmmmtl
studytudy treatmrey
, treatment , treatmen
nvestvestigatigatioio
nt((eg, CoCo
wed.wed.
oncomitaoncomita
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 77 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 201510. STATISTICAL ANALYSES
10.1. Overview
This is an open-label, randomized, Phase 2, parallel, dose-ranging, multicenter study of 
sotatercept for the treatment of patients with low- and int-1 risk MDS or non-proliferative 
CMML, with anemia, defined as requiring â‰¥2 units of RBCs within 84 da ys of study enrollment.  
The study is comprised of 2 parts.  In Part 1, subjects will be assigned randomly to one of two treatment groups wherein they will be admin istered sotatercept, SC, 0.1 mg/kg or 0.3 mg/kg 
Q3W.  Randomization w ill be stratified by [CONTACT_380746] (< 500 versus â‰¥500 
mIU/mL) and by [CONTACT_380747] 56 days prior to study enrollment (< 4 RBC units 
versusâ‰¥4 RBC units).  Enrollment will continue without hiatus beyond randomization of five
subjects into each of the 0.1 mg/kg and 0.3 mg/kg treatment groups.  Following treatment of five
subjects in each of the 0.1 mg/kg and 0.3 mg/kg treatment groups (with the last subject for each group having completed at least one cycle of 21 days), all available safety and efficacy data will 
be assessed by a Steering Committee (Section 4.4).  Based upon the occurrences of DLTs in 
Cycle 1, as described in Section 4.1.1 , the 0.5 mg/kg treatment group may be included into the 
randomization scheme. Initiation of ra ndomization into the 1.0 mg/kg and 2.0 mg/kg treatment 
groups w ill have the s ame requirements as initiation of randomization into the 0.5 mg/kg 
treatment group with the exception of requiring at least six subjects completing at least three cycles of 21 days each and all available safety and efficacy data will be assessed by a Steering 
Committee. Meetings of the Steering Committee are planned periodically throughout the study 
to review available safety and efficacy data.  Also, the Steering Committee may meet to review efficacy and safety due to occurrences of DLTs or for lack of efficacy as described in 
Section 4.1.1 .
Intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation up to 
1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on assessment 
by [CONTACT_380775] e level.  Upon completion of up to [ADDRESS_476991] frequency of HI-E.
Note:  Amendment 4:  Based on the 02 Mar 2015 Steering Committeeâ€™s review of safety, 
efficacy and pharmacokinetic data of subjects enrolled in the Part 1 dose levels, including the 
sotatercept 2.0 mg/kg cohort level:
Part 1 - The sotatercept 2.0 mg/kg cohort was closed.  Ongoing and newly enrolled subjects are 
to be dose reduced to sotatercept 1.5 mg/kg.
Part 2 - Subjects enrolled in Part 2 (Expansion Cohort) will receive sotatercept at 1.0 mg/kg.  
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21.    
kgg
[ADDRESS_476992] subjec
y and efficaand ef
ccurrenceccurrence ss
up pmamayybe ib
mg/kg g/kgm and 2d
mization inmization 
subjectsubjects cc
acyacydata wdata wyy
e planned pplanned
, the , the Steeritee
s or for lackor for lac
mg/kg) mamg/kg) m
0.75 mg/kg .75 mg/k
ilable safetilable safe
n the curren the curre
ment groupment grou
ept and idenpt and i
ment of effment of e
nrolled in Prolled in P
he greatest he greate
endment 4:ndment 4:
and pharmd pharm
ercept 2.0 mercept 2.0
art 1 art 1 -T h e-T h e
to be doso be dos
t
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 78 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 201510.2. Definitions of Study Populations
Five study populations w ill be used for analyses.
#The Intent-to-Treat (ITT) Population âˆ€All subjects rando mized
#Safety Population âˆ€All subjects who take at least one dose of study medication
#Efficacy Evaluable (EE) Population âˆ€All ITT subjects who take at least one dose of 
study medication and have baseline and at least one post-baseline assessment of 
efficacy without major deviation from protocol
#Transfusion-dependent E fficacy P opulation (TDE) âˆ€All subjects in the EE 
population who require a transfusion of > 4 units of RBCs in the 8 weeks prior to 
randomization (Part 1) or start of therapy (Part 2) are transfusion dependent at 
randomization.
#Transfusion-independent Efficacy Population (TIE) â€“ All subjects in the EE 
population who require a transfusion of < 4 units of RBCs in the 8 weeks prior to 
randomization (Part 1) or start of therapy (Part 2) are not transfusion-dependent at 
randomization.
10.3. Sample Size and Power Considerations
Subjects will be enrolled to provide up to 115 ev aluable subjects in this study (Parts 1 and 2, 
combined).  An evaluable subject is one who meets criteria for HI-E (Section 3.1), or one who 
completes five cycles of [ADDRESS_476993] a sustained Hgb increase or a decreased 
transfusion burden by [CONTACT_42334] 5 but for a period less than or equal to 8 consecutive 
weeks (potential late responders) may continue  treatment for up to an additional three cycles
(Cycles 6-8) for the purpose of meeting response criteria.
Confidence intervals for response rates based on various sample sizes are presented in Table 10 .
Table 10: 95% Confidence Intervals for Selected Sample Sizes and Response Rates
N Responses Response Rate Lower 95% CI Upper 95% CI
20 4 0.20 0.057 0.437
20 6 0.30 0.119 0.543
20 10 0.50 0.272 0.728
20 14 0.70 0.457 0.881
20 16 0.80 0.563 0.943
15 3 0.20 0.043 0.481
15 6 0.40 0.163 0.677
15 9 0.60 0.323 0.836
15 12 0.80 0.519 0.957
10 2 0.20 0.025 0.556&(*
(/*[ZIP_CODE],(7$5<,1)250$7,21prior to ior to 
dent at dent at 
ts in the EEts in the E
the [ADDRESS_476994] ve a a sustaisustai
for a periodfor a period
inue treatmnue treatm
response cresponse
ates based es based
e e IntervalInterval5
(3 5ponses35
1(3(3
((1(1(61((*(*((1(1(((1*(*(/*(((*(*((*( 20/*
&(/15(/&(&
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 79 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Table 10: 95% Confidence Intervals for Selected Sample Sizes and Response Rates
(Continued)
N Responses Response Rate Lower 95% CI Upper 95% CI
10 5 0.50 0.187 0.813
10 8 0.80 0.444 0.975
5 1 0.20 0.005 0.716
5 2 0.40 0.053 0.853
5 4 0.80 0.284 0.995
10.4. Background and Demographic Characteristics
Subjectsâ€™ baseline transfusion dependency and baseline concentration of serum EPO (< 500 versusâ‰¥500 mIU/mL) w ill be summarized using frequency tabulations.  Subjectsâ€™ age, height, 
weight, and baseline characteristics will be summarized overall and by [CONTACT_145423], while gender, race and other categorical variables will be summarized using frequency tabulations.  Data on medical history will be summarized using frequency tabulations 
by [CONTACT_6657].
10.5. Subject Disposition
Subject disposition (analysis population allocat ion, entered, discontinued, along with primary 
reason for discontinuation) will be summarized overall and by [CONTACT_380776]-up periods.  A summary of subjects enrolled by [CONTACT_27707]. Deviations from protocol will be summarized by [CONTACT_380777].
10.6. Analysis of Efficacy
The primary objective of this study is to deter mine a safe, tolerable, and effective dose of 
sotatercept that results in the greatest frequency of HI-E in patients with anemia and low- or int-1risk MDS or non-proliferative CMML.  The primary endpoint of this study is the rate of HI-E
(Appendix C ) starting before the completion of five cycles of treatment.  Subjects who have 
sustained Hgb increase or decreased transfusion burden by [CONTACT_380738] 5 but for a period less than or equal to 8 consecutive weeks (potential  late responders) may continue treatment for up to 
an additional three cycles (Cycles 6-8) for the purpose of meeting response criteria.
#HI-E (TIE) is an increase â‰¥1.5g/dL Hgb from baseline, sustained over a period of â‰¥8 
consecutive weeks in the absence of RBC transfusion; 
or
#HI-E (TDE) is a decrease â‰¥4 units of RBCs transfused over a period of 8 consecutive 
weeks, relative to the number of units of RBCs transfused in the 8 weeks immediately prior to Day 1.
Erythroid hematological improvement (HI-E) response rates will be presented separately for TIE 
and TDE subjects. The HI-E response rate and other binary endpoints will be summarized using &(/*(1([ZIP_CODE],(7$5<,1)250$7,[ZIP_CODE]$7$777$7$70$75$7$70$$7
m EPOEPO (<(<5
ubjectsâ€™ agubjectsâ€™ ag
treatment gtreatmen
es will be es will be 
ed using fred using fr
ntered, dintered, d sc
erallerall and band bl
eririodsods.  A s.  A 
willwill bblle esumsum
yyiys tos tdetedete
eatest frequeatest frequ
e CMMLe CMM
ore ththe coe
or decreasor decrea
onsecutive secutive 
ee cycles (ee cycles ( C
II--E (E (TIETIE))
consecutconsecut
oror
##H
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 80 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015a point estimate and 95% CI.  
The secondary endpoints of efficacy of this study are:
1. Achievement of transfusion-independence in transfusion-dependent subjects 
(Appendix C ).
2. Time to HI-E ( Appendix C ); the time between randomization (Part 1) and the start of 
therapy (Part 2) and the date the start of HI-E.
3. Duration of HI-E ( Appendix C ); the length of time between the first assessment and the 
last assessment the subject was in HI-E response for subjects who had an HI-E response. 
If the subject had an HI-E response that continued at the subjectâ€™s last assessment, the duration will be censored at the last assessment.
4. Time to progression to AML (TPAML); the time between rando mization (Part 1) and 
start of therapy (Part 2) a nd the date of progression to AML ( Appendix C ).  If a subject 
dies prior to progression, the subject will be censored at the date of death.  If a subject 
does not have a progression to AML, the subject will be censored at the last assessment.
5. Time to progression to events of higher risk MDS (TTPHR); the time between 
randomization (Part 1) and start of therapy (Part 2) and d ate of progression to events of 
higher risk MDS (eg, int-2 or high risk IPSS, Appendix B ).  If a subject dies due to 
reasons other than progression to events of higher risk MDS, the subject will be censored at the death date.  If a subject does not have progression to events of higher risk MDS, 
then the subject will be censored at the last assessment.
6. Progression-free survival (PFS) - the time between randomization (Part 1) and start of 
therapy (Part 2) and PD ( Appendix C ) or death.  Subjects who progress or die will be 
considered to have had an event, except if this event occurs after the start of subsequent 
therapy for MDS, in which case the subject is censored at the time of last assessment of 
MDS prior to or on the first day of the first subsequent therapy for MDS.  The date of 
progression is taken as the earliest date of:  date of PD as evaluation of response, death 
date, if death is caused by [CONTACT_4002], treatment termination date if reason is PD, progression date as documented on treatment termination page, progression date as documented on 
the follow-up visit page.  Subjects who do not progress or die (lost to follow-up or still 
being treated without documented PD or started subsequent antitumor therapy) will be censored at the date of the last assessment of MDS.
7. Overall survival (OS) - the time between rando mization (Part 1) and start of therapy (Part 
2) and death.  A subject, who dies regardless of the cause of death, will be considered to have had an event.  All subjects who are lost  to the follow-up prior to the end of the study 
or who are withdrawn from the study will be censored at the time of last contact.  
Subjects who are still being treated will be censored at the last available date when the subject was known to be alive.
8. Concentration of sotatercept in serum (Section 10.9).
For duration and time-to-event data, the Kaplan -Meier method will be used to estimate the 
distribution function.  For continuous data, descriptive statistics will be provided.  Data listings 
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21d the he 
esponse. ponse. 
ment, thement, the
on (Part 1)n (Part 1
dixdixCC)).  .  If If 
of fdeath.  Ideath
ored at the lred at the l
R)); ; the timtim
d date of prod date of
ndixdixBB)).  .  If If 
r risk MDSrisk MD
rogressiorogressio n t
assessmenassessmen
me betweene betwee
CC) or death) or death
except if thexcept if th
se the subjese the su
t daydaoffy the theff
he earliest dhe earliest 
d by [CONTACT_4002], trd by [CONTACT_4002], tr
d on treatmon treatm
isit page.  Sisit page.  
d without dowithout d
at the date at the date 
ll survivalsurvival
and deathnd death
have had ahave had a
or who or who
SubjSubj
susu
8
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 81 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476995] one dose of study medication will be included in analyses of safety.  Exposure to sotatercept will be summarized.  Adverse events, DLTs, vital signs, clinical laboratory information, ECG interpretations, and concomitant medications will be tabulated and 
summarized overall and by [CONTACT_64240].  The incidence of AEs will be summarized by 
[CONTACT_380778] 4.0 (c urrent active minor version).  The incidence of 
deaths, SAEs, and AEs leading to dose modif ications and discontinuati ons of study treatment 
will be summarized overall and by [CONTACT_64240].  Safety i nformation obtained during 
treatment, post-treatment ([ADDRESS_476996] dose), and during follow-up will be provided for these analyses.  Laboratory results will be  summarized by [CONTACT_380779].
10.8. Interim Analysis
In Part 1, following treatment of five subjects in each of the 0.1 mg/kg and 0.3 mg/kg treatment 
groups (with the last subject for each group having completed at least one cycle of 21 days), all 
available safety and efficacy data will be  assessed by a Steering Committee (Section 4.4).  
Enrollment will continue without hiatus beyond rando mization of five sub jects into each of the 
0.1 mg/kg and 0.3 mg/kg treatment groups.  Based upon the occurrences of DLTs in Cycle 1 as 
described in Section 4.1.1 , the 0.5 mg/kg treatment group may be included into the 
randomizatio n scheme.  Initiation of rando mization into the 1.0 mg/kg treatment group will have 
the same requirements as initiation of randomization into the 0.5 mg/kg treatment group with the 
exception of requiring at least six subjects enrolled in the 0.5 mg/kg treatment group completing 
at least three cycles of 21 days each.  Initiation of rando mization into the 2.0 mg/kg treatment
group will have the same requirements as initiation of randomization into the 1.0 mg/kg 
treatment group.  Meetings of th e Steering Committee are planned periodically throughout the 
study to review available safety and efficacy data.  Also, the Steering Committee may meet to review efficacy and safety due to occurrences of DLTs or for lack of efficacy as described in 
Section 4.1.1 .
Intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation up to 
1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on assessment 
by [CONTACT_380775] e level.  Upon completion of up to 20 evaluable 
subjects in each of the treatment groups (Part 1), analyses will be conducted in order to evaluate 
the safety profile of sotatercept and identify the dose that results in the greatest frequency of 
HI-E.
Note:  Amendment 4:  Based on the 02 Mar 2015 Steering Committeeâ€™s review of safety, 
efficacy and pharmacokinetic data of subjects enrolled in the Part 1 dose levels, including the 
sotatercept 2.0 mg/kg cohort level:
Part 1 - The sotatercept 2.0 mg/kg cohort was closed.  Ongoing and newly enrolled subjects are 
to be dose reduced to sotatercept 1.5 mg/kg.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e of of 
ment en
ng g 
 provided fprovided 
verall and bverall and b
/kg and 0.3/kg and [ADDRESS_476997] leas one 
ng Commitng Comm
tioon of n of fivefiv
n the occurrn the occu
group roup mamayb
on into the on into the
zation into ation into
nronrolled in tlled in t
iatatioion of ran of ra
s as inits as init iatioi
Steering Coeering Co
and efficacand efficac
e to occurre to occurr
not to excenot to exce
o 2.0 mg/kgo 2.0 mg/kg
Committee Committee
clesesofoftreatreaff
each of theeach of th
ty yprofile orofile o
.
Note:  Note:  AmeAme
efficacyfficac
ate
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 82 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Part 2 - Subjects enrolled in Part 2 (Expansion Cohort) will receive sotatercept at 1.0 mg/kg.  
10.9. Pharmacokinetics
Pharmacokinetic parameters for sotatercept, such as C max, time to maximum serum concentration 
(Tmax), and AUC, will be estimated.  Dose proportionality may be assessed using exposure data 
after the first dose.  Descriptive statistics will be provided for serum concentrations and PK 
parameters.  The relationship between exposure to sotatercept and response (ie, safety, efficacy, 
) may be explored, if appropriate.  
 
 
 
 
 
 
 5<,
(7$
5235235(31(1(*(1/*((/*&(/&(&
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 83 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 201511. ADVERSE EVENTS
11.1. Monitoring, Recording and Reporting of Adverse Events
An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may 
appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a 
worsening concomitant illness, an injury, or any concomitant impairment of the subjectâ€™s health, 
including laboratory test values (as specified by [CONTACT_65801]), regardless of etiology. Any worsening (ie, any clinically significant adverse ch ange in the frequency or intensity of a pre-
existing condition) should be considered an AE .  A diagnosis or syndrome should be recorded on 
the AE page of the CRF rather than the indi vidual signs or symptoms of the diagnosis or 
syndrome. 
An overdose, accidental or intentional, whether or not it is associated with an AE, or abuse, 
withdrawal, sensitivity or toxicity to an investigational product should be reported as an AE.  If an overdose is associated with an AE, the overdose and adverse event should be reported as 
separate terms.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subjectâ€™s clinical symptoms, laboratory, 
pathological, radiological or surgical fi ndings, physical examination findings, or other 
appropriate tests and procedures.
All AEs will be recorded by [CONTACT_380780] 
[ADDRESS_476998]â€™s source documents.  All SAEs must be reported to Celgene Drug Safety within 24 hours of the investigatorâ€™s knowledge of the event by [CONTACT_6972], or other appropriate method, 
using the SAE Report Form, or approved equivalent form.
11.2. Evaluation of Adverse Events
A qualified investigator will evaluate all adverse events as to:
11.2.1. Seriousness 
An SAE is any AE occurring at any dose that:
#Results in death;
#Is life-threatening (ie, in the opi[INVESTIGATOR_871], the subject is at immediate 
risk of death from the AE);
#Requires inpatient hospi[INVESTIGATOR_27588] 
(hospi[INVESTIGATOR_19357], regardless of length of stay);
#Results in persistent or significant disability/incapacity (a substantial disruption of the 
subjectâ€™s ability to conduct normal life functions);
#Is a congenital anomaly/birth defect;
#Constitutes an important medical event.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ny
re--
corded on rded o
s or s or 
AE, oAE r abur abu
eported as eported as 
hould be reuld be
ments may ents may
al symptomal sympto
aminatminat ioion n f
he time the he time th
will be recowill be rec
must be repmust be rep
e event by [CONTACT_380781]
d equivalend equival
erse Evense Even
valuate all aluate all
ccurring atcurring a
lts in deathlts in death
s lifes life --ththreareah
ririsk of desk of d
##RequReq
(h(h
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 84 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_476999] or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be considered serious.
Events not considered to be SAEs are hospi[INVESTIGATOR_5315]:
#A standard procedure for protocol therapy administration.  However, hospi[INVESTIGATOR_72612] a complication of therapy administration will be 
reported as an SAE. 
#Routine treatment or monitoring of the st udied indication not associated with any 
deterioration in condition.
#The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospi[INVESTIGATOR_27589] a complication 
of such transfusion remains a reportable SAE.
#A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, hospi[INVESTIGATOR_27590] a complication of such procedures 
remains a reportable SAE.
#Hospi[INVESTIGATOR_27591], practical, or social 
reasons, in absence of an AE.
#A procedure that is planned (ie, planned prior to starting of treatment on st udy); must 
be documented in the source document and the CRF.  Hospi[INVESTIGATOR_72613] a complication remains a reportable SAE.
#An elective treatment of a pre-existing condition unrelated to the studied indication. 
#Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the investigator will provide i nformation on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
11.2.2. Severity / Intensity
For both AEs and SAEs, the investigator must assess the severity /intensity of the event.The severity of AEs will be graded based upon the subjectâ€™s symptoms according to the current 
active minor version of NCI CTCAE Version 4.0; 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
AEs that are not defined in the NCI CTCAE shoul d be evaluated for severity according to the 
following scale:&(/*(1([ZIP_CODE],(7$5<,1)250$7,21thh any anyhh
ent of student of stu
n for a n for a cocomm
g, surgery, surgery
samsapling)plingm
mmplicatplicammm ion
atioion nfor tefor t
ned prined pri or tor to
ment and thment and th
on remainsn remains
prepre--existingexisting
reatmatent ont o
er seriousner seriousne
ous, both thus, both t
nvestigavestiga tortor
P, action tak, action tak
SeveritySeverity /I/I
h AEs and h AEs and 
severitseverit y y oo
active minoctive mino
hthttp://ctetp://c
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 85 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015#Grade 1 = Mild â€“ transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
#Grade 2 = Moderate â€“ mild to moderate limitation in activity, some assistance may be
needed; no or minimal medical intervention/therapy required
#Grade 3 = Severe â€“ marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospi[INVESTIGATOR_27594]
#Grade 4 = Life threatening â€“ extreme limitati on in activity, si gnificant assistance 
required; significant medical intervention/therapy required, hospi[INVESTIGATOR_380725]
#Grade 5 = Death - the event results in death
The term â€œsevereâ€ is often used to describe th e intensity of a specific event (as in mild, moderate 
or severe myocardial infarction); the event itself, however, may be of relatively minor medical 
significance (such as severe headache).  This criterion is notthe same as â€œseriousâ€ which is 
based on subject/event outcome or action criteria associated with events that pose a threat to a 
subjectâ€™s life or functioning.  
Seriousness, not severity, serves as a gui de for defining regulatory obligations.
11.2.3. Causality 
The investigator must determine the relationshi p between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: Means a causal relationship of the adverse event to IP 
administration is unlikely or remote ; or other medications, 
therapeutic interventions, or underlying conditions provide a sufficient explanation for the observed event.
Suspected: Means there is a reasonable possibility that the administration 
of IP caused the adverse event. â€˜Reasonable possibilityâ€™ means there is evidence to suggest a causal relationship between the 
drug and the adverse event.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provide d by [CONTACT_27718], please provide the name [CONTACT_208924].
11.2.4. Duration
For both AEs and SAEs, the investigator will provide a record of the start and stop dates of the 
event.
11.2.5. Action Taken
The investigator will report the action taken with IP  as a result of an AE or SAE, as applicable 
(eg, discontinuation or reduction of IP, as  appropriate) and report if concomitant and/or 
additional treatments were  given for the event. &(/*(1([ZIP_CODE],(7$5<,1)250$7,21spi[INVESTIGATOR_380726] 
n mild, modn mild, mo
ly minor mly minor m
eriousâ€ wheriousâ€ wh
s that pose s that pos
ryy obligatobligaty ioi
en the admen the adm
ected as deected as d
oonshipnship ofoftff
unlikely orunlikely or
erventervent ioions
xplanatxplanat ioin 
there is a there is a 
IP caused thP caused t
here is evidere is evi
drug anddrug an
ssed as suspsed as susp
en manufacn manufac
r when repr when rep
DuratDurat
r both AEs both AEs 
eventven.
25
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 86 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477000]â€™s participation in the study 
must be followed until recovered, recovered with sequelae, not recovered (death due to another 
cause) or death (due to the SAE). 
11.3. Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
#results in discontinuation from the study;
#requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
#is judged to be of significant clinical importance.
Regardless of severity grade, onl y laboratory abnormalities that  fulfill a seriousness criterion 
need to be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/scr een of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the labor atory abnormality should be recorded as the AE.
11.4. Pregnancy
11.4.1. Females of Childbearing Potential
Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or 
disease state) of a female subject occurring while the subject is on IP, or within [ADDRESS_477001]â€™s last dose of IP, are considered immediately re portable events.  IP is to be discontinued 
immediately.  The pregnancy, suspected pregnancy, or positive pregnancy test must be reported 
to Celgene Drug Safety immediately by [CONTACT_6972], or other appropriate method, using the Pregnancy Initial Report Form, or approved equiv alent form.  
The female subject may be referred to an obstetr ician-gynecologist (not necessarily one with 
reproductive toxicity experience) or another appropriate healthcare professional for further evaluation.
The investigator will follow the f emale subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow- up Report Form, or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous or therapeutic abortion), the 
investigator should report the abnormal outcome as an AE.  If the abnormal outcome meets any 
of the serious criteria, it must be reported as  an SAE to Celgene Drug Safety by [CONTACT_6972], or 
other appropriate method, within 24 hours of the investigatorâ€™s knowledge of the event using the 
SAE Report Form, or approved equivalent form.
All neonatal deaths that occur within [ADDRESS_477002] to 
causality, as SAEs.  In addition, any infant d eath after 28 days that the investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by &(/*(1([ZIP_CODE],(7$5<,1)250$7,21eutic tic 
usness critusness cr
ome, then ome, then o
F.  If.  Ifththe abe a
y shouly shou d be
ng a positng a posit iv
while the subhile the sub
mediatelymediately ry
d pregnancypregnanc
y by [CONTACT_380782]
r approved r approved
ferred to ferred to aa
rienceence) or a)o ra
ll fofollollow thw th
Drug SafetDrug Safet y
comome) e) usinusin
come of theme of th
gatorgato shoushou
he serihe seri ous cous 
other approther appro
SAE RepSAE R
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 87 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015facsimile, or other appropriate method, within 24 hours of the investigatorâ€™s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2. Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant, the male 
subject taking IP should notify the investigator, and the pregnant female partner should be 
advised to call their healthcare provider immediately.
11.5. Reporting of Serious Adverse Events
Any AE that meets a criterion for an SAE re quires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF.  All SAEs must be reported to 
Celgene Drug Safety within 24 hours of the investigatorâ€™s knowledge of the event by [CONTACT_6972], or other appropriate method, using the SAE Report Form, or approved equivalent form.  This 
instruction pertains to initial SAE report s as well as any follow-up reports.
The investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to IP) that occur during the study 
(from the time the s ubject signs informed consent up to and including [ADDRESS_477003] 
study treatment), and those made known to the investigator at anytime thereafter that are 
suspected of being related to IP.  SAEs occurring prior to treatment will be captured.
The SAE report should provide a detailed description of the SAE and include summaries of 
hospi[INVESTIGATOR_27598].  If a subject died and an autopsy has been performed, copi[INVESTIGATOR_27599] d eath certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data will be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by [CONTACT_19666], the investigator is responsible for informing the IRB/EC of 
the SAE and providing them with all relevant init ial and follow-up information about the event. 
The investigator must keep copi[INVESTIGATOR_198476]/EC.
11.5.1. Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (eg, missing causality assessment) may be handled by [CONTACT_648].
11.6. Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to so tatercept based on the Investigator Brochure.
In the [LOCATION_002], all suspected unexpected serious adverse reactions will be reported in an 
expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) in accordance &(/*(1([ZIP_CODE],(7$5<,1)250$7,21rm in m in 
orted to orted to 
by[CONTACT_380783].  Tnt form. 
urate and coate an
) that occurthat occur
ing n42 42daysday
nytnytime therime ther
atment willatment wi
the SAE anhe SAE
ubject died ubject died 
certificate acertificate a
ffollollfffowow-up dup
orm, and seorm, and se
nvestnvest igatorigator
elevant inielevant
of all SAE f all SAE
SAEs will bAEs will b
nic mail.  Tc mail.  T
eries (eries ( egeg, m
ExpediteExpedite
e purpose oe purpose o
nts suspectnts suspect
In the Unin the Uni
xpeditxpedit
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 88 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical studies of investigational products 
for human use (ENTR/CT3) and also in accordance with country-specific requirements.  
Celgene or its authorized representative sh all notify the investigator of the following 
information:
#Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (ie, S[LOCATION_003]R);
#Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by [CONTACT_19666], the investigator shall notify his/her IRB/EC promptly of new 
serious and unexpected AE(s) or significant risks to subjects.
The investigator must keep on file a copy of  pertinent safety information including 
correspondence with Celgene and the IRB/EC.  (See Section 15.[ADDRESS_477004] retention 
information.)
Celgene Drug Safety Contact [CONTACT_7171]:
For Local Drug Safety Affiliate Office contact [CONTACT_3031], please refer to the Serious Adverse 
Event Report Form / Completion Guidelines or to the Pregnancy Report Form / Completion Guidelines.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21enicitnicity.y.
mptly omptly o f f nene
uding udin
d retentiond retention
ase refer toase refer to
ancyancy ReporRepo
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 89 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477005] and/or from the study:
#Hgb > 14 g/dL (not influenced by [CONTACT_27752]), sustained for â‰¥7 days, confirmed by 
[CONTACT_380755] â‰¥1 week apart.
#Hypertension DLT as defined in Section 4.1.1 .
#Any other (ie, excluding Hgb and hypertensi on) treatment-re lated (suspected) toxicity 
â‰¥Grade 3.
#Treatment-related (suspected) toxicity â‰¤Grade 2 that delays treatment by [CONTACT_726] 3 
months.
#Adverse event that, in the judgment of the investigator, may cause severe or 
permanent harm or that rules out continuation of treatment.
#Lack of therapeutic effect, defined by [CONTACT_380784]-E ( Appendix C ) after five cycles (or 
up to eight cycles for potential late responders) of treatment.
#Requirement for reduction of dose to < 0.075 mg/kg Q3W.
#Hypersensitivity reaction to sotatercept.
#Disease progression.
#Withdrawal of consent.
#Death.
#Lost to follow-up.
#Pattern of significant noncompliance.
#Completed study, per protocol (5 complete cycles of 21 days each).  Subjects who 
have a sustained Hgb increase or a decreas ed transfusion burden by [CONTACT_380738] 5
but for a period less than or equal to 8 cons ecutive weeks (potential late responders) 
may continue treatment for up to an additi onal three cycles (Cycles 6-8) for the 
purpose of meeting response criteria.  Survival data and AML progression will 
continue to be collected for up to [ADDRESS_477006] dose of study treatment.
The reason for treatment discontinuation should be recorded in the CRF and in the source 
documents.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21toxicitoxicit y y
by[CONTACT_380785]))af
tmment.e
/kg /kg Q3WQ3W
ncocompplianlian
per protocoer protoc
d Hgb increHgb incr
od less thanod less th
nue treatmenue treatm
e of meetof meet inin
inue to be cinue to be c
for treatmefor treatme
ts.
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 90 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477007] the responsible Clinical Research 
Physician/Medical Monitor or designee by [CONTACT_27722](s) listed on the Emergency 
Contact [CONTACT_27723] (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact [CONTACT_27724] (after title page).  This global 
Emergency Call Center is available 24 hours a day and 7 days a week. The representatives are 
responsible for obtaining your call-back information and contact[CONTACT_27725]/Clinical 
Research Organization (CRO) Medical M onitor, who will then contact [CONTACT_27726].
Note: The back-up [ADDRESS_477008] call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls. 
13.2. Emergency Identification of Investigational Products
This is an open-label study.  The identity of the investigational product is clearly indicated on the 
packaging and labeling.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21not be ot b
ed on d on 
ntatives arentatives ar
Celgene/Celgene/ ClinCli
romomptmly.y.
nlynlybby[CONTACT_380786] (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 91 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477009], evaluation, and 
documentation of this study are designed to ens ure that Celgene, its authorized representative, 
and investigator abide by [CONTACT_23663] (GCP), as described in International Conference 
on Harmonization (ICH) Guideline E6 and in accorda nce with the general ethical principles 
outlined in the Declaration of Helsinki. The study will receive approval from an IRB/Ethics 
Committee (EC) prior to commencement. The investigator will conduct all aspects of this study 
in accordance with applicable national, state, and local laws of the pertinent regulatory 
authorities.
14.2. Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for GCP and in the local 
regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.
The investigator should ensure that all persons assi sting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions. 
The investigator should maintain a list of Sub-investigators and other appropriately qualified 
persons to whom he or she has delegated significant study-related duties.
The investigator is responsible for keepi[INVESTIGATOR_007] a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subjectâ€™s source documents.
The investigator, or a designated member of the investigatorâ€™s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospi[INVESTIGATOR_1332], and study-related charts) for source data verification.  The investigator must ensure timely and accurate completion of CRFs and queries.
14.3. Subject Information and Informed Consent
The investigator must obtain informed consent of a legal representative prior to any study related procedures.
Documentation that informed consen t occurred prior to the study subjectâ€™s entry into the study 
and of the informed consent process should be recorded in the study subjectâ€™s source documents 
including the date.  The original informed consent document signed and dated by [CONTACT_380787]â€™s entry into the 
study, must be maintained in the investigatorâ€™s study files and a copy given to the study subject.  
In addition, if a protocol is amended and it impacts on the content of the informed consent, the informed consent document must be revised.  St udy subjects participating in the study when the 
amended protocol is implemented must be re-conse nted with the revised version of the informed 
consent document.  The revised informed consent document signed and dated by [CONTACT_1758]&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e e 
s 
his studyhis study
ryry
d in the locin the
ate and appte and app
the studythe study ary
as studys study --rer
tors and othors and o
studystud -relrelate
ord of all surd of all su
study.  Subjtudy.  Subj
documents.ocuments
ber of the er of the ini
olve querieolve quer
ospi[INVESTIGATOR_380727] c
ng the dateng the date
ect and by [CONTACT_380788], m, must ustm
In additn addit ioio
formform
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 92 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477010] be maintained in the investigatorâ€™s 
study files and a copy given to the study subject.
14.4. Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (w hichever is most stringent). Celgene requires 
the investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require  a waiver or authorization separate from the 
subjectâ€™s signed informed consent document, it is  the responsibility of the investigator to obtain 
such permission in writing from the appropriate individual.
14.5. Protocol Amendments
Any amendment to this protocol must be approved by [CONTACT_184693]/Medical Moni tor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The written signed approval from the IRB/EC shoul d specifically referen ce the investigator name, 
protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC for information purposes.
14.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol , informed consent document, and any other 
appropriate documents will be submitted to the IRB/EC with a cover letter or a form listing the 
documents submitted, their dates of issue, and the site (or region or area of jurisdiction, as 
applicable) for which approval is sought. If applicable, the documents will also be submitted to the authorities in accordance with local legal requirements.
IP can only be supplied to an investigator by [CONTACT_72648] a nd legal requirements for starting the study has been received by 
[CONTACT_380789]. This documentation mu st also include a list of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue a statement confirming that the composition of the committee is in accordance with GCP. For 
example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by [CONTACT_1201]/EC should mention the protocol title, number, amendment number (if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a commi ttee membe r. Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to &(/*(1([ZIP_CODE],(7$5<,1)250$7,21the the 
ororto obtainto obtain
cal Researcal Rese
RB/EC for B/EC for
mended vemended v
ference theferenc
is applicabis applicab
but will bebut will be
dependdepend enen
otocolotocol , info, info
ted to the IRted to the IR
fissue, andssue, and
s sought. s sought. II
witwith h lolocalcallll
o ano investinv i
ethical and thical and 
orized reprezed repre
IRB/EC anIRB/EC an
cupations acupations 
t confirminconfirmin
e, the IRB e, the IRB 
mal approvamal approv
fapplicableapplicable
&documdocum entent
fficialfficia
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 93 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477011] of all comm unication with the IRB/EC  and, if applicable, 
between a Coordinating investigator [INVESTIGATOR_72616]/EC. This statement also applies to any communication between the investigator (or Coordi nating investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by [CONTACT_27734]/EC prior to use.
14.7. Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by [CONTACT_27735]/EC, the investigator must submit to the IRB/EC:
#Information on serious or unexpected AEs as soon as possible; 
#Periodic reports on the progress of the study;
#Deviations from the protocol or anything that may involve added risk to subjects.
14.8. Closure of the Study
Celgene reserves the right to terminate this study at any time for reasonable medical or 
administrative reasons. Any premature disc ontinuation will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc.).
In addition, the investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
#Unsatisfactory enrollment;
#GCP noncompliance;
#Inaccurate or incomplete data collection;
#Falsification of records;
#Failure to adhere to the study protocol.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21/EC:/EC:
ve added rive added
me mefofor rear rea
n will be apn will be ap
atoryatory authoauthyy
riight to dight to di
e reasons se reasons s
pplete data clete data c
records;ecords;
dhere to thedhere to th
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 94 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 201515. DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_1645] 
15.1. Data/Documents
The investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigat ional product are complete, accurate, filed and 
retained.  Examples of source documents include: hospi[INVESTIGATOR_1097]; clinic and office charts; 
laboratory notes; memoranda; subjectâ€™s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copi[INVESTIGATOR_27602]; microfiche; x-ray film and re ports; and records kept at the pharmacy, and 
the laboratories, as well as copi[INVESTIGATOR_27603]-ROM.
15.2. Data Management
Data will be collected via CRF and entered into the clinical database per Celgene SOPs. This data will be electronically verified through use of programmed edit checks specified by [CONTACT_6098].  Discrepancies in the data will be brought to the attention of the clinical team, and 
investigational site personnel, if necessary.  Resolutions to these issues will be reflected in the 
database.  An audit trail within the system will track all changes made to the data.
15.3. Record Retention
Essential documents must be retained by [CONTACT_249317] a minimum of [ADDRESS_477012] retain these 
documents for the time period described above  or according to local laws or requirements, 
whichever is longer.  Essential documents include, but are not limited to, the following:
#Signed informed consent documents for all subjects
#Subject identification code list, screening log (if applicable), and enrollment log
#Record of all communications between the investigator and the IRB/EC
#Composition of the IRB/EC
#Record of all communications between the inve stigator, Celgene, and their authorized 
representative(s)
#List of Sub-investigators and other appropriately qualified persons to whom the 
investigator has delegated significant study-related duties, together with their roles in the study, curriculum vitae, and their signatures
#Copi[INVESTIGATOR_3110] (if paper) and of documentation of corrections for all subjects
#IP accountab ility rec ords
#Record of any body fluids or tissue samples retained&(/*(1([ZIP_CODE],(7$5<,1)250$7,21on as n as 
macy, and acy, and
elgene SOPelgene SOP
cks specifies speci
on of the cln of the c
sues will bsues will 
s made to tmade
atoratorfoor a mr a
ion and untion and unt
H region, or region, o
ent of the IPent of the IP
above or acabove or ac
ents includets includ
nt documennt docume
oon code lisn code li
ommumunica
on ofon of  the Itheff
d of all cod of all co
presentativeesentativ
List of SuList of Su
investinvesti
ththee
##
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 95 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015#All other source documents (subject records , hospi[INVESTIGATOR_1097], laboratory records, 
etc.)
#All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial)
The investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The investigator must obtain approval in writi ng from Celgene prior to destruction of any 
records. If the investigator is unable to meet this obligation, the investigator must ask Celgene for permission to make alternative arrang ements. Details of these arrangements should be 
documented.
All study documents should be made available if required by [CONTACT_27737]. 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.ne 
ities. ties.
destructiondestruction
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 96 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477013] keepi[INVESTIGATOR_007], and reporting of AEs/SAEs with the investigator.  Monitoring 
will include on-site visits with the investigator and his/her staff as well as any appropriate 
communications by [CONTACT_2319], email, fax, or telephone.  At each monitoring visit, the facilities, investigational product storage area, CRFs, subjectâ€™s source documents, and all other study 
documentation will be inspected/reviewed by [CONTACT_380790], adherence 
to the protocol and GCP.
Accuracy will be checked by [CONTACT_12939] a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the investigator and/or his/her staff.  Any necessary corrections will be made directly to the CRFs or via queries by [CONTACT_1755]/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2. Audits and Inspections
In addition to the routine monitoring procedure s, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs to evaluate compliance with GCP guidelines and 
regulations.
The investigator is required to permit direct acce ss to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by [CONTACT_1744]/IECs, regu latory authorities (eg, FDA, EMA, H ealth Canada) and 
company authorized representatives.  The investigator should make every effort to be available 
for the audits and/or inspections.  If the inve stigator is contact[CONTACT_72652], he/she should contact [CONTACT_27740].fter ter 
ects of cts of 
nto the to the 
ining ining 
tortor.  Moni.  Moni ti
appropriatappropria
it, the facilit, the facil
and all othnd all 
tiive fve fiior acor acff
oon that in that s a
rce documece docum
d/or his/her /or his/he
queries by [CONTACT_380791] t
d consents, d consents, 
roper recoroper reco
udyudy--specifispecifi
s
ng procedung procedu
presentativeresentative
Celgene Celgene S
quired to pquired to 
 CRFs andCRFs and
ectectioions by [CONTACT_380792]/or ts and/or i
ing an inspeng an inspe
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 97 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477014] authorship 
will be based on several considerations, including, but not limited to study participation, 
contribution to the protocol development, and analysis and input into the manuscript, related 
abstracts, and presentations in a study.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 98 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 201518. REFERENCES
Acceleron Report Number A011-01:  A single-center, randomized, double-blind, placebo-
controlled, single-dose, dose-escalation study  to evaluate the safety, tolerability, 
pharmacokinetics, and effects on bone biomarkers of ACE-011 (ActRIIA-IgG1) administered to 
healt hy, postmenopausal volunteers. Report included in Original IND submitted on 27 March 
2009 (Serial No. 0000).
Acceleron Report Number A011-02:  A randomized, double-blind, placebo-controlled, multiple-
dose, dose-escalation study to evaluate the safety, tolerability, and pharmacodynamics of ACE-011 (ActRIIA-IgG1) in h ealthy postme nopausal women. Report included in Original IND 
submitted on 27 March 2009 (Serial No. 0000).
 
 
Chen YG, Lui HM, Lin SL, Lee JM, Ying S-Y.  Regulation of cell proliferation, apoptosis, and 
carcinogenesis by [CONTACT_380793].  Exp Biol Med. 2002;227:75-87. 
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical 
application and proposal for modification of the International Working Group (IWG) response 
criteria in myelodysplasia. Blood. 2006;108:419-25.
Cockcroft DW, Gault MH.  Prediction of creatinine clearance from serum creatinine.  Nephron 
1976; 16: 31-41.
 
 
Greenberg P, Cox C, Lebeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring 
system for evaluating prognosis in myel odysplastic syndromes. Blood. 1997;89:2079-88.
Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999;340:1649-60.
 
 
 
 
 
Komrokji RS, Sekeres MA, List AF. Management  of lower-risk myelodysplastic syndromes: the 
art and evidence. Curr Hematol Malig Rep. 2011;6:145-53.
 &(/*(1(3523M, Fenaux M, Fenaux 
sisis in myels in myel
MyelMyel odyspod
KoKomrmrokjiokjiRRii
art and evrt and e*(/*(/*1((1((15,(7$5<,1)250$7,21ipleple-
AACECE--
ND ND 
 propliferatliferat i
jermans PWermans PW
onalonal W Wllorko
ne clearancne clearan25)251)2
&35,[ZIP_CODE]
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 99 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Mathews LS.  Activin receptors and cellular signaling by [CONTACT_380794].  
Endocr Rev. 1994;15: 310-25.
Murata M, Onomichi K, Eto Y, Shibai H, Muramats u M.  Expression of eryt hroid differentiation 
factor (EDF) in Chinese hamster ovary cells.  Biochem Biophys Res Commun. 1988;151:230-5.
Nakao K, Kosaka M, Saito S.  Effects of erythroid differentiation factor (EDF) on proliferation 
and differentiation of human hematopoietic progenitors.  Exp Hematol. 1991;19: 1090-5.
National Heart, Lung, and Blood Institute, N ational Institutes of Health.  [LOCATION_001] Heart 
Association Classification. 2008.
 
 
 
Perrien DS, Akel NS, Edwards PK, Carver AA, Be ndre MS, Swain FL, et. al.  Inhibin A is an 
endocrine stimulator of bone mass and strength.  Endocrinology. 2007;148:1654-65.
Raza A., Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, et al. Phase 2 study of 
lenalidomide in transfusion-dependent, low- risk, and intermediate-1 risk myelodysplastic 
syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86-93.
Rivier J, Spi[INVESTIGATOR_94053] J, McClintock R, Vaughan J, Vale W.  Purification and partial characterization 
of inhibin from porcine follicular fluid.  Biochem Biophys Res Commun. 1985; 133:120-7.
Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW, et. al.  Single-dose, 
randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.  J Bone Miner Res. 2009;24:744-52.
  
 
 
 
Shiozaki M, Sakai R, Tabuchi M, Nakamura T,  Sugino K, Sugino H, et al.  Evidence for the 
participation of endogenous activin A/erythroid differentiation factor in the regulation of 
erythropoiesis.  Proc N atl Acad Sci [LOCATION_003]. 1992;89:1553-6. 
Shiozaki M, Sakai R, Tabuchi M, Eto Y, Kosaka M, Shibai H.  In vivo treatment with erythroid 
differentiation factor (EDF/activin A) increases erythroid precursors (CFU-E and BFU-E) in 
mice.  Biochem Biophys Res Commun. 1989;165:1155-61.
Sitnicka E, Ruscetti FW, Priestley GV, Wolf NS, Bartelmez SH. Transforming growth factor 
beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating 
hematopoietic stem cells. Blood. 1996;88:82-8.&(/*(1(R, Tabuchi Tabuchi 
endogenousndogenous
  Proc NatProc Na
M, Sakai R, Sakai R
nttiatiaion nfacfac
e.  e.  BiBiochemochem
SiSitnicka E,tnicka Eiii
beta 1 deta 1 d5235,(7$5<,1)2et. alet. al .  .InhIn
07;148:1657;148:165
eg HJ, eg H et al
diatediate -1 ri1 risk
2008;111:2008;111
 PurificatPurificat ii
iiophys Reophys Re
Kumar R, Uumar R, U
ed study oed study o ff
ResRes..2009;[ZIP_CODE];2
235235235(350$7,210
250)25
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 100 ACE-011-MDS-001 Amendment 4 Final: [ADDRESS_477015], Borowitz MJ, Porwit A, et al. The 2008 
revision of the World Health Organization (W HO) classification of myeloid neoplasms and acute 
leukemia: rationale and important changes. Blood. 2009;114:937-51.
Woodruff TK.  Regulation of cellular and system function by [CONTACT_380793].  Biochem Pharmacol.
1998;55:953-63. 
Ying SY.  Inhibins, activins, and follistatins:  gonadal proteins modulating the secretion of 
follicle-stimulating hormone.  Endocrine Rev. 1988;9:267-93.
Zermati Y, Fichelson S, Valensi F, Freyssinier JM, Rouyer-Fessard P, Cramer E, et al.
Transforming growth factor inhi bits erythropoiesis by [CONTACT_380795]. Exp Hematol. 2000a;28:885-94
Zermati Y, Varet B, Hermine O. TGF-beta1 drives and accelerates erythroid differentiation in 
the epo-dependent UT-7 cell line even in the absence of erythropoietin. Exp Hematol.
2000b;28:256-66.
Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, et al. Reduced SMAD7 leads to 
overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of 
TGF-beta receptor I kinase. Cancer Res. 2011;71:955-63.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21ting ing
ententiatiatioion nin
matolmatol .
uced SMAced SM
a spa specific ecific 
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 101 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 201519. APPENDICES
Appendix A: The World Health Organization (WHO) Classification of the 
Myeloid Neoplasms and Leukemia ( Vardiman, 2009 )
* For this study only non-prolifer ative CMML will be included.Category Peripheral Blood Bone Marrow
Refractory anemia (RA) Anemia
< 1% blasts
< 1x109monocytesErythroid dysplasia
< 10 % myeloid or megakaryocytic dysplasia
< 5% blasts< 15% sideroblasts 
Refractory anemia with ring 
sideroblasts (RARS)Anemia
< 1% blasts 
< 1x109monocytesErythroid dysplasia
< 10 % myeloid or megakaryocytic dysplasia
< 5% blasts
> 15% sideroblasts
Refractory cytopenia with 
multilineage dysplasia (RCMD)Bi-or pancytopenia
< 1% blasts< 1x10
9monocytesDysplasia in > 10% of the cells in 2 or more cell lines
< 5% blasts< 15% sideroblasts
Refractory anemia with 
multilineage dysplasia and 
ring sideroblasts (RCMD-RS)Bi-or pancytopenia
< 1% blasts
< 1x109monocytesDysplasia in > 10% of the cells in 2 or more cell lines
< 5% blasts 
> 15% sideroblasts
Refractory anemia with excess 
blasts type I & II (RAEB-1 & 
RAEB II)Cytopenia
Type I: 1-5% blasts
Type II: 5-19% blasts Uni or multilineage dysplasia
Type I 5-9% blasts
Type II 10-19% blasts
5q- syndrome Anemia
Normal or elevated 
platelets
< 5% blastsNormal or increased megakaryocytes
<5% blasts
MDS unclassified (MDS-U) Cytopenia
< 1% blastsunilineage dysplasia of myeloid or megakaryocytic line
< 5% blasts
MDS/MPNMyelodysplastic 
syndromes/myeloproliferative neoplasms
-CMML
*
--MDS/MPN-U&For this For this&(-&(/*(1stic tic 
s/myeloprolifyeloprol
msms
MMLML*(1(352iaa
rmal omal o235,(7$5<,1)250$7,2177$7a$7$7$7
yocytic dyspocytic 2
0% of the cel0% of th
deroblastseroblasts<,
lasia in > 10lasia in > 
5% blasts 5% blasts 
>>15% sid15% sid7$
5blastsblasts
19% blasts 19% blasUnUni oi o
Ty555,(35
r elevr eleooo
plateletsplatelets
<5% bla5%23
(U)U) CyCytoy((((
MDS/MPNMDS/MPN(1
&
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 102 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Appendix B: International Prognostic Scoring System for MDS
(Greenberg, 1997 )
Survival and AML Evolution Score Value
Prognostic Variable 0 0.5 1.0 1.5 2.0
Marrow Blasts (%) < 5 5 to 10 n/a 11 to 20 21 to 30
Karyotype Good
Normal or any 1 
of:
-Y
del(5q)
del(20q)Intermediate
Any other 
chromosome 
anomalyPoor
chromosome 7 
anomalies;
Complex:
!3 chromosome 
anomaliesn/a n/a
Cytopenias:
Neutrophil c ount < 1800/ %L
Platelets < 100,000/ %L
Hb < 10 g/dL0 or 1 2 or 3 n/a n/a n/a
The total IPSS score and IPSS risk category are calculated as the sum of three individual scores 
based on the marrow blast percentage, the karyotype, and the number of cytopenias.
Risk Category Combined Score = Sum of Marrow blast + Karyotype + Cytopenia Score
Low 0
Intermediate-1 0.5 to 1.0
Intermediate-2 1.5 to 2.0
High !2.5
&(/*(1([ZIP_CODE],(7$row blast + ow blast + (77$5<,1)250$7,2177$7a$7$7
25$7
aa252525
,125
hhe sume sum ofm tf
he numbere numbe
7$(75,3525
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 103 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Appendix C: International Working Group (IWG) Response Criteria in 
Myelodysplasia ( Cheson, 2006 )
Altering Disease Natural History
Complete remission (CR) Bone ma rrow: â‰¤5% myeloblasts with normal maturation of all cell lines
Persistent dysplasia will be notedPeripheral blood:
Hemoglobin â‰¥11 g/dL
Platelets â‰¥100 x 10
9/L
Neutrophils â‰¥1.0 x 109/L
Blasts 0%
Partial remission (PR) All CR criteria if  abnormal before treatment, except:
Bone ma rrow blasts decreased by â‰¥50% over pretreatment but still > 5%
Cellularity and morphology not relevant
Marrow CR Bone ma rrow:  â‰¤5% myeloblasts and decrease by â‰¥50% over 
pretreatment
Peripheral blood:  if HI responses, they will be noted in addition to marrow 
CR
Stable disease (SD) Failure to achieve at least PR, but no evidence of progression for
> 8 weeks
Failure Death during treatment
Disease progression characterized by [CONTACT_55579], increase in 
% of bone marrow blasts, or progression to a more advanced MDS FAB 
subtype than pretreatment
Disease Progression (PD) For patients with:
#Less than 5% blasts:  â‰¥50% increase in blasts to > 5% blasts
#5%-10% blasts:  â‰¥ 50% increase in blasts to > 10% blasts
#10%-20% blasts:  â‰¥50% increase in blasts to > 20% blasts
#20%-30% blasts:  â‰¥50% increase in blasts to > 30% blasts
Any of the following:
#At least 50% decrement from maximum remission/response levels in 
granulocytes or platelets
#Reduction in Hgb concentration by â‰¥2 g/dL 
#Transfusion dependence&(/*(1(&(352r patients wipatients wi
##Less thaLess th
#5%5%
##5235,(7$5<,1)250$7,21$7
ept:pt:
pretreatmenpretreatme)2
decrease by[CONTACT_380796], they wiles, they w<,
st PR, but nst PR, but n7$
atmentatment
ression charression ch
marrow blamarrow
e than pretrehan pretre5,(
52
(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 104 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Appendix C: International Working Group (IWG) Response Criteria in 
Myelodysplasia ( Cheson, 2006 ) (Continued)
Altering Disease Natural History
Disease transformation Transformation to AML (30% or more blasts)
Relapse after CR or PR At least one of the following:
#Return to pretreatment bone marrow blast %
#Decrement of â‰¥50% from maximum remission/response levels in 
granulocytes or platelets
#Reduction in Hgb concentration by â‰¥1.5 g/dL or transfusion 
dependence
Cytogenetic Response
Complete Disappearance of the chromosomal abnormality without appearance of 
new ones
Partial At least 50% reduction of the chromosomal abnormality
Hematological Improvement (HI)
Erythroid response (HI-E)
(Pretreatment < 11 g/dL) Hgb increase by â‰¥1.5 g/dL
Relevant reduction of units of RBC transfusions by [CONTACT_51244] 4 RBC transfusions/8 weeks compared with the pretreatment 
transfusion number in the previous 8 weeks.  Only RBC transfusions 
given for a Hgb of â‰¤9.0 g/dL pretreatment will count in the RBC 
transfusion evaluation
Platelet response (HI-P)
(Pretreatment < 100 x 109/L)Absolute increase of â‰¥30 x 109/L for patients starting with > 20 x 109/L
Increase from < 20 x 109/L to > 20 x 109/L and by [CONTACT_2669] 100%
Neutrophil response (HI-N)(Pretreatment < 1.0 x 10
9/L)At least 100% increase and an absolute increase of > 0.5 x 109/L
Progression/relapse after HI At least one of the following:
#At least 50% decrement from maximum response levels in 
granulocytes or platelets 
#Reduction in Hgb by â‰¥1.5 g/dL
#Transfusion dependencevels in ls in 
nsfusion sfusion 
2$7
)2
rmality withmality with1)
omosomal abomosomal<5<$5g/dLg/d
n of units of of units o
C transfusioC transfusio
number in thumber in th
a Hgb of a Hgb of â‰¤â‰¤
sion evaluatsion eva7$
solute incresolute incr
Increase frIncrease fr23
3/L)/L)At leaAt3335(3 after HI after HI 1(((
(/(
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 105 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Appendix D: ECOG Performance Status Scale
The ECOG Performance Status Scale is used to score a subjectâ€™s quality of life through
evaluation, by a health professional, of daily activities and how thos e activities are aff ected by 
[CONTACT_380797].
Score Description
0 Fully active, able to carry on all pre-disease performance without restriction.
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light housework, office work.
2 Ambulatory and capable of all self-care but unable to carry out any work activities.  Up and 
about more than 50% of waking hours.
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours.
4 Completely disabled.  Cannot carry on any self-care.  Totally confined to bed or chair.
5D e a d
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7$7$7$7
out work of out work of0$
work activiwork activi25
more than 5more than1
e.  Totally co.  Totally c<
$57$
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 106 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Appendix E: [LOCATION_001] Heart Association âˆ€âˆ€Classification of Heart Failure
Classification of Heart Failure
Class Symptoms
Class [ADDRESS_477016], confined to bed or chair; any physical activity brings on discomfort and 
symptoms occur at rest
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21$7$7$7$70$
 on discomfon discomf25
1)
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 107 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Appendix F: National Cancer Institute (NCI) Common Terminology Criteria 
for Adverse Events (CTCAE) Version 4.0
Currently active minor version of NCI CTCAE, Version 4.0:
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21
*(1([ZIP_CODE],(7$5<,1)250$7,2
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 109 ACE-011-MDS-001 Amendment 4 Final: 4 Aug 2015Appendix H: Cockcroft-Gault Estimation Of Creatinine Clearance (Crcl)
Cockcroft-Gault estimation of creatinine clearance (CRcl): CRcl (mL/min) = (140 â€“ age) (weight 
[kg]) / 72 (serum creatinine [mg/dl]); for females, the formula is multiplied by 0.85 ( Cockcroft, 
1976 ;Luke, 1990 ).
&(/*(1([ZIP_CODE],(7$5<,1)250$7,[ADDRESS_477017] that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature [CONTACT_13695].
8VHU1DPH 
7LWOH 'DWH7KXUVGD\$XJXVW$0(DVWHUQ'D\OLJKW7LP H
0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\                                                
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21   
Sotatercept (ACE-011)
Summary of Changes ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 3 ACE-011-MDS-001 A mendment 4 Final: 04 Aug [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below:
!Subjects in the sotatercept 2.0 mg/kg dosing group were dose reduced to sotatercept 1.5 
mg/kg.
!Subsequent enrollment into this dosing group is at sotatercept 1.5 mg/kg.
!Enrollment into Part 2 (expansion) to commence without delay at a sotatercept dose 
level of 1.0 mg/kg. 
Revised Sections: Summary of Protocol, Section 4.1, 4.2, 7.1, 8.2, 8.2.1, 8.3.2, 10.1 and 10.8
The ACE-011-MDS-001 Steering Committee met on 02 Mar 2015 to review available safety, 
efficacy and pharmacokinetic data up to and including the sotatercept 2.0 mg/kg dose level (five subjects at 2.0 mg/kg). The following recommendations were made:
!Closure of the 2.0 mg/kg cohort to further enrollment and sotatercept dose reduction to 
1.5 mg/kg, at the next planned dose administration, for active patients and subsequent patients enrolled to this cohort. 
!Begin enrollment into Part 2 (expans ion) of the study immediately at 1.0 mg/kg 
sotatercept.
A letter was sent to the investigative si tes on [ADDRESS_477018] been incorporated in Amendment 4.
!Language was added to include the availability of a roll-over protocol for subjects that 
remain on study following the analysis of all key endpoints and objectives of the study.
Revised Sections: Summary of Protocol and Section 4.[ADDRESS_477019] the opportunity to 
continue therapy when enrolled into the planned rollover protocol, per investigator discretion.
!A request for historic MDS molecular mutational analysis data, if available, has been
added.
Revised Sections: Summary of Protocol, Sections 5 (Table of Events) and 6.Historic MDS molecular mutational analysis data is requested to assess any correlation of a 
specific mutation(s) and safety and efficacy parameters.   
!Recently published preclinical data has been added.
Revised Section:  Sections 1.1 and 1.2.1
 
!Addition of references related to recently published preclinical data .
Revised Section:  References&(/*(1([ZIP_CODE],(7$5<,1)250$7,21se e 
and 10.8and 10.[ADDRESS_477020]
above. above. 
ve been incbeen inc
he availabilhe availabi
analysis ofnalysis o
tocoloc and Sand l
benefit frombenefit from
lled into theled into t
storic MDSstoric MD
: : SummarSummar
S mS mololeculaecul
mutation(s) tation(s) 
RecentlyRecent
evised Secevised Sec&&
Sotatercept (ACE-011)
Summary of Changes ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 4 ACE-011-MDS-001 A mendment 4 Final: 04 Aug 2015The amendment also includes several other minor clarifications and corrections:
!Addition of the name [CONTACT_380803].
Revised Section:  Celgene Therapeutic Area Head Signature [CONTACT_3490]
!Clarifying language has been added to describe the completion of treatment in the 
Treatment Period versus the completion of tr eatment in the Extension Period to facilitate 
more accurate data capture and assessment implementation. 
Revised Sections: Summary of Protocol , Sections 4.1.2, 4.3 and 5 (Table of Events)
!Clarification on when transfusions should be recorded and recording of pre-transfusion
hemoglobin levels.
Revised Sections: Summary of Protocol , Section 5 (Table of Events), and 6
!Clarification of subject eligibility for the Extension Period of the study has been added. 
Revised Section: Section 4.1.2
!Clarification of bone marrow aspi[INVESTIGATOR_380728].
Revised Sections: Section 5 (Table of Events) and 6
!Other administrative changes (e.g., correction of  typographical errors, editorial changes, 
etc.) were also incorporated.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21he he
to fto faciliaciliff tataiii
Events)Events)
ding of ng of pre
ents), and 6ts), and 6
erieriod ofod of  thethff
taining has aining ha
) and 6) and 6
.,.,ccorrectiorrecti oo
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 3 ACE-011-MDS-001 Amendment 3 Fin al: 05 Aug [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized in this section.
The main objective of this amendment is to include additional dose levels beyond 0.5 mg/kg, as 
described below:
!Additional dose levels added beyond 0.5 mg /kg cohort (ie, 1.0 mg/kg SC Q3W and 2.0 
mg/kg SQ Q3W), as 0.5 mg/kg may be sub-therapeutic in study population.  
!Additional safety measure added to ensure adequate data are available and reviewed by 
[CONTACT_380798].
!Additional safety measure added to allow potential exploration of intermediate dose 
levels (eg, 0.75 mg/kg and 1.5 mg/kg) at time of dose escalation to 1.0 mg/kg and 2.0 
mg/kg respectively upon Steering Committee review of safety and efficacy data.
!Additional dose reduction levels added to account for additional dose levels added 
beyond 0.5 mg/kg.
!New text added to provide guidance to sites when total volume of calculated dose 
exceeds what is typi[INVESTIGATOR_380729].  
!  
!New text added related to timing of Steering Committee meetings to account for 
additional dose levels beyond 0.5 mg/kg.
The following changes are based on feedback from the Steering Committee, site investigators, or 
site staff after commencement of enrollment and additional experience obtained during conduct 
of the trial.
!Additional guidance related to pre-dose H gb level prior to Cycle 1 Day 1 treatment 
administration for subjects who are deemed TIE per protocol.  
!New text added related to Steering Committee guidance on closure of treatment group to 
further enrollment due to lack of efficacy to minimize number of patients enrolled at sub-
therapeutic doses after their rev iew of safety and efficacy data.
!New text added to account for varying operational logistics at study sites related to timing 
of availability of pre-dose Hgb result.  
!Clarification on HI-E definition for subjects who are classified as TIE per protocol.
!Clarification added that hypertension DLT should be confirmed by [CONTACT_290240]/clinical site at the clinical site and not based solely on a measurement taken at home by [CONTACT_380760].&(/*(1([ZIP_CODE],(7eering Coeering Co mm
g/kg.g/kg.
n feedback feedback
f enrollmenf enrollmen
nce related nce relat
for subjectfor subject
added relatadded relat
enrollmentenrollme
apeutiapeuti c dosc dos
New N texttextaa
ofof availa availff$5<,1)250$7,21.0 .0 
viewed by [CONTACT_380799] d
.0 m.0 mg/kg ag/kg mm
nd efficacy effica
nal dose leal dose le
al voal vo lume me
njectnject ioion.  
!!ClClara
!!7$(7$
Sotatercept (ACE-011)
Protocol ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 4 ACE-011-MDS-001 Amendment 3 Fin al: 05 Aug 2013!Clarification added related to protocol-required prior ESA treatment, accepting either 
alpha or beta (applicable in EU) rHu EPO and to account that subjects may receive optimal dose regimen at varying frequencies.
 
Additional inclusion criteria added to limit number of lines of prior MDS treatment (not 
including ESAs) to balance heavily pre-treated  and non-heavily pre-treatment patient population.
 
 
New text added to account for varying operational logistics at study sites related to timing of 
availability of pre-dose Hgb result.  
New text added to clarify that weekly blood pressure monitoring at home (if applicable to 
subject) may be measured by [CONTACT_380800].
New text added related to â€œEnd of Trialâ€ and â€œOverdoseâ€ definition from updated Celgene 
protocol template.
Other changes (eg, update of protocol template sections, correction of typographical errors, 
editorial changes, changes to ensure consistency of text throughout document, modifications 
related to Celgene Style Guide, etc.) were al so incorporated and are detailed in Section 2, 
Itemized Changes.
&(/*(1([ZIP_CODE],(7$5<,1)2ites relatedtes relatedi
ng at homeng at ho
eâ€ definiteâ€ definit ioi
sections, cosections, co
ncy of ncy of texttext
also incorpalso incorp0$7,21pululataioion.n.
50$[ZIP_CODE])25
Sotatercept (ACE-011)
Summary of Changes ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 3 ACE-011-MDS-001 Amendment 2 Final: 13 Feb [ZIP_CODE]. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below.
The following changes are based on feedback received from the Steering Committee, study 
investigators, and site staff upon review of Amendment 1 of protocol ACE-011-MDS-001 in forums such as the Steering Committee Kick-Off Meeting, Investigator Meeting, Site Initiation 
Visits, or site ad hoc review of the protocol:
!Add clarification related to the hypertension dose- limiting toxicity (DLT) definition to 
ensure harmonization of DLT assessment for hypertension across all study sites due to 
unique attributes of th e study population.  
!Provide clear parameters for Extension Period eligibility to offer flexibility for those 
subjects who do not meet protocol-defined er ythroid hematological improvement (HI-E) 
to enter the Extension Period, at the investigatorâ€™s discretion, if clinical benefit is seen at 
the conclusion of the Treatment Period.  
!Remove the Cycle 3 Day 1 mandatory MDS response assessment as it is deemed too 
soon after initiation of treatment of study drug.
!Continue to follow efficacy parameters (ie Hgb and transfusions) for up to [ADDRESS_477021] dose of study drug or start of next treatment to assess potential late response after 
study drug discontinuation as is somet imes observed with erythroid stimulating agents 
(ESAs).
!Modify the adverse event reporting period to [ADDRESS_477022] dose is administered
(regardless of causality) to account for the lik elihood that the subject will begin 
additional cytotoxic treatment after treatment discontinuation.  Beyond [ADDRESS_477023] ill be re ported.
!Include chromosome del5q MDS patients who have failed on lenolidomide, intolerable to 
lenalidomide, or have other cytopenia precluding use of lenalidomide, as these patients 
could potentially benefit from  treatment with sotatercept.
The following changes are based on  
 review of Amendment 1 of protocol ACE-011-MDS-001:
!Increase the frequency of blood pressure monitoring from once per cycle to weekly 
during the first 5 cycles of treatment, with the added flexibility of home monitoring.  
!Addition of an Independent Cardiologist to  the Steering Committee to  focus on potential 
cardiovascular effects of the study drug.
!Increase the contraception use requirement for males after the last administration of study 
drug from 112 days to 7 months/210 days to account for the limited data on the study drugâ€™s effect on spermatogenesis.  
The following changes are based on review 
of Amendment 1 of protocol ACE-011-MDS-001:&(/*(1([ZIP_CODE],(7$5<,1)250$7,21n 
ititiionon to  to nn
testesdue todue to
bilitbility yfoor tr
ll improvem improvemll
clinical beclinical b
sessment sessm
and transfusd transf
tment ment to asto as
observed observe
period to 4period to 
nt for nt for ththe l
after treatmafter tr
o studystudy  drudruy
del5q MDS el5q MDS
ve other cye other c
benefit fbenefit f rof
ges are basees are bas
view of Amview of Am
ase se ththe efreqfreq
ring ngththe e firfir
AddAditioion
cardicardi oo
!InIn
Sotatercept (ACE-011)
Summary of Changes ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 4 ACE-011-MDS-001 Amendment 2 Final: 13 Feb 2013!Agreement on additional language related to clarification of the hypertension DLT 
definition.
!Exclusion of subjects at high risk for cardiovascular events, including those requiring 
chronic anticoagulant therapy during the course of the study and those with myocardial 
infarction within 6 months of study start.  
!Addition of ECG assessments during the Treatment Period to further explore potential 
cardiovascular effects of the study drug.
Other administrative changes (eg, update of p rotocol template sections, correction of 
typographical errors, editorial changes) were also incorporated and are detailed in Section 2, Itemized Changes.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21cttioion 2, n 2, 
Sotatercept (ACE-011)
Summary of Changes ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 3 ACE-011-MDS-001 AMENDMENT 1 FINAL: 13SEP20121. JUSTIFICATION FOR AMENDMENT
Significant changes included in this amendment are summarized below.  
The following changes are based on feedback received following  
review of the final protocol ACE-011-MDS-001:
1. Revision of protocol title and Inclusion Criteria to reflect the inclusion of CMML as a 
sub-classification of the MDS/MPN sub-group as outlined in protocol Appendix A â€˜The 
World Health Organization (WHO) Classification of the Myeloid Neoplasms and 
Leukemiaâ€™.
2. Revision of the dose- limiting toxicity (DLT) cr iteria, Rules for Delay, Reduction and 
Discontinuation of Treatment (Table 7) and Reasons for Discontinuation for:
a. Hemoglobin > 12 g/dL, sustained for â‰¥7 days, confirmed by 2 assessments â‰¥1 
week apart.
b. Hypertension â‰¥Grade 2 according to National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 (current active minor version), blood pressure values must be confirmed by [CONTACT_380801] 5 minutes apart.
c. Treatment-related (suspected) toxicity â‰¥Grade 3.
3. Clarification of definition of favorable safety profile as a safe, tolerable and effective 
dose of sotatercept that results in the gr eatest frequency of erythroid hematological 
improvement in patients with anemia and low- or intermediate-1 risk myelodysplastic 
syndromes.   
4. Addition of specific early stoppi[INVESTIGATOR_380730] a dose cohort.
5. Revision of inclusion criteria to:
a. Only allow sub jects requiring red blood cell transfusions to be eligible for the 
study. 
b. Add language that females of child bearing potential must agree to use effective 
contraception while participating in this study. 
c. Add pregnancy prevention language for males participating in this study.
6. Revision of exclusion criteria to excl ude subjects with uncontrolled hypertension 
(systolic blood pressure (SBP) >
140 mm Hg or diastolic blood pressure (DBP) â‰¥90).  
a. Controlled hypertension for this protocol is considered â‰¤ Grade 1 according to 
NCI CTCAE version 4.0 (current active minor version).
7. Revision of Rules for Delay, Reduction and Discontinuation of Treatment Section,
including Table 7, to:
a. Clarify discontinuation due to treatment-related  (suspected) toxicity â‰¥Grade 3.&(/*(1([ZIP_CODE],(7$5<,1)250$7,21e e
ctctioion and n and 
for:r:
2 assessme assessme
Institute Constitute C
CAECA ))versiovers
st be confirt be c
Grade 3rade [ADDRESS_477024] freque
and lownd low -oror
ing criteriang criteri
hort.ort.
teriteria toa to::
ubjectsubjects reqre
anguage thnguage t
ntraceptionntraception
AddAdd pregpreg
evisioision of en of e
(systolic b(systolic b
aa
7.7
Sotatercept (ACE-011)
Summary of Changes ACE-011-MDS-001 Celgene Corporation
Confidential and Propri etary 4 ACE-011-MDS-001 AMENDMENT 1 FINAL: 13SEP2012b. Clarify discontinuation due to treatment-related  (suspected) toxicity â‰¤Grade 2 
that delays treatment by [CONTACT_726] 3 months.
c. Provide dose reduction guidance for sub jects who experience a rapid rise in 
hemoglobin.
8. Revision of Causality Section to define that a temporal relationship is not necessary to 
make causality possible. 
9. Clarification of the Treatment Plan for Part 1 and Part 2 of the study. 10. Clarification of reporting of all Suspected Unexpected Serious Adverse Reactions in 
accordance with 21 Code of Federal Regulations (CFR) 312.32.
Additional changes include:11. Addition of serum erythropoietin assess ment during screening period to determine 
stratification
12. Modification of Introduction to include information about variation of anemia associated 
with myelodysplastic syndromes and revise description of sotatercept.  
13. Clarification of the scope of activity and meeting schedule of the steering committee.
14. Clarification of the start of enrollment into Part 2 of the study.15. Clarification of the study start timeframe as the date of rando mization in Part 1 and the 
date of start of therapy in Part 2 of the study.
16. Revision of the approximate number of study  sites to participate in the study.
17. Clarify use of central laboratory for clin ical laboratory assessments and when a local 
laboratory is allowed to be utilized.
18. Clarify version of NCI CTCAE to be utilized in the study.19. Addition of a reference.
Other administrative changes (eg, protocol template section updates, correction of 
typographical errors, editorial changes, etc.) were also incorporated and are outlined in Section 2, Itemized Changes.
&(/*(1([ZIP_CODE],(7$5<,1)250$7,21n 
determine determine 
on of anemn of an
atercept.atercept.     
ofof the f steestee
he study.he study.
te of te of randorando
udydysisyytes to es to i
nicalcalllllaborabor
to be o be utilizutili
ges (eg, pros (eg, pro
itorial chantorial cha
Changes.Changes.